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CD4+ effector (Teff) and regulatory (Treg) T cells play different roles in the immune system. 
Teffs promote innate and adaptive immune responses, while Tregs suppress immune 
responses, maintain immunological tolerance and prevent autoimmune diseases. Naïve 
CD4+ T cell can be induced in vitro to become Teffs or inducible Tregs (iTregs). This work 
focused on comparing the spatiotemporal organisation of T cell signalling intermediates 
upon activation of Teffs and iTregs, using the Tg4 murine model of experimental 
autoimmune encephalomyelitis. Live cell imaging data of Tg4 Teffs were previously 
acquired. Compared to Teffs, iTregs were found to show impaired spatiotemporal patterning 
of LAT, TCR-ζ and F-actin, suggesting their activation to be defective. T cell-APC couples 
formed by iTregs were found to be less stable. iTregs show a reduced ability to secrete IFN-
γ and tend to secrete more IL-10 than Teffs. To investigate whether iTreg function can be 
controlled by proximal T cell signalling, CTLA-4 and PD-1 coinhibitory pathways, the 
spatiotemporal distribution of LAT during iTreg activation were manipulated.  
 
Results show that blocking CTLA-4 and PD-1 significantly inhibited iTreg generation. Dual 
blockade of CTLA-4 and PD-1 was found to improve cell coupling and partially enhance 
LAT accumulation at the T cell-APC interface. Previous work has shown that fusing LAT 
with the PKC-θ V3 or Vav1 SH3SH2SH3 domain enhances LAT central accumulation at the 
interface under attenuated T cell stimulation. Here we show that in iTreg activation, fusion 
with PKC-θ V3 excessively enhanced LAT overall accumulation at the interface, but slightly 
reduced their IFN-γ and IL-10 secretion, while fusion with Vav1 SH3SH2SH3 fully restored 
LAT overall accumulation at the interface, and slightly enhanced IL-10 secretion. Both 
conditions improved cell coupling. These data indicate that blocking coinhibitory pathways 
and enhancing LAT spatiotemporal organisation improve iTreg activation, but regulate their 
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SSC   Side scatter 
STAT   Signal transducer and activation of transcription 
TCR   T cell receptor 
TGF   Transforming growth factor 
Th cells  T helper cells (CD4+ T cells) 
TIGIT   T cell immunoreceptor with immunoglobulin and ITIM domains 
TIM-3   T-cell immunoglobulin and mucin-3 
TLR   Toll-like receptor 
Tr1   Type 1 regulatory cells 
Treg   Regulatory T cell 
tTreg   Thymically derived Treg 
Vav1   Vav guanine nucleotide exchange factor 1 
WASP   Wiskott-Aldrich syndrome protein 
ZAP-70  Zeta-chain associated protein kinase-70 
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1.1 Innate and adaptive immune immunity 
The human body protects individuals from infections and diseases caused by 
microorganisms including bacteria, fungi and viruses. As a product of evolution, the immune 
system of vertebrates not only protects the host from invasions of exogenous pathogens but 
also functions in a sophisticated fashion to maintain immune homeostasis. It comprises of 
two powerful lines of defence: the innate and adaptive immune system. When microbes 
invade, the innate immune system initiates efficient responses to recognise and eliminate 
the potential pathogens. This first barrier can discriminate self and non-self antigens. If the 
innate immune system is breached, recognitions of pathogens will be presented further, and 
adaptive immune responses are triggered. Activated B cells will secrete antibodies targeting 
these intruders and T cells can produce signalling proteins (cytokines) for reinforcement and 
induce apoptosis of infected cells. It is of note that none of these events can be properly 
executed if the host cannot identify pathogens at the beginning of the battle, and 
mechanisms of recognition lie within the immune receptors. 
  
The innate immune system comprises various cells including macrophages, dendritic cells 
(DCs), mast cells, neutrophils, eosinophils and natural killer (NK) cells. With germline-
encoded pattern-recognition receptors (PRRs), they can recognise pathogen-associated 
molecular patterns (PAMPs) from microorganisms (1). There are mainly four classes of 
PRRs including the Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-like 
receptors (RLRs) and C-type lectin receptors (CLRs) (2). Endogenous signalling induced by 
the ligation of PRRs mediates inflammatory responses, provides costimulatory signals for T 
cell activation, and promotes effector T cell (Teff) differentiation (3). 
 
Two main components of the adaptive immune system are T and B cells, and they express 
T cell receptors (TCRs) and B cell receptors (BCRs) on their cell surface respectively. T 
cells originate from common lymphoid progenitors from the bone marrow or foetal liver and 
mature in the thymus, while B cells originate from haematopoietic stem cells in the foetal 
liver which migrate to bone marrow after birth (4, 5). Mature T and B cells translocate to 
lymph nodes and the spleen where adaptive immune responses can be initiated, usually by 
receiving signals from the innate immune system (4). 
 
B cells can efficiently differentiate into plasma cells and secrete pathogen-specific 
antibodies to promote neutralisation of pathogens after their BCR binds a cognate antigen 
(6). Moreover, B cells are also capable of presenting antigens to T cells (7). 
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T cell recognition is a key part of triggering effective adaptive immune responses. A TCR 
binds a specific antigen presented by an antigen presenting cell (APC), via its major 
histocompatibility complex (MHC). MHC class I molecules are expressed by many 
mammalian cells while MHC class II molecules are expressed mainly on APCs including 
DCs, B cells, and macrophages (8). T cell-APC interactions are required for T cell activation 
and differentiation, and cytotoxic T cells expressing cluster of differentiation 8 (CD8) are 
associated with MHC class I while helper T cells expressing CD4 are associated with MHC 
class II. 
 
1.2 T cell differentiation and maturation 
Common lymphoid progenitors enter the thymus and do not express TCRs, CD4, and CD8, 
termed double negative thymocytes (9). Double negative thymocytes can become T cells 
expressing either αβ or γδ TCRs (10). During the development of αβ T cells at the double 
negative stages, they initially express a pre-TCR consist of a non-rearranging pre TCR-α 
and a TCR-β chain which undergoes V(D)J gene recombination regulated by RAG proteins 
(9, 11).  After several rounds of cell divisions, the pre-TCR-α is replaced by a newly 
rearranged TCR-α, and cells during this stage often start to express CD4 and CD8. 
Subsequently, a large number of CD4+ CD8+ thymocytes bearing a mature αβ TCR are 
generated (9). These double positive cells then first make contact with cortical thymic 
epithelial cells (cTECs) presenting self-peptides. If these cells express a TCR with a poor 
affinity for self-peptide MHC complexes, delayed apoptosis of these cells will be induced 
(death by neglect) (9). Double positive thymocytes expressing TCRs with intermediate 
affinity for self-peptide MHC complexes become CD4 or CD8 lineage-committed and then 
enter the medulla (positive selection) (12). They interact with medullary thymic endothelial 
cells (mTECs) which express numerous genes representing all tissues from the body. This 
is regulated by the autoimmune regulator (AIRE) (13), allowing the elimination of 
thymocytes which respond to self-peptides from all tissues with high affinity (negative 
selection or central tolerance). Cells expressing TCRs with intermediate affinity for self-
peptides will eventually survive and differentiate into CD4+CD8- or CD4-CD8+ single positive 
T cells (9, 14). Some T cells with high affinity for self-peptides leave the thymus and 
become regulatory T cells (Tregs) (15).  
 
Mature naïve CD4+ and CD8+ T cells then leave the thymus and enter lymphoid sites. Upon 
activation, CD8+ or cytotoxic T cells eliminate target cells by secreting cytokines such as 
tumour necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), releasing granzymes and perforin, 
and inducing apoptosis via the Fas pathway (16).  Activated CD4+ or T helper (Th) cells 
differentiate into different subsets. 
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1.3 CD4+ T cell subsets 
Initially, APCs present peptide antigens to CD4+ naïve T cells via TCR and peptide-MHC 
(pMHC) interactions, with the assistance of CD4 as a co-receptor. Moreover, with signals 
from costimulatory molecules (mainly CD28) and cytokines secreted by APCs, CD4+ T cells 
can be fully activated. Depending on cytokines on-site, the strength of TCR signals, APC 
cell types, and costimulatory molecules, CD4+ T cells can differentiate into different T helper 
cell (Th) lineages including Th1, Th2, Th17, Treg, T follicular helper (Tfh), Th9 and Th22 T 
cells (17, 18). Th cell differentiation is regulated by master regulators and signal transducer 
and activator of transcription (STAT) family members (19).  Here we describe four of these 
subsets. 
 
1.3.1 Th1 cells 
Activation of naïve CD4+ T cells in the presence of interleukin 12 (IL-12) and IFN-γ, drives 
Th1 cell differentiation (19), and strong TCR signals enhance Th1 but not Th2 responses 
(20). Th1 cells secrete IFN-γ, as a signature cytokine, and other pro-inflammatory cytokines 
including TNF-α and TFN-β (21, 22).  The T-box transcription factor (T-bet) and IL12-
induced STAT4 are important transcription factors for Th1 cell development and they both 
induce IFN-γ production of Th1 development (17, 22). IFN-γ plays roles in both innate and 
adaptive immune responses including upregulating expression of TLR4 (23), activating 
macrophages (24), enhancing phagocytosis (25), mediating immunoglobulin G (IgG) class 
switching (26), and stimulating CD8+ T cell responses in viral infections (27). IFN-γ 
promotes the assembly of subunits (LMP2, MECL-1, and LMP7) of the immunoproteasome, 
which presents antigenic peptides to CD8+ T cells during immune responses (28). Moreover, 
IFN-γ induces transporter-associated antigen processing (TAP) by upregulating expression 
of TAP1 and TAP2 subunits (29). Expression of MHC class I and II molecules on the cell 
surface can also be upregulated by IFN-γ (24). IFN-γ or IFN-γ receptor 1 knockout mice are 
susceptible to bacterial, parasitic, and viral infections (24).  
 
IFN-γ-secreting Th1 cells are often associated with autoimmune diseases including type 1 
diabetes, multiple sclerosis (MS), and rheumatoid arthritis (RA) (30). Experimental 
autoimmune encephalomyelitis (EAE), which is a mouse model for MS, has been widely 
applied to study autoimmune immune diseases in the central nervous system (CNS) and 
MS has been long considered to be mediated by IFN-γ secreting Th1 cells (31). After the 
discovery of Th17 cells in 2005, studies have revealed that their signature cytokine IL-17A 
and IL-17F play important roles in the development of EAE (32). The presence of Th17 cells 
and increased expression of IL-17A, IFN-γ, granulocyte-macrophage colony-stimulating 
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factor (GM-CSF) secreted by these cells have been observed in MS patients (33). Both Th1 
and Th17 cells contribute to the pathogenesis of EAE and MS, but at different stages (34). 
 
1.3.2 Th2 cells 
Th2 cells secrete IL-4, IL-5, IL-9, IL-10 and IL-13 and their polarisation is induced by IL-4 
and IL-2 with a weak TCR signal (17, 20, 21). Th2 differentiation is regulated by GATA3 and 
IL-4-induced STAT 6 (17). Th2 cells regulate immune responses against extracellular 
infections such as helminths and IL-4 is involved in IgE switching and production by B cells 
(17).  
 
Overactive Th2 responses can lead to chronic inflammatory diseases such as asthma, 
which is associated with airway hyperresponsiveness and allergic inflammation in the lung 
(35).  
 
1.3.3 Th17 cells 
Differentiation of Th17 cells is regulated by the transcription factor RORγt, STAT3 and 
several cytokines. Naïve CD4+ T cells can be induced into Th17 cells in the presence of 
transforming growth factor beta (TGF-β) and IL-6 or IL-21 and their expansion is promoted 
by IL-1 and IL-23 (36). IL-17 secreted by Th17 cells can promote pro-inflammatory cytokine 
(e.g. IL-1 and TNF-α) and chemokine secretion which activates and recruit macrophages to 
the site of infection (36). IL-17 promotes granulopoiesis by upregulating the release of 
granulocyte colony-stimulating factor (G-CSF) and expression of membrane-bound stem 
cell factor (SCF) (37). Elevated G-CSF levels induced by IL-17 also increase mobilisation of 
mature neutrophils from the bone marrow (38). Additionally, Th17 cells secrete IL-21 and IL-
22. IL-21 can induce differentiation of activated B cells into plasma cells and enhance the 
cytotoxic activity of both NK cells and CD8+ T cells (39), and IL-22 plays a key role in 
mucosal host defence against bacterial infection in the lung (40).  
 
Moreover, Th17 cells and related cytokines are involved in the development of a wide range 
of autoimmune diseases including systemic lupus erythematosus (SLE), type I diabetes, RA 
and MS (41). IL-23, which induces Th17 differentiation shares the same p40 subunit of IL-
12 and together with IL-17 and IL-21 secreted by Th17 cells contribute to the induction of 
EAE (42). Both Th1 and Th17 cells are able to induce EAE, and the ratio of Th1 to Th17 
cells can determine whether T cell infiltration and inflammation will occur in the brain or 
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1.3.4 Regulatory T cells 
CD4+ regulatory T cells (Tregs) have been discovered, categorised and investigated for 
over the past 40 years. They are mostly known for their ability to suppress immune 
responses, maintain self-tolerance and play roles in helping tumour cells escape immune 
surveillance (44-47). In 1995, Sakaguchi et al (45) identified a subpopulation of CD4+ T cells 
in mice expressing IL-2 receptor α-chains (CD25) which play roles in maintaining self-
tolerance. Elimination of these CD4+ CD25+ T cells (about 10% of peripheral CD4+ T cells) 
leads to inflammatory lesions in different organs and causes autoimmune diseases. 
Subsequently in 2003, forkhead-winged-helix transcription factor 3, Foxp3 was found to be 
specifically expressed in CD4+ CD25+ Tregs and define this Treg population (46, 48). Treg 
suppression can be induced via cell to cell contacts (e.g. Tregs constitutively express 
cytotoxic T lymphocyte antigen-4 (CTLA-4) which competes with costimulatory molecule 
CD28 for binding CD80/86), IL-2 deprivation, immunosuppressive cytokines (e.g. IL-10 and 
IL-35) and molecules (e.g. adenosine) (49) (Figure 1.1). Recently, Ovcinnikovs et al show 
that Tregs recruit CTLA-4 to the cell membrane and rapidly capture CD80/86 of APCs via 
trans-endocytosis upon stimulation (50).  
 
CD4+ CD25+ Foxp3+ Tregs can be naturally derived from the thymus (tTregs), generated 
peripherally in vivo (pTregs) and induced in vitro (iTregs) in the presence of TGF-β and IL-2 
(51-53). Unlike tTregs and pTregs, Treg-specific DNA hypomethylation does not occur in 
Treg-specific demethylated regions (such as the Foxp3 conserved non-coding sequence 2 
(CNS2) region) of iTregs, and their Foxp3 expression is unstable (54-56). Naturally 
occurring tTregs are capable of suppressing self-reactive T cells escaping from negative 
selection thus play important roles in maintaining self-tolerance (57). It has been reported 
that a high-affinity TCR which recognises a cognate peptide and CD28 costimulation are 
both required for tTregs development (15, 58). pTregs exist in the periphery, such as the 
intestine and liver, where they are generated under weak TCR stimulation with IL-2,  TGF-β 
or retinoic acid (59, 60). Low dose administration of antigen enhances pTreg induction, and 
increased DC activation impedes this process (61). Moreover, strong TCR stimulation and 
CD28 costimulation can inhibit iTreg generation (62, 63). A recent study suggests that 
efficient iTreg induction requires optimal TCR stimulation strength (64). It was shown that 
1.0 µg/ml anti-TCRβ antibody leads to a higher frequency of iTregs, compared with 0.1 and 
10 µg/ml anti-TCRβ, but a high concentration of anti-TCRβ antibody stabilises Foxp3 
expression in iTregs by inducing demethylation of conserved non-coding sequence 2 
(CNS2) of the Foxp3 locus. These studies reveal that different signal strengths of TCR and 
costimulation are required in the development of tTregs, pTregs and iTregs. Unstable Foxp3 
expression of iTregs is one major issue for applying iTregs for therapeutic approaches (65). 
In general, iTregs can be generated by stimulating naïve CD4+ CD25- T cells with anti-CD3 
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antibody in the presence of APCs and TGF-β, or with plate-bound anti-CD3 and anti-CD28 
antibodies in the presence of TGF-β and IL-2 (51, 66). IL-2 is required for TGF-β mediated 
iTreg induction (66). 
 
Apart from CD25+ Foxp3+ Tregs, two other CD4+ Tregs subsets were reported. Type 1 
regulatory (Tr1) T cells were discovered when a specific peptide was repeatedly presented 
to naïve CD4+ T cells with IL-10 in the culture (67). Tr1 cells secrete high level of IL-10  and 
are capable of suppressing naïve T cell proliferation but do not express Foxp3 (68). 
Coexpression of CD49b and lymphocyte-activation gene 3 (LAG-3) can identify Tr1 cells in 
mouse and human (69).  
 
The third subset of CD4+ Tregs, Th3 cells were identified from an EAE mouse model after 
oral administration of MBP (70). They secrete TGF-β, IL-4 and IL-10 and suppress EAE. 
Th3 cells are Foxp3- cells and express latency-associated peptide (LAP) in humans and 
mice (71). Nevertheless, numerous studies over the last few decades have focused on 
CD4+ CD25+ Foxp3+ Tregs for their various mechanisms of suppression and therapeutic 





Figure 1.1 Basic mechanisms of Treg suppression  
1. Tregs secrete inhibitory cytokines such as IL-10, TGF-β and IL-35 to inhibit Teff 
proliferation and differentiation. 2. Tregs release granzymes to induce T cell apoptosis. 3. 
Tregs express a high level of CD25 (IL-2Rα) which leads to IL-2 deprivation and generate 
adenosines that induce immunosuppression. 4. Tregs express CTLA-4 on the cell surface 
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1.4 Immune tolerance and autoimmunity 
Most T cells recognising self-antigens with high affinity are deleted by the central tolerance 
(negative selection) or converted into Tregs. However, central tolerance is imperfect, as 
some autoreactive T cells with a low affinity for self-pMHC can escape from central 
tolerance (73). The fact that these cells normally do not trigger autoimmune responses 
indicates that additional modifications exist in the periphery, known as peripheral tolerance. 
There are several mechanisms of peripheral tolerance including keeping these autoreactive 
cells from cells expressing autoantigens, downregulating T cell responses by tolerogenic 
APCs, Treg suppression, peripheral deletion of autoreactive T cells, and expression of 
coinhibitory molecules on self-reactive T cells (74). If the balance of tolerance and immunity 
is broken, autoimmune cells could induce immune responses against healthy cells and lead 
to autoimmune diseases. Autoimmunity could be triggered by various factors including 
genetic background, tissue damage, hidden or new self-antigens, inflammation and 
infections (75). A wide range of autoimmune diseases have been studied for decades and 
based on the tissue involved, they can be categorised into organ-specific diseases (e.g. MS) 
and systemic diseases (e.g. SLE) (75). 
  
1.5 Multiple sclerosis  
MS is a chronic inflammatory disease affecting the brain and spinal cord, characterised by 
various clinical symptoms including cognitive impairment, impaired vision, tremor, vertigo, 
weakness and pain (76, 77). Based on the dominant phenotype, MS can be classified into 
five forms including relapsing-remitting MS, clinically isolated syndrome, radiologically 
isolated syndrome, primary-progressive MS and secondary-progressive MS (78). Infiltration 
of autoreactive T and B cells into the brain result in inflammations, demyelination and 
axonal injury in MS patients (79). Myelin associated autoantigens, such as myelin basic 
protein (MBP), myelin proteolipid protein (PLP) and myelin oligodendrocyte glycoprotein can 
be recognised by self-reactive T cells thus lead to immune responses (80, 81).  
Autoreactive T and B cells are initially activated and differentiated in the periphery, possibly 
by molecular mimicry, bystander activation, recognition of novel and CNS sequestered 
autoantigens (76). Activated CD8+ T cells, Th1 cells, Th17 cells, B cells and innate immune 
cells pass through the blood-brain barrier (BBB) and enter the CNS, where T cells are 
reactivated by CNS-resident or immigrant APCs (such as DCs, microglia and macrophages) 
presenting autoantigens and induce inflammation and tissue damage (42, 76). Early cohort 
studies showed that physical trauma does not cause or exacerbate MS (82, 83). Many 
researchers suggest that viral infections cause MS, for example, significantly increased 
immune responses to Epstein-Barr virus (EBV) were found in the serum and cerebrospinal 
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fluid of MS patients (84). Other environmental factors, such as chemicals, smoking and 
vitamin D levels, and genetic factors are also involved in the pathogenesis of MS (85). 
 
1.5.1 Experimental autoimmune encephalomyelitis 
Experimental autoimmune encephalomyelitis (EAE) is an animal model which shows 
pathological similarities to MS and has been widely used for studying the pathogenesis of 
MS and developing immunotherapies (86). One main difference between these two 
diseases is that EAE requires induction of immunisation while the development of MS in 
human is not artificial and induced by unknown autoantigens (31). EAE usually can be 
induced by inoculation of myelin-associated peptides in the presence of complete Freund’s 
adjuvant (CFA) (87). In addition, there are spontaneous models of EAE and these 
transgenic mice carry TCRs recognising specific peptides such as the myelin 
oligodendrocyte glycoprotein (MOG) or MBP peptide and develop spontaneous EAE (88, 
89). 
 
1.5.2 The Tg4 mouse model 
The Tg4 mouse model was established by the Wraith laboratory and more than 90% of Tg4 
CD4+ T cells express a transgenic TCR recognising the acetylated MBP Ac1-9 peptide. 
EAE in Tg4 mice can be induced by the administration of MBP Ac1-9 peptides with CFA 
(73). Tg4 T cells have also been applied to study peptide-induced T cell tolerance. Studies 
of antigen-specific immunotherapy using the Tg4 mouse model have shown that 
autoimmune responses in EAE can be dampened, and Tg4 CD4+ T cell anergy can be 
induced by repetitive administration of MBP Ac 1-9 [4Y] peptides under non-immunogenic 
conditions (90, 91). Such peptide treatment leads to the generation of IL-10 secreting CD4+ 
T-bet+ Foxp3- regulatory T cells and IL-10 secreted by these Tregs contributes to the 
peptide-dependant protection of EAE (90, 92). These studies suggest the Tg4 TCR 
transgenic mouse be an appropriate animal model for studying the pathological mechanism 
and antigen-specific immunotherapies for MS.  
 
1.6 T cell activation 
As mentioned in section 1.3, T cell-APC interaction is a key step for initiating proliferation 
and differentiation of naïve T cells, known as T cell activation. T cell activation requires 
signal transduction from the engagement of TCR with pMHC, costimulation and cytokines. 
 
1.6.1 TCR-pMHC interaction (signal one) 
For αβ T cells, TCR α and β subunits are noncovalently associated with CD3 γε and δε 
dimers, and linked with CD3 ζζ dimers via disulfide bonds, forming the TCR/CD3 complex 
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(93). Proximal TCR signalling is briefly described in Figure 1.2. In early T cell signalling, 
TCRs recognise short peptides bound to MHC class I or II molecules expressed on the 
surface of APCs. With the assistance of CD4 or CD8 co-receptors, protein tyrosine kinase 
Lck is then recruited to the TCR/CD3 complex and phosphorylates immunoreceptor 
tyrosine-based activation motifs (ITAMs) on CD3 ζ chains (93-95). Two phosphorylated 
tyrosines on the ITAMs of TCR-ζ become binding sites for SH2 domains of zeta-chain-
associated protein kinase 70 (ZAP-70), which further phosphorylates linker of activated T 
cells (LAT) and continue to transmit TCR signalling (94, 96). LAT is phosphorylated by ZAP-
70 on tyrosine residues which bind the SH2 domain of adaptor protein Grb2, Gads and 
phospholipase PLC-γ1 (97), and these binding events assemble a LAT nucleated 
signalosome.   
 
Grb2 consists of one SH2 domain and two flanking SH3 domains, which recruits Sos, a Ras 
activator to the membrane (98). Activated Ras induces activation of the mitogen-activated 
protein kinase (MAPK) cascade, which eventually activates transcription factor activator 
protein-1 (AP-1) (99).  
 
The adaptor protein Gads is another member of the Grb2 family and has similar domains as 
Grb2. Its SH3 domain displays a different binding specificity and binds SLP-76 which is then 
recruited to the LAT signalosome. SLP-76 is phosphorylated by ZAP-70 and continues to 
recruit vav guanine nucleotide exchange factor 1 (Vav1), Nck adaptor protein (Nck) and IL-2 
inducible tyrosine kinase (Itk) to the complex (98, 100). Vav1 and Nck regulate recruitment 
and activation of Wiskott-Aldrich syndrome protein (WASP), which interacts with actin-
related protein 2/3 (Arp2/3) complex and promotes actin polymerisation (101-103). Itk not 
only regulates Vav1 associated actin rearrangement, but also activates PLC-γ1 (104, 105).  
 
PLC-γ1 hydrolyses phosphatidylinositol 4,5-bisphosphate (PIP2) to produce membrane-
bound diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) (106). DAG recruits 
protein kinase C theta (PKC-θ) and Ras guanyl nucleotide-releasing protein (RasGRP) to 
the membrane. The former eventually leads to activation of NF-κB in the nucleus and the 
latter promotes transduction of MAPK signalling pathways (107). IP3 binds IP3 receptors in 
the endoplasmic reticulum (ER) and induces Ca2+ influx which leads to nuclear 
translocation and activation of nuclear factor of activated T cells (NFAT) (108).  
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Figure 1.2 A schematic diagram of the proximal TCR signalling pathway.  
Arrows indicate activation or (directions of) recruitment of signalling molecules, p in yellow 
circles indicate phosphorylation.  
 
1.6.2 Costimulation (signal two) 
T cell activation also requires costimulation induced by CD28  and CD80 (B7.1)/CD86 (B7.2) 
engagement (109). CD80 and CD86 are widely expressed on the surface of APCs and are 
members of the B7-CD28 superfamily (110). CD28 is constitutively expressed by CD4+ and 
CD8+ T cells (109). Upon binding, tyrosine-based signalling motifs of CD28 cytoplasmic tail 
are phosphorylated by protein tyrosine kinases and together with proline-rich motifs, they 
recruit kinases and adaptor proteins to the membrane including phosphoinositide 3-kinase 
(PI3K), Gads, Grb2, Itk and Lck. These signalling events eventually induce secretion of 
cytokines including IL-2, IL-4, IL-5, TNF-α and IFN-γ (111, 112), actin cytoskeleton 
remodelling, and activation of NFAT, NF-κB and AP-1 (95). CD28 deficiency or blockade of 
CD28 and CD80/86 interactions in mice could reduce expression of IL-2 and IL-2R (113), 
inhibit T cell proliferation (114) and impair Th2 responses against infections (115).  
 
T cells require not only positive signals from costimulatory receptors to trigger immune 
responses, but also need negative signals from coinhibitory receptors to regulate immune 
responses, induce tolerance and prevent autoimmunity. Coinhibitory molecules including 
CTLA-4, programmed cell death protein-1 (PD-1), T-cell immunoglobulin mucin-3 (TIM-3), 
lymphocyte activation gene-3 (LAG-3) and T cell immunoreceptor with immunoglobulin and 
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1.6.3 Cytokines (signal three) 
Signal one and two are sufficient to drive the proliferation of naïve T cells but further optimal 
differentiation for their effector function require a third signal from cytokines (117). As 
mentioned in section 1.3, differentiation of different helper subsets from CD4+ naïve T cells 
is regulated by the cytokine environment. For CD8+ T cells, IFN-α, β, γ and IL-12 play roles 
in regulating their expansion, survival and cytotoxic function during immune responses 
against infection (118, 119).  
 
1.7 The immunological synapse  
Initial formation of T cell-APC junction is regulated by engagement of TCR-pMHC, co-
receptors and adhesions molecules, known as the immunological synapse (IS) (120). The 
formation of a stable immunological synapse is characterised by a central TCR cluster and 
a peripheral ring of adhesions molecules at the T cell-APC interface. Based on different 
spatial segregation patterns, TCR/CD3 complex and PKC-θ assemble the central 
supramolecular activation cluster (cSMAC), while lymphocyte function associated antigen 1 
(LFA-1) and talin assemble the peripheral SMAC (pSMAC), supported by dynamic actin 
cytoskeleton (120-122). The formation of these supramolecular signalling complexes 
stabilises the IS and is important for efficient T cell activation and cytokine production (121). 
Tyrosine protein kinase Lck/Fyn and lipid PIP3 are recruited to the cSMAC (121, 123, 124). 
The LAT nucleated signalling complex (including Grb2, Gads and SLP-76) transiently forms 
after TCR ligation and disappears within 3 minutes, while localisation of Zap-70 to the 
cSMAC remains steady for more than 30 minutes once recruited (125, 126). These 
observations indicate the composition of the cSMAC to be dynamic and time dependant. 
The role of the cSMAC at the synapse has been controversial. In a study using naive T cells, 
TCR-mediated tyrosine kinase signalling and accumulation of TCR and Lck were found at 
the periphery of the IS before the cSMAC is formed, and that the role of cSMAC was 
proposed to downregulate TCR signalling and mediate degradation of receptors and 
phosphorylated proteins (127, 128). Moreover, the cSMAC formation was found to inhibit 
signalling in strong agonist peptide-induced T cell activation, but enhance the stimulatory 
capacity of weak peptides (128, 129). However, these studies mainly focused on 
investigating SMAC formation after 30 minutes of T cell-APC cell coupling, thus initial 
signalling events within minutes after the IS formation have been less considered. Singleton 
et al have shown that within the first few minutes of T cell-ACP interactions, translocation of 
signalling intermediates including receptors, tyrosine kinases and lipids can be observed 
and are highly diverse (130). Subsequently, manipulation of localisation of LAT, one of the 
key components of the cSMAC revealed that transient accumulation of LAT at the centre of 
the IS is sufficient to promote IL-2 secretion (126). Clark et al proposed that the cSMAC to 
play two roles: the cSMAC recruits various signalling intermediates required for proximal 
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TCR signal transduction within the first two minutes of T cell activation, and later it 
selectively drives proteins like Vav1 and SLP-76 away from the cSMAC, assisted by the 
actin network and they continue to form smaller signalling complexes. Thus the cSMAC not 
only enhances early T cell activation but continues to regulate proximal TCR signalling by 
sequestering key signalling proteins (126). Although TCR accumulation in these two studies 
was consistently found at the centre of the IS at early time points, which is contradictory to 
that observe by Lee et al (127), different mouse and experimental (fixed cell conjugates vs 
live cell imaging) models may contribute to such inconsistency. 
 
It should be noted that the bull’s-eye structure of the cSMAC and pSMAC is mainly found in 
T-B cell interactions while synapses formed by T cells and DCs display a multifocal 
patterning without large segregation of CD3 and LFA-1, suggesting formation of the SMACs 
in T cell activation is restricted to specific conditions (131, 132). 
 
1.8 Spatiotemporal organisation of T cell activation  
Proximal signalling of T cell activation is initiated by ligation of TCR and pMHC, assisted by 
co-receptors and transduced via tyrosine phosphorylation, which eventually promotes cell 
proliferation, polarisation and effector function. Investigations about T cell signalling events 
at the IS, such as the assembly of TCR-induced signalling complexes and actin polarisation 
help us better understand the roles of the cSMAC and pSMAC in early T cell activation (125, 
133). Many studies were conducted on 2D systems or with fixed T cell-APC conjugates 
using immunofluorescence to investigate localisation of signalling molecules in T cell 
signalling. These results provide good insights of TCR signal transduction but factors like 
dynamic membrane undulations and cytokine regulation have been less considered. Thus, 
it is of great interest to investigate distributions of signalling intermediates in T cell activation 
using a 3D live cell imaging systematic approach, developed by the Wuelfing laboratory. 
Signalling proteins can be labelled with GFP and tracked using fluorescence microscopy. 
Accumulation of one signalling protein within a cell is less physiologically meaningful, but 
localisation of two or multiple proteins at the same location and time point indicates that 
they are more likely to interact with each other, which often reflects their roles in signal 
transduction (130, 134). By applying live cell imaging on mouse TCR transgenic T cells, 
spatiotemporal organisation of T cell signalling proteins can be verified (134). Seven 
different spatiotemporal patterns (central, invagination, diffuse, lamellal, peripheral, 
asymmetric and distal) were defined to describe how signalling molecules distribute at the T 
cell-APC interface upon activation (130, 135).  Criteria to identify the seven different 
patterns are given below (Figure 1.3). The Wuelfing laboratory has established a library of 
imaging data for more than 90 signalling intermediates, which were applied to study their 
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spatiotemporal organisation and roles in signal transduction of T cell activation (134, 135). 
  
1.9 Thesis aims 
CD4+ Teffs promote both innate and adaptive immune response by secreting inflammatory 
cytokines such as IFN-γ, while Tregs play roles in maintaining self-tolerance and 
suppressing immune response mainly by secreting anti-inflammatory cytokines such as IL-
10, and expressing coinhibitory ligands such as CTLA-4 (21). The mechanisms of Treg 
mediated immune regulation are not fully understood. Spatiotemporal organisation of 
proximal T cell signalling is associated with T cell function. For example, transient 
accumulation of LAT at the centre of the immunological synapse is associated with efficient 
IL-2 production (126). Naïve CD4+ T cells from Tg4 TCR transgenic mice can be effectively 
induced into effector or regulatory phenotypes in vitro. As a library of substantial imaging 
data of Tg4 Teffs was previously established by a former lab member Helen Tunbridge, this 
study mainly focused on investigating spatiotemporal organisation of key signalling 
intermediates in Tg4 iTregs, which was then compared to that of Tg4 Teffs. The major aims 
of this study were to 1) generate Tg4 iTregs, 2) compare functional differences, 
morphological characteristics and T cell signalling of Tg4 Teffs and iTregs upon activation, 3) 
investigate whether manipulations of T cell activation signalling in Tg4 iTregs could alter 
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Figure 1.3 Spatiotemporal accumulation patterns of fluorescent sensors in T cell 
activation 
Pattern diagrams, representative images and criteria for identifying seven spatiotemporal 
accumulation patterns are listed. Fluorescence intensity is shown in false colour and 
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 Method Chapter 2
 
2.1 Media and reagents  
2.1.1 Complete medium  
RPMI 1640 Medium with L-glutamine (Gibco) with 10% fetal bovine serum (FBS) (HyClone), 
50µM β-Mercaptoethanol (Gibco) and PenStrep (100 U/ml Penicillin, 100 µg/ml 
Streptomycin Gibco) and 50µM β-Mercaptoethanol (Gibco). 
 
2.1.2 IL-2 complete medium 
Complete medium prepared above, with 50 U/ml recombinant human (rh) IL-2 (NIH/NCI 
Biological Resource Branch). 
 
2.1.3 Treg medium  
Complete medium supplemented with 100 U/ml rh IL-2 and 10 ng/ml rh transforming growth 
factor-beta 1 (TGF-β1) (BioLegend). 
 
2.1.4 Incomplete Phoenix cell medium 
DMEM with 4.5% D-glucose, 110 mg/L sodium pyruvate and l-glutamine (Gibco), 10% FBS 
(Hyclone), 100 U/ml Penicillin, 100 µg/ml Streptomycin, MEM nonessential amino acids 
(Gibco), MEM nonessential amino acids (Gibco). 
 
2.1.5 Complete Phoenix cell medium 
Incomplete Phoenix cell medium prepared as above, with 300 µg/ml hygromycin (Invitrogen) 
and 1 µg/mL Diphtheria toxin (Sigma). 
 
2.1.6 Cell separation buffer 
DPBS (without calcium or magnesium) (Gibco), with 3% FBS (Hyclone) and 10 mM EDTA. 
 
2.1.7 FACS buffer 
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2.1.8 Antibodies 




















































































   
 
2.1.9 Imaging buffer  
DPBS (without calcium or magnesium) (Gibco), with 10% (FBS) (Hyclone), 1 mM CaCl2 
(Sigma) and 500 µM MgCl2 (Sigma). 
 
2.1.10 Chloroquine solution 
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2.1.11 HEPES buffered saline (2x solution)  
HEPES buffered saline is prepared in 500 mL (2x solution) as the following protocol: 
1. Prepare a stock solution of Na2HPO4 dibasic (5.25 g in 500 mL of dH2O). 
2. Dissolve 8.0 g NaCl, 6.4g HEPES (sodium salt) in 10 mL of the Na2HPO4 stock solution.  
3. Adjust pH to precisely 7.0 using NaOH or HCl. Adjust the volume to 500 mL with dH2O.  
4. Adjust the pH again to exactly 7.0.  
Sterile filters are used in each step and the solution is autoclaved.  
 
2.1.12 Paraformaldehyde solution 
Paraformaldehyde (Sigma) in dH2O (16% w/v). Dilute this solution in PBS to further prepare 
4% and 1% paraformaldehyde  
 
2.1.13 Peptides 
Lyophilised MBP Ac1-9 [4K] (Ac-ASQKRPSQR-NH2) and MBP Ac1-9 [4Y] (Ac-
ASQYRPSQR-NH2) purchased from GL Biochem, with N-terminus acetylation and C-
terminus amidation. Dissolve peptides in sterile PBS at 4mg/ml and store at -20°C. 
 
2.1.14 Fixation and permeabilisation buffers 
Foxp3/transcription factor staining buffer set purchased from eBioscience. Dilute 1 part of 
Fixation/Permeabilisation Concentrate with 3 parts of Fixation/Permeabilisation Concentrate 
to prepare 1x fixation buffer. Dilute 1 part of 10x Permeabilisation Buffer with 9 parts of 
dH2O to prepare 1x permeabilisation buffer. 
 
2.1.15 Reagents for ELISA  
Coating buffers: 
For IFN-γ capture antibody, 0.1M Na2CO3 is prepared as follow: Dissolve 3.57 g NaHCO3, 
0.80 g Na2CO3 in 500 mL dH2O, adjust pH to 7.0 with NaOH. For IL-10 capture antibody, 
0.2 M Na3PO4 is used: Dissolve 12.49 g Na2HPO4, 15.47 g NaH2PO4 in 1 L dH2O, adjust pH 
to 6.4. Buffers stored at 4°C. Both IFN- and IL-10 capture antibody were diluted 1:250 in 
their corresponding coating buffer. 
  
Assay diluent: 
PBS with 10% FBS, pH 7.0, freshly prepared. 
 
Wash buffer: 
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1 M H3PO4 or H2SO4 
 
2.2 Cell lines 
2.2.1 Phoenix cells  
Phoenix-E (ϕNX-E) cell lines were used for retrovirus transduction (136). They are a type of 
human embryonic kidney cell derived from 293T cells modified to produce ecotropic and 
amphotropic retroviruses. Cells were cultured with complete phoenix cell medium on 60 x 
15mm Primaria culture dishes (BD Falcon) at 37°C with 6% CO2, and were split twice a 
week (Tuesday and Friday). When splitting, medium in a dish was discarded and 1mL 0.02% 
EDTA was added to the dish to detach cells. Then cells were centrifuged 200g for 3 minutes 
and resuspended in complete phoenix cell medium. For one dish, 6 x 105 cells were added.  
 
2.2.2 PL8 cells 
PL8 cells were used for APCs to activated Tg4 T cells. They were generated by PEF-fusion 
of blast cells with M12.C3 I-A-negative B cell lymphoma, and PL8 cells were selected for 
their expression of MHC II molecules I-AU (137). PL8 cells were cultured with complete 
medium in T25 vented tissue culture flasks at 37°C with 6% CO2, and split 1:10 every 2 
days. 
 
2.3 Experimental Animals 
2.3.1 Breeding and maintenance   
All mice were bred and maintained by the animal service unit of the University of Bristol. 
Mice were housed in cages with unlimited supply of water and mouse chow, and paper rolls 
and sawdust as bedding. Breeding stocks were kept in the Bristol Veterinary School and 
mice between 6-12 weeks were culled for experiments. 
   
2.3.2 Tg4 transgenic mice  
Tg4 mouse model was modified to express a transgenic αβ TCR (Vα4, Vβ8.2) of a MBP 
Ac1-9 specific T cell hybridoma (1934.4), which originated from an encephalitogenic T cell 
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2.3.3 Primary T cell isolation 
Tg4 mice were culled with schedule one method. Spleens and lymph nodes were harvested 
from Tg4 mice and homogenised using a 5 ml syringe. Then cells were washed with 5 ml 
RPMI 1640 Medium (Gibco) through a 40 µm cell strainer (Falcon) and collected in a 50 ml 
Falcon tube, then centrifuged at 311 g, room temperature for 5 minutes. Cells were 
resuspended in 1 ml complete medium. To lyse red blood cells, Red Blood Cell Lysing 
Buffer (Sigma) was added to resuspended cells for 4 minutes and then quenched in 10 ml 
complete medium. Cells were then centrifuged at 311 g, room temperature for 5 mins and 
resuspended with lymphocytes in 10 ml complete medium. 
 
2.3.4 Cell priming and culturing 
For peptide stimulation, cells were cultured in a 24-well plate (4-5 x 106 per well) and primed 
with 10 µg/ml MBP Ac 1-9 [4K] in complete medium, rhIL-2 was added (50 U/ml) after 24 
hours to induce Teffs, and cell were cultured in IL-2 complete medium.  
 
To induce iTregs, cells were resuspened in Treg medium and cultured in a 24-well plate 
(3.5-4 x 106 per well) and primed with 10 µg/ml MBP Ac 1-9 [4K]. For anti-CD3/28 
stimulation, after red blood cell lysis, cells were purified with MagniSort Mouse CD4 T cell 
Enrichment Kit (ebioscience) according to the MagniSort Negative Selection Protocol III. 
Naïve CD4+ T cells were cultured in a 48-well plate (1.5 x 106 per well) coated with mouse 
anti-CD3ε (1 or 10 µg/ml) and anti-CD28 (2 µg/ml) antibodies (Bio X cell) for 48 hrs and 
then transferred to antibody-free wells. To induce Teffs, cells were culture with IL-2 
complete medium after 24 hours. To induce iTregs, cells were cultured in daily changed 
Treg medium. 
 
After initial cell priming, cells were usually cultured in relevant medium at 37°C with 6% CO2 
for five days before sorting for imaging and retroviral transduction with a sensor of 
interested was performed 24 hours after cell priming.  Medium was changed daily and cells 
were split when required.  
 
2.4 Retroviral transduction  
2.4.1 Transfection of phoenix cells  
The calcium phosphate transfection method was applied to introducing DNA plasmids into   
phoenix cells. First, 25 µl chloroquine solution (4.1 mg/ml), which inhibited lysosome-
autophagosome fusion and lysosomal protein degradation (138) was added to a phoenix 
plate. Then the plate was kept in the incubator at 37°C with 6% CO2 while calcium 
phosphate co-precipitation was being performed. One 15 ml Falcon tube was added with 
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0.5 ml 2 x HBS and 2 µl 1 M NaOH (tube A). Another Falcon tube was added with 428 µl 
sterile ddH20, 10 µl plasmid DNA and 62 µl 2M CaCl2 (tube B). CaCl2 solution was added 
drop by drop. The solution in tube B was gently added to tube A using a P1000 pipette and 
bubbles were generated using a pipette controller during this process. The mixed solution 
sat at room temperature for 1 minute and was gently added to the phoenix plate prepared 
without disturbing the cell monolayer. The plate was incubated at 37°C with 6% CO2 
overnight. On the next day, the plate was examined under a microscope for calcium 
phosphate–DNA co-precipitates and the media was exchanged with 3 mL incomplete 
phoenix medium. Phoenix plates were further cultured for 48 hours to produce retroviruses 
and used to transduce T cells.  
 
2.4.2 Transduction of Tg4 T cells 
On the following day of T cell priming, T cells and phoenix medium containing retroviruses 
were collected separately into 15 mL Falcon tubes and centrifuged at 311 g for 3 minutes. 
Supernatants from the tube of T cells were discarded and for every 1.5-2 x105 T cells, 1 ml 
of the phoenix medium supernatant was added for transduction.  Resuspended cells were 
added with 8 mg/mL protamine sulphate to neutralise negative charges and enhance viral 
entry. Cells were added to a 24 or 48-well plate depending on cell numbers and then 
centrifuged at 1083 g, 32 °C, for 2 hours. Cells were resuspended in medium and cultured 
for four days before sorting. 
 
2.5  Surface and intracellular staining of cells in flow cytometry 
Cells were first washed with PBS (centrifuged at 311g for 3 minutes) and then stained with 
Zombie Aqua/NIR live/dead dye (Biolegend) diluted in PBS at 1:100 for 1 x 106 cells, for 20 
minutes at room temperature in the dark. After another two washes, cells were resuspended 
in FACS buffer and stained with anti-mouse monoclonal antibodies (mAbs) for surface 
markers on ice for 30 minutes in the dark. After one wash with FACS buffer, cells were 
resuspeneded in FACS buffer ready for flow cytometry or intracellular staining.  
 
For intracellular staining of Foxp3, Foxp3/Transcription Factor Staining Buffer Set 
(eBioscience) was used. After centrifugation, cells were first fixed in 
Fixation/Permeabilization reagent on ice for at least 30 minutes in the dark and then 
washed twice with Permeabilization buffer. Cells resuspended in Permeabilization buffer 
and stained with Fopx3 PE mAb (eBioscience) on ice for 30 minutes in the dark. After 
another two washes with Permeabilization buffer, cells were resuspended in FACS buffer 
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2.6 Suppression assay  
Teffs and iTregs were prepared as described above and collected for suppression assays 
on the day five of culture. Intracellular Foxp3 staining was performed to confirm the 
percentage of Foxp3+ iTregs. PL8 cells were treated with 2 µg/ml mitomycin C (Sigma) for 
24 hours prior to the experiment. To set up co-cultures, naïve Tg4 CD4+ T cells were 
purified as described above. Cells were then washed twice with PBS (centrifuged at 311g 
for 3 minutes). For a negative control, 2.5 x 105 cells were fixed in 1% PFA. The rest were 
resuspended in PBS and labelled with the CellTrace Violet (CTV) dye (ThermoFisher) with 
a working concentration of 5 µM. Cells were incubated at 37°C for 20 minutes and then 
quenched with equal volume of complete medium for 5 minutes at room temperature. After 
another 3-4 times washes with PBS, another 2.5 x 105 cells were fixed in 1% PFA and used 
as a CTV control on day 1. The other CTV+ naïve T cells would be used as responder cells 
for suppression assay. Either Teffs or iTregs, CTV+ native T cells and pre-treated PL8 cells 
would be co-cultured in a 48-well plate for three days.  Cells were either activated with 10 
µg/ml MBP Ac1-9 [4K] or plate-bound anti-CD3/28 (1/2 µg/ml) in the absence of PL8 cells. 
After 72 hours, cells were harvested and cell surface staining was performed to identify 
CD4+ CTV+ T cells. Histograms showing CTV fluorescence intensity of double positive cells 
were used to compare cell divisions of CD4+ naïve T cells in different groups. All iTregs 
used in suppression assays were >75% Foxp3+. To ensure the numbers of Teffs and iTregs 
added were the same in corresponding wells, the number of iTregs added was justified 
based on the percentage of Foxp3+ cell. Cell samples were analysed on Acea Novocyte 
3000. 
 
2.7 Live cell imaging 
After retroviral transductions, cells were continued to be cultured for another four days and 
sorted for GFP+ cells. Cells were first harvested, centrifuged at 311 g for 3 minutes and 
resuspended in imaging buffer. GFP+ cells were sorted with a BD Influx cell sorter (BD 
Bioscience). FACS sorting gate for GFP+ cells were set as 1-1.5 (or 1/3, for ELISAs) log 
shift above the negative population. In parallel, 1-2 x 106 PL8 cells were pulsed with 10 
µg/ml MBP Ac1-9 [4Y] peptide in 1ml on a 24-well plate for at least 4 hours before imaging. 
To perform live cell imaging, 300 µl peptide-loaded PL8 cells (around 300-600k cells) from 
one well were collected into a 1.5 ml Eppendorf tube. All sorted GFP+ cells were collected 
into another tube. Both tubes were centrifuged at 344 g for 4 minutes. After supernatants 
were discarded, PL8 cells were in in 50 µl imaging buffer and T cells were resuspended in 5 
µl imaging buffer (for every 10-40k cells). Depending on cell numbers, two kinds of imaging 
plates were either used: 348-well (35-40k T cells per well) or 1536-well (11-14k T cells per 
well) glass bottom MatriPlate. First, 50 µl imaging buffer was added to an empty well (not 
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needed in a 1536-well plate) and 5 µl of T cells were added to the bottom of the well. The 
plate was then set on a confocal microscope. After cells were settled, 1-3 µl of APC-
containing buffer were gently added to the well, avoiding disruption of T cell distribution. 
Once T cells began to make contact with APCs added, imaging should begin. Acquisition 
configurations (detailed settings refer to Ambler et al (136)): a z-stacking of 21 images (1 
µm each) in the fluorescent channel, 3 time points (every 20s) per minute, 1 DIC reference 
image taken at the mid-stack from each time point, 2 X 2 binning used to improve signal-to-
noise ratio of the data, 15 minutes of acquisition. For one experiment, 46 DIC and 966 GFP 
z-stacks were generated and exported using Volicity software. 
 
2.8 Analysing imaging data  
Metamorph software was used to analyse imaging data. DIC images were used to identify 
onsets of cell coupling and 0s indicates when a stable cell couple is formed. Fluorescence 
images were used to identify accumulation patterns of a sensor. Pseudocolor was applied in 
maximum projection images and fluorescence intensity increases from purple to red. 
Spatiotemporal patterns (Figure 1.1) were used to analyse signalling intermediate 
distributions. 
 
2.9 Enzyme-linked immunosorbent assays (ELISAs) 
Supernatants were collected from cell culture by centrifugation at 311 g and stored at -20 °C 
or used on the day.  The level of IFN-γ and IL-10 in cell culture supernatants were 
determined using mouse IFN-γ and IL-10 OptEIA ELISA sets from BD Biosciences with 
manufacturer’s protocol. Briefly, Nunc-Immuno MicroWell 96-Well Plates (Thermofisher) 
were coated with 100 µL capture antibody diluted in coating buffer, sealed and kept at 4°C 
overnight. For IFN-γ ELISAs, wells were first aspirated and washed with >300 µl wash 
buffer for 5 times and then blocked with >200 µl assay diluent for 1 hours at room 
temperature. A washing step was then repeated for 5 times and 100 µL standard or 
samples were added and incubated at room temperature for 2 hours. Wells were again 
washed for 5 times added with 100 µL detection antibody and enzyme reagent and 
incubated for 1 hour at room temperature. A final washing step was repeated for 10 times 
and added with 100 µL substrate solution. The plate was incubated in the dark at room 
temperature for 30 minutes. Finally, 50 µL stop solution was added to each well and 
absorbance of each well was read at 450 and 570 nm. The final reading was obtained by 
subtracting absorbance at 570 nm from that at 450 nm. For IL-10 ELISAs, a same protocol 
was followed with fewer washes (3 times in the first and second washing step, 7 times for 
the last). Standard curves were generated using optical density (OD) values of sample 
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standards and sample concentrations were back-calculated using the linear standard 
curves. Duplicate or triplicate samples were applied in each experiment.   
  
2.10 Morphological measurements 
To study T cell morphology upon T cell-ACP interaction, four morphological parameters 
were measured using Metamorph software. These parameters were: cell depth (the length 
from the interface centre to the distal pole of a T cell), cell width (the width of the main cell 
body), interface width (the width of the contact interface) and lamellal depth (the vertical 
length from interface centre to the narrowest width of the lower part of a T cell). Lamellal 
depth would be recorded only if a visible extended lamella was observed. Its length should 
be >1.3 µm (Figure 2.1 A). A diagram is shown below showing the four parameters (Figure 
2.2 B).  
  
 
Figure 2.1 Measuring four morphological parameters upon T cell-APC interactions 
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2.11 Statistical analysis 
Depending on the type and distribution of data, statistical significance was calculated using 
a Student’s T-test, Analysis of Variance (ANOVA), a two proportion z-test or Chi-square test. 
When analysing the frequency of occurrence of spatiotemporal accumulation patterns, a 
two proportion z-test was applied. Proportion data were arcsine-transformed and ratio data 
generated in the computational analysis were log-transformed so that transformed variables 
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 Model establishment and optimisation Chapter 3
 
3.1 Introduction  
Due to TCR gene rearrangement, diverse TCRs which hold different affinities for peptide 
antigen are expressed on the surface of T cells. The TCR repertoire enables the adaptive 
immune system to recognise various pathogens from the environment. A well-established T 
cell model expressing specific TCR is commonly used to induce iTregs, so that T cell 
activation can be initiated and compared in the same manner using TCR-specific peptide 
antigens. To generate iTregs in this study, we applied the Tg4 TCR transgenic mouse 
model, which was previously established by the Wraith group (73). Tg4 T cells were heavily 
skewed to express CD4 and about 90-95% of Tg4 CD4+ T cells specifically recognise MBP 
Ac1-9 peptides. Purified Tg4 CD4+ naïve T cells can be induced into iTregs by activation 
with anti-CD3 and anti-CD28 (up to 95% iTregs) or MBP Ac1-9 peptides in the presence of 
irradiated B10.PL splenocytes (up to 75% iTregs) (139), and the former is more efficient and 
widely applied.  
 
In this study, we generated Tg4 iTregs primed with anti-CD3 and anti-CD28 or stimulated by 
endogenous APCs presenting TCR-specific peptide in the presence of IL-2 and TGF-β. T 
cell signalling intermediates were labelled with GFP in Tg4 CD4+ Teffs and iTregs (>75% 
Foxp3+) for spatiotemporal distribution analysis. Live cell imaging library of Tg4 CD4+ Teffs 
were previously established by Helen Tunbridge, and therefore we aimed to generate 
comparable imaging data from Tg4 iTregs in this project. Additionally, we have also 
compared frequencies of Foxp3+ cells induced by anti-CD3/CD28 and endogenous APCs 
primed with TCR-specific peptide. 
 
 
3.2 Chapter aims 
• To induce Tg4 Foxp3+ iTregs in vitro and perform retroviral transduction of GFP sensors 
on Tg4 Foxp3+ iTregs 
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3.3 Purified Tg4 naïve T cells are CD4+ Vβ8.2+ 
A full stimulus of T cell activation requires signalling from MHC-TCR interaction presenting 
antigen peptide (signal one), costimulatory signals of CD28 and B7.1/7.2 (signal two) and 
cytokines released at site such as IL-1, IL-12 and type I interferons (IFNs) (signal three) 
(140, 141). Whereas CD4+ naïve T cells activated with plate-bound anti-CD3 and anti-CD28 
in the presence of TGF-β and IL-2 has been shown to be sufficient to induce Tregs, and 
leads to high frequencies of Foxp3 expression (over 80%) (66). In this setting, naïve CD4+ T 
cells are required to generate iTregs. In initial experiments, Tg4 splenocytes and 
lymphocytes were purified with the MagniSort® Mouse CD4 Naïve T cell Enrichment Kit 
after red blood cell lysis. Transgenic Tg4 T cells are mostly CD4 positive and are highly 
responsive when primed with MBP Ac1-9 peptide (73). To validate CD4+ naïve T cell 
population after negative selection, unpurified and purified cells prior to stimulations were 
stained with anti-mouse CD4, Vβ8.1/8.2, CD19, and MHC-II antibodies. Comparison 
between these two populations (Figure 3.1) indicates that negative selection effectively 
isolated CD4+ Vβ8.1/8.2+ population and excluded B cells and APCs such as dendritic cells 
and monocytes. Over 97% purified cells were CD4+ Vβ8.1/8.2+, twice as many as those 
from unpurified cells population. Less than 0.2% of B cells (CD19+) and APCs (MHC-II+) 
remained after purification. CD4+ T cells were enriched and proceeded for anti-CD3/28 
stimulation. 
 
Figure 3.1 Tg4 splenocytes and lymphocytes were purified into CD4+Vβ8.1/8.2+T cells 
Tg4 splenocytes and lymphocytes with and without negative selection were stained for CD4, 
CD19, Vβ8.1/8.2 and MHC-II. FACS plot shows mouse Vβ8.1/8.2 vs CD4 and CD19 vs 
MHC-II and four quadrant gates are drawn. The percentage of each cell population was 
indicated within each quadrant. Data are from one experiment.  
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3.4 Compared with 10 µg/ml anti-CD3, 1 µg/ml anti-CD3 leads to 
higher Foxp3 expression and has no significant effects on 
retroviral transduction  
Previously described by the Wraith group (139), 1 µg/ml plate-bound anti-CD3 and 2 µg/ml 
anti-CD28 were used to activate CD4+ naïve T cells, and with 100 U/ml IL-2 and 10ng/ml 
TGF-β added in complete medium to induce iTregs. They used 1 µg/ml anti-CD3 for TCR 
activation and in this project, we compared which concentration of anti-CD3 (1 and 10 µg/ml) 
would induce a higher frequency of Foxp3+ iTregs (anti-CD28 concentration was the same 
in both conditions). Pilot experiments contained 0.1 µg/ml anti-CD3 conditions in which cells 
were not fully activated and failed to proliferate and differentiate (data not shown). Results 
(Figure 3.2) show that activating Tg4 naïve CD4+ T cells with 1 µg/ml anti-CD3 led to higher 
Foxp3 expression than cells activated with 10 µg/ml anti-CD3 (p<0.001). This implies that 
TCR stimulus provided by 1 µg/ml anti-CD3 is enough to trigger Tg4 naïve CD4+ T cell 
proliferation and differentiation which leads to better iTreg induction outcome.  
 
 
Figure 3.2 Tg4 naïve T cells primed with 1 µg/ml anti-CD3 have higher Foxp3 
expression than cells treated with 10 µg/ml anti-CD3 
Percentages of Foxp3+ iTregs induced from Tg4 naïve CD4+ T cells activated with 1 and 10 
µg/ml anti-CD3 were compared. Statistical significance was calculated using paired 
Student’s T-test with arcsine transformed data. Asterisks indicate p-value (***<0.001). A 
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To investigate spatiotemporal distributions of signalling molecules in Teffs and iTregs, GFP 
expressing T cells needs to be isolated. Prior to imaging, retroviral transduction was 
synchronised with Teff and iTreg induction. The transduction efficiency and percentage of 
GFP+ T cells vary in experiments with different GFP-tagged signalling sensors.  Therefore, 
we standardised our cell sorting strategy and isolated cells with high florescent signals, so 
that distributions of GFP-tagged molecules within T cells could be well identified in the 
fluorescent channel. We set a specific GFP+ sorting gate which is 1-1.5 log shift brighter 
than the negative population, to identify GFP+ cell populations with high fluorescent intensity.  
 
TCR stimulations from anti-CD3 might have impacts on percentages of GFP+ cells, as 
stronger TCR signals tend to enhance cell proliferation and influence retroviral transduction.  
Thus, we investigated whether activating cells using 1 or 10 µg/ml anti-CD3 would lead to 
different frequencies of GFP+ cells. GFP+ cell populations were compared using iTregs 
transduced with three different sensors (F-tractin-GFP, LAT-GFP and VAV1-GFP). Result 
(Figure 3.3) shows that there was no significant difference in percentages of GFP+ cells 
between cells activated with 1 and 10 µg/ml anti-CD3. Based on the results above, we 






Figure 3.3 Activating Tg4 naïve T cells with 1 µg/ml and 10 µg/ml anti-CD3 have same 
GFP expression 
GFP+ populations of Treg-induced Tg4 naïve T cells activated with 1 and 10 µg/ml anti-CD3 
were compared. Statistical significance was calculated using paired Student’s T-test with 
arcsine transformed data. NS: not significant. A total of nine experiments were analysed. 
Error bars indicate standard error of the mean.  
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3.5 Repeated freezing and thawing of TGF-β damage Foxp3 
expression 
Foxp3 intracellular staining was applied to confirm Tg4 iTreg populations. iTregs used to 
acquire live cell imaging data were all over 75% Foxp3+. In the first 10 repeated Tg4 iTregs 
induction experiments, Foxp3+ cell population showed inconsistency in the 1 and 10 µg/ml 
anti-CD3 group (Figure 3.1A). Notably, the TGF-β aliquots (aliquoted in 50 µl per vial, 
refrozen and used continuously, noted as “normal TGF-β”) used in these 10 experiments 
had gone through several freeze-thaw cycles. As one of the key factors which convert CD4+ 
naïve T cells into Foxp3 expressing iTregs (51), the potency of TGF-β is critical. We 
hypothesised that repeated freeze-thaw cycles would damage TGF-β activity and lower 
Foxp3 expression in Tg4 cells.  
 
To verify this, we carried out another 10 experiments with fresh TGF-β aliquots, noted as 
“fresh TGF-β” (aliquoted in 25 µl per vial, used on the same day when T cell cultures were 
prepared, each aliquot was subsequently disposed), shown as Figure 3.4B. Unlike the 
previous experiments, Foxp3+ cells treated with fresh TGF-β are more stable in both 1 and 
10 µg/ml anti-CD3 group. Fluctuation of Foxp3 expression is observed in the normal TGF-β 
group, which could be a result of constant freeze-thaw cycles of TGF-β. Results (Figure 
4.3C-D) also show that compared with cells induced with normal TGF-β, percentage of 
Foxp3+ of cell induced with fresh TGF-β is significantly higher in the both groups (p<0.05). 
These results indicate that in the first 10 experiments, the potency of TGF-β to induce 
Foxp3 expressing T cells was damaged owing to repeated freeze-thaw cycles. To avoid the 
loss of Foxp3 expression in following experiments, we used fresh TGF-β aliquots for each 
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Figure 3.4 Repeated freeze-thaw cycles of TGF-β result in lower Foxp3 expression  
Tg4 CD4+ naïve cells were primed with plated-bound anti-CD3/28 for 48 hours and cultured 
in Treg medium and on day 6 of culture, cells were stained with Foxp3 antibodies. Cells 
were induced with normal TGF-β (aliquots went through multiple freeze-thaw cycles) or 
fresh TGF-β (new aliquots for each experiment). Both data from cells primed with 1 and 10 
µg/ml anti-CD3 were analysed. Plot graph showing percentages of Foxp3+ cells induced 
with A) normal TGF-β and B) fresh TGF-β. Comparing Foxp3+ frequencies in cells induced 
with normal and fresh TGF-β primed with C) 1 µg/ml anti-CD3 and D) 10 µg/ml anti-CD3. A 
total of 20 experiments were used. Statistical significance was calculated using unpaired 
Student’s T-test with arcsine transformed data. Asterisks indicate p-values (*<0.05). Error 
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3.6 Priming Tg4 T cells with anti-CD3/28 leads to higher Foxp3 
expression, compared with cells primed with MBP Ac1-9 peptides 
and APCs 
During T cell recognition, CD4+ or CD8+ T cells bind antigenic peptides presented by MHC 
molecules on the surface of APCs, and once activated they continue to form an IS and 
eventually trigger their helper or cytotoxic functions (142). In peptide induced activation, T 
cells receive three activation signals from TCR-MHC interactions, co-stimulatory molecules 
and cytokines released by APCs (140, 141) . Tg4 transgenic TCRs recognise MBP peptides 
presented by APCs and initiate T cell activation, which is physiological comparable to 
antigen presentation in vivo. Previous studies have shown that CD103+ lamina propria DCs 
in the intestine can prove antigens, retinoic acid and TGF-β to induce generation of iTregs 
and pTregs (59). In this project, we have induced Tg4 Teffs from RBC-lysed splenocytes 
and lymphocytes primed with MBP peptide (data are shown in Chapter 4). However, this 
might not be the most effective priming method for iTregs generation.  Activating Tg4 naïve 
CD4+ T cells with MBP Ac1-9 [4K] and irradiated APCs for iTreg induction was shown to 
have lower frequencies of Foxp3+ cells than cells activated with anti-CD3/28 (139). Shevach 
and Thornton mentioned (53) that when inducing TCR transgenic Rag1 deficient mouse 
Tregs in the presence of DCs and anti-CD3, Foxp3+ cells among induced cells only ranged 
from 50%-60%. With anti-CD3/28 stimulation they could generate over 90% Foxp3+ cells, 
which is mostly applied for iTregs generation to date. They suggested this might be a result 
of DCs secreting pro-inflammatory cytokines such as IL-6, as IL-6 inhibits TGF-β-induced 
Treg differentiation and promtes generation of Th17 cells (143). Moreover, cytokines 
produced by APCs may also induce differentiation of other helper subsets, for example DC-
derived IL-12 meditates Th1 cell development (144). Therefore, T cells activated by peptide-
primed APCs receive more complete activation signals and are more comparable to cells 
activated in vivo.  To investigate whether peptide activation can be applied and optimised 
for iTreg induction, we activated Tg4 naïve T cells with endogenous APCs primed with MBP 
Ac1-9 [4K], with additional IL-2 and TGF-β to generate iTregs and compared their 
frequencies of Foxp3+ populations with those of anti-CD3/28-primed iTregs.  
 
Tg4 splenocytes and lymphocytes were initially lysed with RBC lysis buffer and primed with 
MBP Ac1-9 [4K] and cultured in Treg medium for five days.  Representative Foxp3 staining 
result shows that Tg4 naïve T cells could be induced into CD4+ Foxp3+ cells (Figure 3.5) in 
the presence of endogenous APCs presenting with MBP Ac1-9 [4K] peptides. Dominant 
CD4+ population remained (>95%) after culturing for five days and >88% cells were Foxp3+, 
suggesting that high frequencies of Tg4 Foxp3+ cells can be induced in the present of 
endogenous APCs presenting MBP peptides. 
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A direct comparison of Foxp3 staining results shows that (Figure 3.6) the percentage of 
Foxp3+ cells induced from anti-CD3/CD28 activated Tg4 naïve CD4+ T cells was 
significantly higher than cells activated by MBP Ac1-9 (4K) peptide-primed endogenous 
APCs (p<0.05). This indicates that transforming purified naïve CD4+ T cells into Tregs, 
rather than activating mixed splenocytes and lymphocytes with TCR specific peptide, leads 
to better iTreg generation in vitro. This is consistent with previous studies (53). However, 
the difference in frequencies of Foxp3+ cells was not dramatic, as cells from both groups 















Figure 3.5 Tg4 splenocytes and lymphocytes can be induced into CD4+ Foxp3+ cells 
when activated with MBP Ac1-9 (4K) peptide and endogenous APCs. 
Tg4 splenocytes and lymphocytes were harvested, primed with MBP Ac1-9 [4K] peptide 
and cultured for five days with IL-2 and TGF-β added, CD4 and Foxp3 staining was 
performed on day six. FACS plot shows CD4 vs Foxp3 and four quadrant gates are drawn. 






Figure 3.6 Tg4 CD4+ naïve T cells activated with anti-CD3/28 have higher Foxp3 
expression than cells activated with MBP Ac1-9 [4K] peptide and endogenous APCs. 
Foxp3+ frequencies of CD4+ naïve T cells activated with antibodies (anti-CD3 and anti-CD28) 
and native T cells activated with MBP Ac1-9 (4K) peptide and endogenous APCs were 
compared on day six of culture. Cells were stained for Foxp3. Error bars indicate standard 
error of the mean. Statistical significance was calculated using unpaired Student’s T-test 
with arcsine transformed data. Asterisks indicate p-values (*<0.05). A total of 20 
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3.7 Tg4 Foxp3+ cell populations remain after FACS sorting 
To generate live cell imaging data of iTreg activation, GFP+ Foxp3+ T cells needed to be 
identified. A direct method was to first sort GFP+ T cells and then validate their iTreg 
populations with Foxp3 intracellular staining. However, result (Figure 3.7) shows GFP 
fluorescence was impaired after intracellular staining. In this experiment, 11% of live cells 
transduced with F-tractin-GFP were GFP positive (upper plot), while after fixation and 
permeabilisation, less than 1% of the cells remained GFP positive (lower plot). It has been 
reported that the Foxp3 staining kit (eBioscience) resulted in complete loss of EYFP 
fluorescence, because of its insufficient fixation which failed to maintain fluorescent proteins 
within a cell (145). Alternatively, fixation could have destroyed the GFP fluorophore. 
Therefore, we were not able to directly identify Foxp3+ population among live GFP+ cells.  
 
An alternative method was to perform Foxp3 intracellular staining on pre-sorted cells and 
assume the percentage of Foxp3+ cells in pre-sorted and GFP+ cells to be the same. We 
need to consider whether Foxp3+ cell populations in FACS sorted GFP+ cells would remain 
the same as that in pre-sorted cells. Therefore, we set up an experiment to identify Foxp3+ 
cell populations among pre-sorted, sorted GFP- and GFP+ iTregs from day 6 of culture. 
Investigating frequencies of Foxp3+ cells in these three conditions helped us to check 
whether cells sorting would have impacts on percentages of Foxp3+ cells. Result shows 
(Figure 3.8) that the major cell population in both sorted GFP- (>80%) and GFP+ (>74%) 
cells are Foxp3+, comparable with that in unsorted cells (81.1%). This indicates that 
fluctuations of the frequency of Foxp3+ cells in pre-sorted, sorted GFP- and GFP+ cells were 
minor. It is reasonable and practical to use Foxp3 staining results from pre-sorted samples 
to deduce percentages of Foxp3+ cells, or iTregs in FACS sorted GFP+ cells. This method to 
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Figure 3.7 Fixation and permeabilisation lead to a loss of GFP+ signals. 
iTregs transduced with F-tractin-GFP were first sorted for GFP+ cells (upper plot) and then 
identified for Foxp3+ cells after fixation and permeabilisation (lower plot). FACS plots shows 
forward scatter (FSC) vs GFP and Foxp3 vs GFP, two square gates were drawn indicating 
GFP+ and GFP- cells in the upper plot, and quadrant gates are drawn in the lower plot. The 
percentage of each cell population was indicated within each gate. Data from one 
experiment were used. 
 
Figure 3.8 Major cell population remains Foxp3+ in sorted GFP- and GFP+ cells 
Foxp3 expression of pre-sorted cells, GFP- and GFP+ are compared. FACS plot shows 
Foxp3 vs forward scatter (FSC), a gate was drawn to indicate Foxp3+ cells based on 
unstained cells, and the number indicates the percentage of the population. One experiment 
is shown.  
35 
 
Chapter 3  
3.8 Discussion  
There are two main purposes in this chapter: Firstly, to induce Tg4 Foxp3+ iTregs, and 
secondly to validate retroviral transduction with GFP-labelled signalling sensors on iTregs 
for further live cell imaging experiments. 
 
Studies have demonstrated that IL-2 and TGF-β are indispensable in iTreg induction (51, 
66). In terms of activating naïve T cells for iTreg differentiation, stimulating purified CD4+ 
naïve T cells with anti-CD3 and anti-CD28 has been a common choice for their high efficacy 
of generating iTregs (>90% Foxp3+) (53, 146). Our results show that, when comparing 
frequencies of Foxp3+ T cells induced  by 1 and 10 µg/ml anti-CD3, the former generates 
cells with a higher Foxp3+ cell percentage, as recommended by a previous study inducing 
Tg4 iTregs (139). Moreover, thaw-freeze cycles have been shown to damage TGF-β activity 
and lower Foxp3 expression. We have optimised our anti-CD3/28-primed iTreg induction 
protocol. CD4+ naïve T cells were stimulated with 1 µg/ml anti-CD3 and 2 µg/ml anti-CD28, 
then cultured in complete medium with IL-2 and TGF- β. Only fresh TGF-β aliquots which 
had gone through only one freeze-thaw cycles (for aliquoting stocks) were used for culturing 
iTregs.  
 
Apart from iTreg induction using anti-CD3/28 antibodies, we have shown that in the same 
medium condition with IL-2 and TGF-β, Tg4 iTregs could be generated with TCR-specific 
peptide stimulation and endogenous APCs. Such activation is more physiological 
comparable to naïve T cell activation in vivo. MBP Ac1-9 [4K] peptides were added and 
presented by endogenous APCs to activated Tg4 naïve T cells. Day six Foxp3 staining 
shows that these cells were polarised to be CD4+ Foxp3+. In addition, for iTreg generation, 
activating naïve CD4+ T cells with plate-bound anti-CD3/28 or in the presence of APCs and 
TCR-specific peptides might have different impacts on Treg phenotypes. Helios from the 
Ikaros transcription factor family, has been shown to be a possible marker to distinguish 
tTregs and pTregs (147). Thornton et al have observed that Helios expression was found in 
all tTregs, and both human and mice Treg generated in vitro did not express Helios. 
However, Verhagen and Wraith (148) have reported that iTreg priming methods could 
change Helios expression: Tg4 Rag-deficient CD4+ splenocytes activated with MBP Ac1-9 
(4K) peptide and irradiated APCs could induce Helios expressing iTregs, which was not 
observed in plate-bound anti-CD3 and anti-CD28 activated ones. Further study revealed 
that Helios+ and Helios- Tregs display different suppressive abilities on autoreactive cells 
and TCR repertoires (149). Moreover, cells activated with anti-CD3/28 tend to have higher 
frequencies of iTreg populations than cells activated in the presence of APCs, this was 
consistently observed in this project and previous studies (53, 139). One possible factor 
contributing to the relatively low Foxp3 induction in the presence of APCs is IL-6 expression 
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at the activation site. IL-6 can be found in antigen-stimulated PBMCs and secreted by 
various cell types such as B cells, T cells, monocytes, fibroblasts and tumour cells (150). IL-
6 and TGF-β together have been shown to drive naïve T cells to become Th17 cells and 
inhibit TGF-β-induced Foxp3 expression (143). Th17 cells play opposite roles against Tregs 
by secreting pro-inflammatory cytokines such as IL-17, IL-21 and GM-CSF to promote 
inflammatory responses (151). Differentiations of Tregs and Th17 cells are both regulated 
by TGF-β and a balance between these two cell types can be shifted by cytokines as IL-2 
correspondingly inhibits Th17 differentiation (152, 153). It is likely that purified CD4+ T cells 
in antibody activation have less IL-6 in the culture because of fewer cell types. Therefore, 
identifying the Th17 cell population or level of IL-6 in antibody and peptide activated Tregs 
might help us to understand how Foxp3 expression is regulated by activation methods.  
 
Foxp3 staining on of iTregs on day 6 of culture was performed to verify iTres populations. 
An initial FACS staining experiment identifying Foxp3+ GFP+ cells have failed owing to the 
loss of GFP fluorescence after cell fixation and permeabilisation. This was very likely 
caused by the insufficient fixation of the Foxp3 staining kit (eBioscience) (145). In addition, 
the fluorescent protein used in this experiment, the F-tractin-GFP, is not a membrane 
associated protein and more likely to diffuse from cells after permeabilisation. Therefore, we 
used an alternative approach: To determine the percentage of iTreg cell populations in pre-
sorted cells and assume it to be the same as that in GFP+ cells. Intracellular staining shows 
that approximate iTreg frequencies were found in pre-sorted, sorted GFP- and GFP+ cells, 
which supports our assumption. In this project, most iTregs generated with both anti-
CD3/28 and MBP peptides priming raged from 60% to 90%, and cells used for iTregs 
imaging were mainly >75% Foxp3+. The threshold was set mainly owing to minor 
fluctuations of iTreg induction rates and therefore, these up to 25% systemic errors needed 
to be considered. Overinterpretations of differences found when comparing iTreg and Teff 
spatiotemporal distribution patterns should be avoid.  
 
In summary, with optimised iTreg induction protocol, we have generated Tg4 Foxp3+ iTregs 
in vitro and performed initial retroviral transduction experiments with three signalling 
sensors (F-tractin-GFP, LAT-GFP and Vav1-GFP) on Tg4 iTregs. Further functional assays, 
morphological studies and spatiotemporal patterning analysis in iTregs and Teffs would be 
conducted in the next chapter. The frequency of Foxp3+ cells activated with anti-CD3/28 
was significantly higher than that of cells activated by MBP Ac1-9 [4K] peptide and 
endogenous APCs. We would further compare these iTregs in terms of their morphology 
and spatiotemporal distribution patterns of LAT-GFP, TCR-ζ-GFP and F-tractin-GFP during 
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 Tg4 Teffs and iTregs: different cell functions, Chapter 4




As the differentiation protocol of Tg4 iTregs with high Foxp3 frequency was established, we 
could then investigate their biological characteristics, in comparison to Tg4 Teffs. There are 
three aspects in this project that we are interested in: immunological cell functions, 
morphological features and distributions of key signalling molecules in T cell activation. 
 
First, cell functional assays were applied to study and compare how Teffs and iTregs could 
impact CD4+ naïve T cell proliferation. Based on cytokine profiles, lineage-specific 
transcription factors and immunological functions, CD4+ T helper (Th) cells are mainly 
divided into several subsets: Th1, Th2, Th9, Th17, Tfh cells and Tregs (21). Tregs suppress 
immune responses and prevent autoimmunity. When co-cultured, CD4+ CD25+ Tregs are 
capable of suppressing CD4+CD25- T cell proliferation in the presence of APCs or soluble 
anti-CD3 or both, and inhibit IL-2 production of CD4+CD25- T cells. In the Tg4 model, when 
activated with MBP Ac1-9 peptide and irradiated APCs, Tg4 iTregs suppress naïve CD4+ T 
cell proliferation (139).  
 
However, these studies focused on investigating Treg-induced suppression in co-culturing 
conditions where activated responder T cells are mixed with Tregs with certain ratios, while 
parallel assessments of the effect of adding Teffs were usually missing. Therefore, we 
performed T cell suppression assays by co-culturing CTV labelled naïve Tg4 T cells with 
Tg4 Teffs or iTregs, to investigate their impacts on naïve CD4+ T cell proliferation. In MBP 
Ac1-9 triggered T cell activation, Th1 response is the dominant effector pathway in Tg4 
CD4+ T cells and they are capable to secrete IFN-γ (154). Thus, we mainly characterised 
and compared Tg4 Th1 cells in Teffs with Foxp3+ iTregs.  
 
T cell functions are usually related with their cytokine profiles. As one of the signature 
cytokines of Th1 cells, IFN-γ induces activation of macrophages, stimulates IgG production 
of B cells and promote cytotoxic T cell differentiation in defence against microbial infections 
(155). In contrast, IL-10 is an immunoregulatory cytokine expressed by different cell types 
such as macrophages, DCs, Th1, Th2, Tr1 and NK cells (156). It has been found to 
naturally suppress inflammatory reactions in skin and IL-10 knockout mice develop chronic 
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enterocolitis (157, 158). IL-10 has been related with Treg mediated immune suppression 
(159) and both Foxp3+ and Foxp3- Tregs are capable of secreting cytokine IL-10 (68, 160, 
161). To further compare functions of Tg4 Teffs and iTregs during T cell activation, we 
investigated their expression and secretion of these two distinct cytokines, IFN-γ and IL-10 
by utilising intracellular cytokine staining and ELISAs. 
 
Secondly, with defined morphological parameters, we assessed and compared cell shapes 
of Teffs and iTregs during their activation. Dynamic morphological changes of T cells during 
antigen recognition were observed in early studies (162, 163). Interaction of T cells and 
antigen-presenting B cells was found to undergo three stages (contact, recognition and 
stabilisation), which could last > 20 minutes (163). First, a T cell starts to explore around a B 
cell (contact) and then move towards the B cell and covers a part of its surface (recognition). 
In the third stage (stabilisation), the T cell partially retracts from the B cell and forms a round 
shape. After a cell couple is stable, the T cell will not seek to interact with other B cells.  
Rounder T cell shape has been found to be positively related with increasing intracellular 
Ca2+ concentration (162, 163). When forming a stable conjunction with DCs, naive CD4+ T 
cells were found to become flattened and went through either elongated-flattened or round-
flattened morphological changes during the IS formation (164). Compared with elongated-
flattened CD4+ T cells, higher level of Ca2+ signalling, increased accumulation of TCR-
signalling molecule and F-actin were found in the IS of round-flattened CD4+ T cells (164). 
This indicates the former might lead to less effective T cell activation and weaker immune 
response. To evaluate and compare morphological changes in Tg4 Teffs and iTregs, we 
defined an extended lamella region and four morphological parameters (interface width, cell 
width, lamella depth and cell depth), described in chapter 2. Between Teffs and iTreg, we 
compared their relative interface width (the ratio of interface width to cell width), relative 
lamella depth (the ratio of lamella depth to cell depth) and overall cell shape (the ratio of 
lamella depth to interface width). A wider interface is indicative of a stable T cell-APC 
interaction which physically promotes binding of TCR-pMHC, co-receptors and adhesion 
molecules and improves activation. A longer lamella indicates a more elongated shape of a 
T cell, which is associated with weaker T cell activation (164). Thirdly, cells with an 
extended lamella region or a high ratio of lamella depth to interface width likely to show a 
slender cell shape, as it has a long lamella or narrow interface or both and forms a less 
stable and compressed cell couple. Clark et al have shown that within the first two minutes 
of T cell activation, recruitment of proximal T cell signalling intermediates (such as LAT and 
SLP-76) is critical for efficient T cell activation (126). Dynamic morphological changes of T 
cells within these two minutes are likely to play roles in T cell activation. Therefore, in this 
study we measured and compared morphological parameters within the first two minutes of 
Teff and iTreg activation. 
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Finally, it is of great interest to investigate how key signalling molecules during T cell 
activation localise in Tg4 Teffs and iTregs, as previous studies show that diverse 
spatiotemporal patterning of signalling intermediates are closely associated with T cell 
activation (130, 134). Moreover, diminishing F-actin structures impaired activation of key 
components of T cell activation and calcium signalling (165), and manipulation of LAT 
localisation alters T cell signalling and effector functions (126). In this chapter, we 
selectively investigated and compared spatiotemporal distributions of five key signalling 
intermediates (LAT, TCR ζ chain, PKC-θ, Vav1 and F-actin) during early activation of Tg4 
Teffs and iTregs.  
 
As one of the key component of the cSMAC, LAT associates with key molecules to 
transduce and amplify proximal TCR signalling. LAT nucleates a signalling complex by not 
only binding signalling proteins such as Grb2, PLC-γ1, and Gads via their SH2 domain, but 
also associating crucial molecules for T cell activation like Cbl, SOS, Vav1 and SLP-76 (97, 
166, 167). Rapid LAT signalosome assembly is associated with dynamic actin network after 
TCR triggering, and actin mediated cytoskeleton assists initiation and maintenance of TCR-
pMHC interactions (168). F-actin accumulation has been found to contribute T cell 
morphological changes and stabilise the IS formation (164), and its polymerisation and 
redistribution at the distal SMAC (dSMAC) and pSMAC at the IS drive TCR microcluster 
towards the cSMAC (169). In summary, we would track and compare localisation of these 
five different but related signalling molecules (LAT, TCR ζ chain, PKC-θ, Vav1 and F-actin) 
during Teff and iTreg activation and investigate their roles in effector and regulatory 
functions. 
 
The seven distinct spatiotemporal patterns defined hold different roles in T cell activation 
(134). Representing the cSMAC, the central accumulation at the interface is related with 
proximal TCR-induced signalling including CD3, TCR-ζ, CD28, Lck, ZAP-70 and LAT, which 
initiate early T cell activation (121, 130, 134). The invagination pattern is preliminarily 
regarded as a reduced central pattern, as T cell invagination removes receptors like CD2 
from the centre of the interface and mediates resetting of proximal T cell signalling (170). 
The peripheral pattern represents the pSMAC which covers the periphery of the IS interface 
and is enriched with actin accumulation (121, 134, 171). The asymmetric pattern shows an 
individual smaller protrusion near the interface, driven by actin (134). A transient lamellal 
signalling network supported by a deep actin matrix represents the lamellal pattern, which 
was prominently found in key activation regulators such as SLP-76 (135). Lamellal 
signalling intermediates covering the entire interface localise similarly with actin, and such 
lamellal distributions are related with signal modulation and amplification (134, 135). The 
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diffuse pattern covers the entire interface and localises near the membrane showing both 
central and peripheral features, which currently needs more functional studies to define their 
biological roles (134). The six patterns above describe accumulation at the interface while 
the last pattern, the distal pattern denotes proteins moving away from the interface to the 
distal pole during T cell activation, and disrupting the formation of this distal pole complex 
impairs cytokine secretion (172). Therefore, spatiotemporal organisation of signalling 
intermediates in early T cell activation could be quantitatively analysed and compared with 
the seven patterns. In addition, large-scale imaging data of sensors of interest (in this 
project, LAT-GFP) could be analysed in parallel by a recently established computational 
approach, as an automated alternative (173). 
 
 
4.2 Chapter aims 
• To assess and compare suppressive abilities and cytokine production of IFN-γ and 
IL-10 of Tg4 Teffs and iTregs. 
• To measure and compare morphological parameters of Tg4 Teffs and iTregs within 
the first two minutes of T cell activation. 
• To acquire and compare live cell imaging data of five key signalling intermediates 
(LAT, TCR ζ, PKC-θ, Vav1 and F-actin) of Tg4 Teffs and iTregs in early T cell 
activation. 
 
A table is shown below denoting symbols used in this chapter for different cell types  
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4.3 Tg4 Teffs and iTregs suppress Tg4 naïve CD4+ T cell 
proliferation in the presence of APCs 
To characterise Tg4 iTregs and Teffs, we first studied and compared their immunological 
features including suppressive functions and cytokine production (IFN-γ and IL-10). 
 
iTregs are capable of suppressing activation and proliferation of CD4+ T cells (174). To 
assess their suppressive ability on T cell activation and proliferation, we set up suppression 
assays by co-culturing responder Tg4 naïve T cells with Teffs or iTregs, and CTV labelling 
was used to track cell proliferation. iTregs used for suppression assays were anti-CD3/28-
primed and >75% Foxp3+ and Teffs were primed with MBP Ac1-9 [4K] and they were 
cultured in relevant medium for five days in advance. We defined control and experimental 
wells and the first experiment was prepared as the following settings: In a control well, CTV 
labelled Tg4 naïve CD4+ T cells were co-cultured with PL8 cells (as APCs) and primed with 
MBP Ac1-9 [4K], 1:0.25 ratio (8 x 105 naïve T cells and 2 x 105 PL8 cells).  In the 
experimental wells, with same cells added as in a control well, Tg4 CD4+ Teffs or iTregs 
were added, with 1:0.25:0.25 ratio (8 x 105 naïve T cells, 2 x 105 PL8 cells and 2 x 105 Teffs 
or iTregs). All cells were cultured for 72 hours before analysis. In addition, 2.5 x 105 naïve 
CD4+ T cells labelled with CTV were fixed on day one to indicate fluorescent intensity of 
naive T cells which did not divide. CTV fluorescent signals were compared among all live 
CD4+ cells. Results show that (Figure 4.1 A) in the control well (peaks in orange), naïve T 
cells proliferated and divided for at least five times. About 3% of CTV+ cells went through 
five cell divisions and less than 2% of the cells did not divide. Unexpectedly, in both 
experimental wells, suppression on cell proliferation was observed. In the well with Teffs 
(Figure 4.1 A, peaks in red), only 0.2% of CTV+ cells divided five times and 15% of them did 
not divide. In the well with iTregs (Figure 4.1 A, peaks in green), 0.1% of the CTV+ cells 
divided five times and 18% of them did not divide. These observations indicate that both 
Teffs and iTregs suppressed naïve T cell proliferation when co-cultured with APCs 
presenting the MBP Ac1-9 peptide.   
 
Next, we increased ratio of Teffs/iTregs to responder cells (from 1:0.25 to 1:1) to investigate 
how this would impact the suppression. In this setting, CTV+ naïve cells in all wells were 
titrated down to 5 x 105. In the control well, the same amount of PL8 cells (5 x 105) were 
added. In the experimental wells, PL8 cells and Teffs or iTregs were added with equal 
number of cells (5 x 105) to corresponding wells (1:1 ratio). Results (Figure 4.2 B) show that 
in the control well (peaks in orange), naïve T cells proliferated but fewer cell divisions were 
observed: 6% of CTV+ cells went through three cell divisions and 28% did not divide. In the 
well with Teffs (Figure 4.2 B, peaks in red), only 3% of CTV+ cells divided and 97% of the 
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cells remained undivided. Only one clear peak was observed and hardly any cells divided 
for more than once. In the well with iTregs (Figure 4.2 B, peaks in green), 12% of the CTV+ 
cells divided and 87% of them remained undivided. It was undistinguishable whether these 
cells divided for more than once but very unlikely.  
 
These results show that in conditions with different cell ratios, Teffs and iTregs showed a 
comparable ability to suppress naïve CD4+ T cell proliferation in the presence of PL8 cells 
with MBP Ac1-9 [4K] added in the culture.  When comparing CTV+ cell proliferation across 
these two experiments, suppression was prominently enhanced by increasing the ratio of 
Teffs or iTregs to responder cells (from 1:0.25 to 1:1), suggesting suppression on naïve T 
cells was positively associated with the proportion of Teffs or iTregs in the co-culture. 
However, increasing the ratio of PL8 cells to responder cells also enhanced the suppression 
(peaks in orange, Figure 4.2), though not as effective. It was unclear whether this 
observation was experimental variance, as there were the only two experiments where the 
suppression induced with different ratios of PL8 cells to responder cells could be compared.  
If not, it might indicate that a low ratio of PL8 cells to naïve CD4+ T cells (0.25:1) is sufficient 
to promote cell proliferation, while a higher ratio of PL8 cells to naïve CD4+ T cells (1:1) 
could inversely inhibit their proliferation. Although treated with mitomycin C, nutrient 




















































Figure 4.1 Teffs and iTregs suppress naïve CD4+ T cell proliferation in the presence of 
APCs. 
CTV labelled native CD4+ T cells were co-cultured with Teffs or iTregs and activated by 
MBP Ac1-9 [4K] peptide. FACS staining were performed after 72 hours of culture to identify 
live CD4+CTV+ population. A and B) Histograms showing CTV cell population in four 
conditions with cell numbers and ratios indicated. Divisions indicate times that CTV+ cells 
had divided, Cell types, numbers and ratios are indicated on the right of each row. Each 
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4.4 Clone 4 CD8+ Teffs suppress Tg4 naïve CD4+ T cell proliferation 
in the presence of APCs 
Results above show that when activated by MBP Ac1-9 [4K]-primed PL8 cells, both Tg4 
Teffs and iTregs suppressed Tg4 naïve CD4+ T cell proliferation. The suppression induced 
by Teffs and iTregs raised a question: did the existence of a second T cell population 
contribute to the suppression observed or Teffs and iTregs both suppress proliferation of 
naïve T cells? The suppression observed might be owing to a competition for nutrients and 
cytokines such as amino acids and IL-2, in a well with three cell types. To investigate this, 
we replaced CD4+ Teffs with CD8+ Teffs from a different transgenic mouse model, the 
Clone 4 model. Clone 4 mice are transgenic for a TCR  that recognises an MHC class I H-
2Kd restricted influenza hemagglutinin (HA) peptide (175).  
 
In this experiment, same numbers of CD4+ CTV+ naïve T cells and PL8 cells were added to 
all wells, 5 x 105 each, 1:1 ratio. Two sets of ratios were adjusted in the experimental wells. 
In wells with iTregs, either 1 x 105 or 5 x 105 iTregs were added. The ratios of CD4+ CTV+ 
naïve T cells to PL8 cells to iTregs were set to be 1:1:0.2 and 1:1:1 in wells with iTregs. 
Same number of cells and ratios were applied in wells with Clone 4 CD8+ T cells, but HA 
peptide was not added. As Clone 4 CD8+ cells were expected to hold a low affinity for the 
MBP Ac1-9 peptide, they were unlikely to be activated by PL8 cells, thus to keep them 
proliferating, supplementary IL-2 was added.  
 
Results show that in the control well (Figure 4.2, peaks in orange), CTV+CD4+ T cells went 
through up to five cell divisions with six clear peaks. About 14% of them divided five times 
and 5.2% did not. In the well with 1 x 105 CD4+ iTregs (Figure 4.2, peaks in light green, 
1:1:0.2 ratio), five clear peaks were identified. About 6% of CD4+ CTV+ T cells divided for at 
least four times and 26% of them did not divide. Suppression was still found in this well as 
when compared with the control well, more cells remained undivided and barely any cells 
divided for five times. In a well with 5 x 105 iTregs (Figure 4.2, peaks in dark green, 1:1:1 
ratio), only two clear CTV+ peaks were detected and about 13% of CD4+ CTV+ cells 
underwent one cell division. Most CD4+ CTV+ cells, about 87% did not divide. These results 
combined show that the level of suppression was related with the number of iTregs in the 
co-culturing well. More iTregs led to stronger suppression on CD4+ naïve T cell proliferation.  
 
Similar results were found upon addition of Clone 4 CD8+ Teffs, as a control for suppressive 
Treg functions. In the well with 1 x 105 CD8+ Teffs (Figure 4.2, peaks in light blue, 1:1:0.2 
ratio), CD4+ CTV+ cells underwent only one cell division (16%), with two clear CTV+ peaks 
found. In the well with 5 x 105 CD8+ Teffs (Figure 4.2 peaks in dark blue, 1:1:1 ratio), more 
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CD4+ CTV+ cells remained undivided (91%) and the rest only divided for once. Together 
with the two experiments above, these results indicate that suppression on Tg4 CD4+ naïve 
T cell proliferation can be induced by co-culturing them with Tg4 CD4+ Teffs, Tg4 iTregs or 
Clone 4 CD8+ Teffs in the presence of PL8 cells presenting the MBP peptide. Therefore, this 
suppression observed might not be specifically induced by one certain type of T cells we 
used here, but by a combination of PL8 cells and an additional Teff/iTreg population. 
However, it was uncertain if the mechanisms of such suppression induced by these three 




Figure 4.2 Clone 4 Teffs suppress Tg4 CD4+ naïve T cell proliferation in the presence 
of APCs. 
Tg4 native CD4+CTV+T cells were co-cultured with Tg4 iTregs or Clone4 CD8+ Teffs and 
activated by MBP Ac1-9 [4K] peptide for 72 hours. FACS staining was performed to identify 
live CD4+CTV+ population. Histograms show CTV cell population in six conditions. Divisions 
indicate times that CTV+ cells had divided. Cell types, numbers and ratios are indicated on 
the right of each row. IL-2 was added to activate Clone 4 CD8+ Teffs. Data from one 
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4.5 Tg4 naïve T cells primed with anti-CD3/28 are not suppressed 
by Tg4 iTregs 
Simplified co-culturing conditions could help to investigate this suppression better. To 
validate this idea, we changed the activation method for the naïve T cells in wells by 
replacing PL8 cells with anti-CD3/28 antibodies. Thus, we could study whether suppression 
observed above was associated with the presence of APCs. We set up two repeated 
independent experiments without PL8 cells and MBP peptide and used anti-CD3/28 to 
provide TCR  activation and co-stimulatory signals. Other conditons remained the same as 
above except that IL-2 was no longer added to wells containing Clone 4 CD8+ Teffs. 
 
In the first experiment, four clear CTV+ peaks were found in the control well (Fgiure 4.3 A, 
peaks in orange) indicating CTV+ cells underwent up to three divisions. Less than 2% of the 
cells divided four times and 20% of them remained undivided. In a well with 1 x 105 Tg4 
Teffs (Figure 4.3 A, peaks in pink, 1:0.2 ratio), CTV+ cells had undergone up to four cell 
divisions. About 16% of the cells divided four times and 9% of them did not divide. In the 
other well with 1 x 105 Tg4 Teffs (Figure 4.3 A, peaks in red, 1:1 ratio), 18% of CTV+ cells 
have divided for four times and lest than 2% of them did not divide.  In both wells with Tg4 
CD4+ Teffs, CTV+ naïve T cells went through the same number of cell divisions and no 
suppression was observed. Moreover, the proliferation rate of CTV+ cells co-cultured with 
Tg4 CD4+ Teffs was increased because more of them had divided for four times and fewer 
of them remained undivided, compare to the control well.  
 
Similar observations were found in wells with Tg4 iTregs and Clone 4 CD8+ Teffs. In the 
well with 1 x 105 Tg4 iTregs (Figure 4.3 A, peaks in light green, 1:0.2 ratio), 13% of CTV+ 
cells underwent four cell divisions and 13% of them did not divide. In the well with 5 x 105 
Tg4 iTregs (Figure 4.3 A, peaks in green, 1:1 ratio), 18% of CTV+ cells underwent four cell 
divisions and only 2.9% of them remained undivided. In the well with 1 x 105 Clone 4 CD8+ 
Teffs (Figure 4.3 A, peaks in light blue, 1:0.2 ratio), 12% of CTV+ cells underwent four cell 
divisions and 13% of them did not divide. More CTV+ cell (32%) had undergone four cell 
divisions in the well with 5 x 105 Clone 4 CD8+ Teffs (Figure 4.3 A, peaks in blue, 1:1 ratio) 
and less than 4% of them remained undivided. No suppression on the proliferation of CTV+ 
cells in all these wells was observed. In contrast, their proliferation was enhanced in all 
wells with Tg4 CD4+ Teffs, Tg4 iTregs or Clone 4 CD8+ Teffs because more CTV+ cells 
divided four times (>11%), compared with the control (1.4%). Possibly, additional Teffs or 
iTregs activated by anti-CD3/28 (without MHC restriction) contributed to the pool of IL-2, 
which promoted better proliferation of naïve T cells. 
47 
 
Chapter 4  
 
In the second repeated experiment (Figure 4.3 B), similar results were observed. In the 
control well (Figure 4.3 B, peaks in orange), about 3% of CTV+ cells had undergone five cell 
divisions and 8% of them did not divide. In this epxeriment, CTV+ peaks in experimental 
wells with Tg4 CD4+ Teffs, Tg4 iTregs and Clone 4 CD8+ Teffs displayed similar patterns. 
CTV+ cells in both control and experimental wells had undergone at least five cell divsions. 
Again, no suppression was found.  
 
In summary, results combined show that when activaed with anti-CD3/28,  Tg4 naïve CD4+ 
T cell proliferation was not suppresed by iTregs, CD4+ or CD8+ Teffs. Tg4 CD4+ naïve T 
cells activated by anti-CD3/28 underwent up to four or five cell divsions when PL8 cells 
were absent. Suppression was found in all wells co-culturing Tg4 CD4+ naïve T cells with 
Tg4 CD4+ Teffs, iTregs or Clone 4 CD8+ Teffs in the presence of MBP peptide-primed PL8 
cells. Higher ratio of PL8 cells might partially suppress naïve T cell prolifeartion. Our results 
suggest that interactions between Tg4 CD4+ Teffs, iTregs or Clone 4 CD8+ Teffs with PL8 
cells evidently suppress Tg4 CD4+ naïve T cell proliferation.  The presence of PL8 cells is 
critical for the suppression to occur but the mechnism of suppression in each condition 
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Figure 4.3 When activated with anti-CD3/28, Tg4 CD4+ naïve T cell proliferation was 
not suppressed by Tg4 CD4+ Teffs, iTregs or Clone 4 CD8+ Teffs.  
Tg4 native CD4+CTV+T cells were co-cultured with Tg4 iTregs or Clone4 CD8+ Teffs and 
activated by anti-CD3/28 for 72 hours. FACS staining was applied to identify live CD4+CTV+ 
population. A and B) Histograms show CTV cell population in eight conditions. Divisions 
indicate times that CTV+ cells had divided. Cell types, numbers and ratios are indicated on 
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4.6 Tg4 Teffs secrete more IFN-γ and iTregs tend to maintain IL-10 
secretion during their development 
Since suppression assays were not be able to distinguish and compare functional impacts 
of Tg4 Teffs and iTregs on Tg4 naive T cells, we then studied their cytokine profiles to 
further inverstigate funtional differences of Tg4 Teffs and iTregs. As mentioned previsouly in 
section 4.1, IFN-γ is critical in inducing immune response against pathogens while IL-10 is a 
key immuesuppressive molecule. Therefore, to assess their effector and suppresive 
fucntion, we studied IFN-γ and IL-10 secretion in Teffs and iTregs.  
 
The combination of phorbol myristate acetate (PMA) and ionomycin is an effective method 
to promote cytokine secretion by T cells, as PMA specifically activates the PKC signalling 
pathway and ionomycin increases Ca2+ influx (176). Thus here we used PMA/ionomyin to 
stimulate Tg4 Teffs and iTregs and study their cytokine secretion. Teffs and iTregs on day 6 
of culturing were harversted and restimulated with 100ng/ml PMA and 1ug/ml Ionomycin for 
1 hour. GolgiStop (BD Bioscience) was then added to the culture to block protein transport 
and increase cytokine accumulation. Intracellular staining was applied to identify IFN-γ and 
IL-10 production after another 3 hours of incubation. For experiments done at early stage of 
this project, iTregs were mainly induced with anti-CD3/28 activation. MBP Ac1-9 [4K]-
primed Teffs and anti-CD3/28-primed iTregs (>74% Foxp3+) were inititaly used for cytokine 
staining experiments. Results (Figure 4.4) show that  frequences of IFN-γ+ or IL-10+ Teffs 
and iTregs on day 6 of culture were not significantly different. The mean percentage of IFN-
γ+ Teffs (Figure 4.4 A) was 8% and iTregs was  5%. Freqencues of IL-10+ Teffs and iTregs 
were even lower (Figure 4.4 B). The mean freqence of IL10+ Teffs was less than 1% and 
that of iTregs was less than 0.5%. This indicates that PMA and Inomycin restimulated Teffs 
and iTregs on day 6 of culture, barely secreted IL-10. The levels of IFN-γ secretion of Teffs 
and iTregs were slightly higher. These data imply that after five days of culture, PMA and 
Inomycin restimulated Teffs and iTregs showed a weak ability to secrete cytokines. 
Therefore, we then inverstigated how the production of these cytokines changed during Teff 
and iTreg differetiation after initial cell priming.  
 
We had switched from the anti-CD3/28 to MBP peptide priming method to induce iTregs 
during the project. MBP peptide-primed iTregs were more comparable with Teffs which 
were primed with the same method, and more comparable to pTreg ELISAs were 
perfomred on MBP peptide-primed T cells, except for one experiment in IFN-γ ELISAs using 
data from anti-CD3/28-primed iTregs (Figure 4.4 C). Its secretion pattern was not different 
from the peptide-primed iTregs so this set of data was also plotted. After cells were peptide 
or antibody-primed on day 1, we collected cell culture supernatants from Teff or iTreg-
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inducing conditions and performed IFN-γ and IL-10 ELISAs on samples from five days of 
culture (Day 2-6). Foxp3 intracellular staining was performed on day 6 to identify Treg 
population and iTregs used in IFN-γ ELISAs were >64% Foxp3+, in IL-10 ELISAs were >63% 
Foxp3+. Results (Figure 4.4 C) show that IFN-γ was dectected in both Teff and iTreg-
inducing condtions. The amounts of IFN-γ dectected over the five days in Teff-inducing 
conditions were significantly higher (p<0.05) than those in iTreg-inducing conditions. When 
comparing IFN-γ concentrations on individual days, significantly higher levels of IFN-γ 
(p<0.01) were detected in Teff-inducing conditions on day 3 and 4 of culture, compared to 
that in iTreg-inducing conditions. Mean concentrations of IFN-γ detected in Teff-inducing 
conditions on days 4-6 were higher than that in iTreg-inducing conditions, but the 
differences were not significant. In addition, IL-10 secretion was also detected in both Teff 
and iTreg-inducing conditions (Figure 4.4 D). However, no significant differences were 
found when comparing daily or overall IL-10 production of the two conditions. More IL-10 
was detected in Teff-inducing conditions on day 2, 3 and 4 while more was found in iTreg-
inducing conditions on Day 6. These indicate that during five days of culture, IL-10 was 
transiently released into cell culture in both conditions, and iTreg-inducing cells tended to 
secrete more sustained but relatively low amounts of IL-10 from day 4. 
 
IFN-γ and IL-10 secretion increased from day 2, peaked on day 3 of culture and decreased 
afterwards in both conditons. It should be noted that cell medium was exchanged on daily 
base and most cells were split 1:2 on day 3-6. This could contibute to the peak accmulation 
of IFN-γ and IL-10 on day 3 and relatively low cytokine serection after day 3. 
 
Low levels of IL-10 were detected during Teff and iTreg development, and  restimulation 
using PMA and inomycin did not enhance IL-10 production. It was previsouly shown that 
antigen-specific iTregs were able to produce IL-10 when co-cultured with peptide-pulsed 
DCs for 18 hours (177). Therefore, we restimulated Teffs or iTreg (>62% Foxp3+) from day 
5 of culture with mitomycin C treated PL8 cells and MBP peptides to investigate their ability 
to produce IL-10 upon restimulation (Figure 4.4 E). The result shows that restimulated 
iTregs produced slightly more IL-10 than Teffs, but the difference was not significant.  
 
In summary, these results show that when restimulated with PMA and ionomycin on day 6 
of culture, low levels of INF-γ were detected in Teffs and Tregs. IL-10 secretion was hardly 
found in either conditon. ELISAs show that IFN-γ and IL-10 were both detected during the 
development of Teffs and iTregs and more IFN-γ production was found in the former. In 
additon, iTregs showed a trend to maintain IL-10 production at later stages of their 
development and produce more IL-10 when restimulated with MBP peptide and PL8 cells. 
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These data suggest that Tg4 iTregs produce less IFN-γ but hold a better ability to produce 
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Figure 4.4 Less IFN-γ secretion was detected during iTreg development. 
Intracellular cytokine staining and ELISA were performed to assess IFN-γ and IL-10 
production of Teffs and iTregs. Teffs and iTregs on day 6 of culture were restimulated with 
PMA and Ionomycin for 1 hour and then treated with GolgiStop protein transport inhibitor for 
3 hours before cytokine staining. Intracellular cytokine staining showing A) IFN-γ+ and B) IL-
10+ cell populations of Teffs and iTregs on day 6 of culture. Data from four experiments 
were arcsine-transformed and statistical significance was calculated using paired Student’s 
T-test. Cell culture supernatants used for ELISAs were daily collected from cell culture of 
Teffs and iTregs for five days (day 2 to 6 of culture). ELISAs showing C) IFN-γ and D) IL-10 
detected in Teff and iTreg-inducing cell culture from day 2 to 6. Data from five experiments 
were used for IFN-γ ELISAs and six for IL-10 ELISAs. Teffs and iTregs from day 5 of culture 
were restimulated with mitomycin C treated PL8 cells and MBP peptides and cell culture 
supernatants were collected for E) Determining IL-10 secretion by restimulated Teffs and 
iTregs on day 5. Statistical significance was calculated using C-D) Two-way ANOVA and E) 
paired Student’s T-test. Asterisks indicates p-values (*<0.05, **<0.01). Error bars indicate 
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In addition, to identify how cytokine secretion was correlated with Foxp3 expression, we 
performed intracellular staining on another sets of cells to examine Foxp3+ cell population 
during Teff and iTreg development. Result shows (Figure 4.5) that the percentage of Foxp3+ 
T cells in iTreg-inducing conditions was significantly higher than that in Teff-inducing 
conditions (p<0.0001), from day 3 to 6 of culture. With additional TGF-β and higher 
concentration of IL-2, naïve T cells were effectively transformed into Foxp3+ iTregs from day 
3 and Foxp3+ cell population gradually increased afterwards. The frequency of Foxp3+ 
iTregs peaked on day 5. Foxp3+ cell population was hardly detected in Teff-inducing 
conditions in any day of culture. This indicates that the cell types in Teff and iTreg-inducing 
conditions were different from day 3 to 6 of culture, which should be noted when comparing 







Figure 4.5 TGF-β and a higher concentration of IL-2 significantly induced Foxp3+ 
iTregs. 
Purified lymphocytes and splenocytes were primed with MBP Ac1-9 [4K] and induced into 
Teffs (50 U/ml IL-2) and iTregs (100 U/ml IL-2 and 10 ng/ml TGF-β) for five days. Cell 
samples were collected, fixed and stained for Foxp3 antibody on each day. Data from four 
experiments were analysed. Statistical significance was calculated with arcsine transformed 
data using Two-way ANOVA. Asterisks indicated p-values (****<0.0001). Error bars indicate 




Chapter 4  
As IFN-γ secretion was mainly detected on day 3 and 4, we next performed cytokine 
staining on Teff and iTreg-inducing T cells from these days to identify IFN-γ producing cell 
populations. Protocol was followed as described earlier in this section. Cells were stained 
with CD4, Foxp3 and IFN-γ antibodies to separate Foxp3- IFN-γ+ Teffs and Foxp3+ IFN-γ+ 
iTregs. Result (Figure 4.6 A) shows that frequencies of Foxp3- IFN-γ+ Teffs and Foxp3+ IFN-
γ+ iTregs on day 3 and 4 of culture were not significantly different and were both around 
100%. This suggests that Teffs and iTreg on day 3 and 4 of culture are prominent producers 
of IFN-γ and highly activated. To assess the expression level of IFN-γ within IFN-γ+ T cell 
populations, the median fluorescence intensity (MFI) of IFN-γ+ populations was compared. 
Result (Figure 4.6 B) shows that both Foxp3- Teffs and Foxp3+ iTregs had higher level of 
IFN-γ expression on day 3 but the MFI of IFN-γ+ cells among these two groups on day 3 
and 4 was not significantly different.  
 
Together, we have investigated IFN-γ and IL-10 expression during Teff and iTreg 
developments (day 2 to 6 of culture). IFN-γ expression was mainly detected in Teff and 
iTreg-inducing conditions on day 2 to 4, and IL-10 expression was mainly found on day 3 
and 4 (but with relatively low concentration). Both cytokines were barely detected on day 5 
and 6. More IFN-γ was detected during the development of Teffs, compared to that of 
iTregs but iTregs displayed a trend of maintaining IL-10 secretion during their development. 
This suggests these mature iTregs will be more suppressive once reactivated. Intracellular 
cytokine staining assays showed that Foxp3- Teffs and Foxp3+ iTregs on day 3 and 4 were 
genuine sources of IFN-γ. In addition, restimulation with PMA and Ionomycin was not able 






















Figure 4.6 Teffs and iTregs were prominent producers of IFN-γ on day 3 and 4 of 
culture. 
Intracellular cytokine staining was performed to assess IFN-γ expression of Teffs and iTregs 
on day 3 and 4 of culture. Teffs and iTregs on day 3 of culture were restimulated with PMA 
and Ionomycin for 1 hour and then treated with GolgiStop protein transport inhibitor for 3 
hours. Cells were stained with CD4, Foxp3 and IFN-γ to identify Foxp3-IFN-γ+ Teffs and 
Foxp3+IFN-γ+ iTregs. A) Comparing percentages of IFN-γ+ cells between Foxp3- Teffs and 
Foxp3+ iTregs from day 3 of culture. B) Comparing MFIs of IFN-γ+ cells of Foxp3- Teffs and 
Foxp3+ iTregs from day 3 of culture. Data were from three experiments and statistical 
significance was calculated using paired Student’s T-test, ns, not significant. Error bars 
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4.7 Tg4 iTregs form a less stable IS in early T cell activation  
To quantify cell shape changes during early T cell activation, we defined three 
morphological ratios based on measurements of four parameters (described section 2.10): 
the ratio of interface width to cell width, lamella depth to cell depth and lamella depth to 
interface width. These three ratios could quantify the level of widening and extension of a 
cell. Live cell imaging was performed to record T cell-APC interactions between Tg4 T cells 
transduced with GFP-sensors and peptide-primed PL8 cells, as APCs. PL8 cells were 
pulsed with MBP Ac1-9 [4Y] for at least 4 hours before imaging. Morphological 
measurements were done on DIC images. We have measured the four parameters in both 
MBP Ac1-9 [4K] and anti-CD3/28-primed Teffs and iTregs (transduced with LAT-GFP) for 
the first two minutes after a stable cell couple was formed. 
 
Representative imaging data showing measurements of four morphological parameters are 
aligned in Figure 4.7 A. A T cell was identified whether they formed an extended lamella, 
otherwise its lamella depth was recorded as “0”. In MBP Ac1-9 [4K]-primed T cells (Figure 
4.7 B), iTregs displayed a narrower interface when forming IS across the first two minutes, 
compared with Teffs (p<0.001). Significant differences were found at the 0s (p<0.05), 20s 
(p<0.01) and 120s (p<0.05) time point. When comparing the ratios of lamella depth vs cell 
depth (Figure 4.7 C), iTregs tended to have a longer lamella (higher mean ratios) than Teffs 
but no significant differences were observed at each time or over the two minutes. The ratio 
of lamella depth over interface width of iTregs was significantly higher than that of Teffs 
over the two minutes (Figure 4.7 D, p<0.0001), suggesting that iTregs form a thinner and 
longer cell shapes within this period. Significant differences were observed at the 0s 
(p<0.0001), 20s (p<0.0001) and 60s (p<0.01) time point, reflecting a narrower interface and 
longer lamella in iTregs.  
 
The lamella depth was only measured if an extended lamella was observed during these 
two minutes, therefore we counted numbers of cells couples with and without an extended 
lamella and compared their percentages.  Result shows (Figure 4.7 E) that at the early time 
points (0s and 20s), more iTreg cell couples formed an extended lamella than Teffs 
(p<0.01). These results suggest that when MBP Ac1-9 [4K]-primed iTregs interact with PL8 
cells, their interfaces of contact are not spreading as wide as that of MBP Ac1-9 [4K]-primed 
Teffs, and they displayed a more extended slender cell shape and formed more lamella 
regions in the first 20 seconds. This might lead to a less stable synapse formation and 
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Figure 4.7 MBP Ac1-9 [4K]-primed iTregs display a narrower immune synapse 
interface, more slender cell shape and form more extended lamellae compared to 
MBP Ac1-9 [4K]-primed Teffϯ in early T cell activation. 
LAT-GFP transduced MBP Ac1-9 [4K]-primed Teffs and iTregs interacted with MBP Ac1-9 
[4Y]-primed PL8 cells and were imaged every 20 seconds for 15 minutes. Morphological 
parameters were measured within the first two minutes of T cell activation, 0s indicates the 
time when a tight cell couple was formed. A) Representative DIC images showing 
measurements of four morphological parameters. Comparing the ratios of B) interface width 
to cell width, C) lamella depth to cell depth, D) lamella depth to interface width between 
Teffs and iTregs. E) Comparing percentages of Teffs and iTregs formed an extended 
lamella region. B-E) 40 cells from four experiments for Teffs and 40 cells from two 
experiments for iTregs were analysed. B-C) Statistical significance was calculated with log-
transformed data using Two-way ANOVA. E) Statistical significance was calculated using 
Chi-square test. Asterisks indicate p-values (*<0.05, **<0.01, ***<0.001, ****<0.0001). Error 
bars indicate standard error of the mean. 
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Same analysis and comparisons were performed in anti-CD3/28-primed T cells. No 
significant differences were found when comparing the ratios of interface width to cell width, 
and lamella depth to cell depth between Teffs and iTregs (Figure 4.8 A and B).  Compared 
to Teffs, iTregs had an overall higher ratio of lamella depth over interface width (p<0.05), 
indicating their shapes were more extended (Figure 4.8 C), but no significant differences 
were observed at individual time points. Figure 4.8 D shows that more anti-CD3/28-primed 
iTreg cell couples formed an extended lamella at late time points (60s and 120s, p<0.01), 
compared to anti-CD3/28-primed Teffs. These suggest that in anti-CD3/28-primed cells, 
iTregs form more extended lamellae and tended to have a more slender cell shape over the 
first two minutes of T cell activation which might be a sign of less stable T cell-APC 
interactions.  
 
In summary, we have measured and compared morphological parameters during the first 
two minutes of Tg4 Teff and iTreg activation with different priming conditions. iTregs 
displayed a more elongated and slender cell shape when forming an IS with APCs, 
compared with Teffs. In addition, more extended lamellae near the IS were observed in 
iTregs. This indicates that iTreg form a less stable IS which might lead to less effective T 
cell activation. The level of differences varied when comparing within MBP peptide and anti-
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Figure 4.8 Anti-CD3/28 iTregs tend to form a more slender cell shape and more 
extended lamellae than anti-CD3/28-primed Teffs in early T cell activation. 
LAT-GFP transduced anti-CD3/28-primed Teffs and iTregs interacted with MBP Ac1-9 [4Y]-
primed PL8 cells and were imaged every 20 seconds for 15 minutes. Morphological 
parameters were measured within the first two minutes of T cell activation, 0s indicates the 
time when a tight cell couple was formed. Comparing the ratios of A) interface width to cell 
width, B) lamella depth to cell depth, C) lamella depth to interface width between Teffs and 
iTregs. D) Comparing percentages of Teffs and iTregs with an extended lamella region. 40 
cells from two experiments for Teffs and 41 cells from four experiments for iTregs were 
analysed. A-C) Statistical significance was calculated using Two-way ANOVA. D) Statistical 
significance was calculated using Chi-square test. Asterisks indicate p-values (*<0.05, 
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4.8 LAT overall and central accumulation at the IS of Tg4 iTregs are 
diminished 
Tg4 Teffs and iTregs have shown different cytokine profiles during their development and 
cell shape changes when activated. Next we studied and compared spatiotemporal 
organisation of key signalling intermediates during early T cell activation of Teffs and iTregs. 
First several minutes of T cell activation are accompanied by various events such as 
changes of calcium signalling and cell shapes, transport of surface receptors, cytoskeleton, 
signalling intermediates, and transcriptional factors (130, 134, 163, 178). As a 
transmembrane adaptor protein, LAT plays indispensable roles in proximal signal 
transduction during T cell activation. Followed by pMHC-TCR-induced activation, LAT is 
phosphorylated by ZAP-70 on tyrosine residues which bind the SH2 domain of Grb2, Gads 
and PLC-γ1 (97). The formation and function of LAT-nucleated multiple signalling 
complexes is summarised in section 1.6.1. LAT deficiency in Jurkat cells leads to impaired 
intracellular calcium signalling, defective phosphorylation of PLC-γ1, Vav and SLP-76 and 
reduced activation of AP-1 and NFAT, which can all be restored by reconstitution of LAT 
(179, 180). 
  
The roles of LAT localisation in T cell activation have been controversial. Early study 
revealed that localisation of LAT into the glycolipid-enriched microdomains (GEMs) by 
palmitoylation was required for T cell activation (181, 182). However, following studies 
showed that LAT localisation to the lipid raft is not essential for T cell activation and 
development, while targeting LAT to the plasma membrane is sufficient for its function in T 
cells (183-185). To investigate LAT localisation and better understand how LAT 
spatiotemporal distributions contributes to its signal transduction upon T cell activation, we 
have previously constructed a LAT-GFP fusion protein to visualise and track LAT 
localisation during T cell activation, using TCR transgenic 5C.C7 T cells (130). Upon 
peptide triggered TCR activation, LAT and other associated signalling intermediates such 
as ZAP-70, PKC-θ, Itk, PLC-γ, Rac and Rho localised at the centre of the T cell-APC 
interface or the cSMAC (130). Clustered by thousands of molecules, supramolecular 
signalling complexes play important roles in innate antiviral responses (186), inflammation 
(187), cell death regulation (188) and cancer cell survival (189). By applying fluorescence 
microscopy, extensive studies of composition and functions of supramolecular signalling 
complexes have been conducted (190, 191). To better explore cSMAC function, Clark et al 
investigated and systematically manipulated localisation of three key adaptor proteins of the 
cSMAC including LAT, SLP-76 and Grb2 under different T cell activation conditions (126).  
They found that when fully activated, LAT was efficiently recruited to the interface in the first 
two minutes of cell coupling and displayed a preference for central accumulation. 
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Attenuation of T cell activation signalling by costimulation blockade and IL2-inducible T-cell 
kinase (ITK) knockout both led to diminished LAT central accumulation and their 
combination prominently impaired LAT accumulation at the interface (126). Moreover, 
costimulation blockade and Itk deficiency or both combined significantly reduced the level of 
IL-2 mRNA. Diminished central LAT accumulation at the interface upon such attenuated 
activation conditions could be restored or even exceedingly enhanced, by fusing LAT with 
additional Vav1 SH2SH3SH2 or PKC-θ V3 protein interaction domain respectively. The 
former also enhanced IL-2 mRNA production (126).  
 
These data together indicate that LAT central localisation at the T cell-APC interface upon 
TCR-pMHC mediated activation contributes to the formation of cSMAC and effector function 
of T cells. It is still unknown how LAT localises at the IS of iTregs upon activation and 
whether this will have effect on iTreg function. To track and observe LAT localisation in Tg4 
T cells, we first investigated LAT-GFP spatiotemporal distributions in early T cell activation 
of Tg4 Teffs and iTregs, with two priming methods (MBP peptides and anti-CD3/28). LAT-
GFP transduced iTregs were >73% Foxp3+. 
 
Representative still images in Figure 4.9 shows LAT-GFP distributions in Teffs and iTregs in 
the first two minutes of T cell activation, under the confocal microscope. Images from the 
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Figure 4.9 Representative live cell images showing LAT-GFP distributions in Tg4 
Teffs and iTregs in the first two minutes of T cell activation (0s, 20s, 60s and 120s 
time points).  
Top: DIC images from four time points. Bottom: matching top-down maximum projections of 
three-dimensional LAT-GFP fluorescent images (intensity is encoded in pseudocolour and 
increases from purple to red). Time is given in seconds relative to the formation of a tight 
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In MBP Ac1-9 [4K]-primed Teffs (Figure 4.10 A), started with low accumulation at the -40s 
and -20s time point, LAT-GFP overall accumulation increased from the -20s time point. The 
percentage of cells showing LAT-GFP accumulation peaked at the 40s time point with 63% 
of cell couples showed accumulation at the interface. The accumulation decreased steadily 
after the peak, reaching the lowest point at the 300s time point (23%). For MBP peptide-
primed Teffs, the dominant spatiotemporal accumulation pattern was the central pattern. At 
the 0s, 20s and 40s time point, respectively 31%, 42% and 35% of Teffs showed LAT-GFP 
central accumulation.  
 
In MBP Ac1-9 [4K]-primed iTregs (Figure 4.10 B), LAT-GFP accumulation peaked at the 
60s time point with 31% of iTregs showed accumulation at the interface and decreased 
afterwards. The distal pattern was observed to be dominant (29% at 0s) before the 20s time 
point, while the invagination was dominant after the 20s time point (18% at 20s). The 
statistical comparison (Figure 4.10 E, first row) shows that LAT-GFP overall accumulation in 
MBP Ac1-9 [4K]-primed iTregs was significantly lower than that of Teffs at eight time points 
(p<0.05, 0s-100s, 180s and 420s). As statistical tests were conducted for 12 times (12 time 
points) for each comparison, pure chances of incorrectly rejecting the null hypotheses 
increased. Therefore, the Bonferroni correction was applied to adjust p-values. P-values 
below 0.05 are indicated with asterisks. Asterisks in black indicates that observed 
differences remain significant with the Bonferroni correction (p<0.004). Asterisks in blue 
indicates that observed differences are no longer significant with the Bonferroni correction 
(0.004<p<0.05). At the 20s and 40s time point, observed differences were still significant 
after the Bonferroni correction (p<0.001). Together, these results suggest that during early T 
cell activation, MBP Ac1-9 [4K]-primed iTreg display impaired overall LAT accumulation at 
the interface, compared to Teffs with the same priming method.  
 
LAT-GFP overall accumulation at the interface in anti-CD3/28-primed Teffs (Figure 4.10 C) 
peaked at the 80s time point (76% of Teffs showing LAT-GFP accumulation at the IS). No 
major reduction of accumulation was found afterward, as more than 60% of cells showing 
LAT-GFP accumulation at the interface from the 80s-420s time point. Before the 80s time 
point, LAT-GFP showed mainly central and invagination accumulation while the diffused 
pattern was more dominant after the 120s time point.  
 
Overall LAT-GFP accumulation of anti-CD3/28-primed iTregs (Figure 4.10 D) peaked at the 
120s with 52% of iTregs showing LAT-GFP accumulation at the IS, which was the latest 
peak of accumulation across the four conditions. The accumulation decreased afterwards. 
Consistent with the differences found in the MBP Ac1-9 [4K]-primed T cells, anti-CD3/28-
primed iTregs displayed lower LAT-GFP overall accumulation at the 0s-100, 180s and 420s 
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time points (Figure 4.10 E, second row). Significant differences were still observed at the 0s, 
40s, 80s, 100s and 420s time points with the Bonferroni correction (p<0.004). These 
observations indicate that during early T cell activation, overall LAT accumulation in ani-
CD3/28 primed iTreg is diminished, compared with anti-CD3/28-primed Teffs. 
 
Comparisons of these four data sets suggest that LAT overall accumulation in iTregs to be 
diminished, compared with Teffs in both MBP Ac1-9 [4K] and anti-CD3/CD28 primed 
conditions. Therefore, signal transduction in LAT nucleated protein complexes in early iTreg 
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Figure 4.10 Overall LAT accumulation at the IS are diminished in both MBP Ac1-9 [4K] 
and anti-CD3/28-primed iTregsϮ, compared with TeffsϮϮ. 
LAT-GFP transduced Teffs and iTregs were activated by MBP Ac1-9 [4Y]-primed PL8 cells 
and imaged every 20 seconds for 15 minutes. DIC and GFP images were analysed to 
identify formations of a tight cell couple (0s) and spatiotemporal distribution patterns of LAT-
GFP for 12 time points in A) MBP Ac1-9 [4K]-primed Teffs (49 cell couples analysed, four 
experiments),  B) MBP Ac1-9 [4K]-primed iTregs (72 cell couples analysed, two 
experiments), C) anti-CD3/28-primed Teffs (42 cell couples analysed, two experiments), D) 
anti-CD3/28-primed iTregs (48 cell couples analysed, four experiments), E) Comparisons of 
LAT-GFP accumulation between different cell types at the IS using a two proportion z-test. 
Numerals and asterisks indicate p-values, and asterisk colours indicate whether differences 
remain significant with the Bonferroni correction (0.004<*<0.05, 0.004<**<0.01, 
0.001<**<0.004, 0.0001<***<0.001, ****<0.0001). Error bars indicate standard error of the 
mean. 
Ϯ LAT-GFP imaging data of Tg4 iTregs were jointly analysed (MBP peptide-primed) and analysed (anti-CD3/28-
primed) by Christoph Wuelfing. 
 ϮϮ LAT-GFP imaging data of Tg4 MBP peptide-primed Teffs were generated and analysed by former PhD 
student Helen Tunbridge, data of anti-CD3/28-primed Teffs were analysed by Christoph Wuelfing. 
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Spatiotemporal accumulation of GFP-sensors can be classified into seven defined 
accumulation patterns: central, invagination, diffuse, lamellal, peripheral, asymmetric and 
distal accumulation and such patterns of signalling molecules were found to be highly 
diverse (130, 135). T cell activation and functions are related with spatiotemporal 
organisation of signalling intermediates. Singleton et al have shown that knocking out the 
gene of tyrosine kinase, IL-2 inducible T cell kinase (Itk) in mice could change the 
spatiotemporal localisation of 14 signalling intermediates (including TCR and LAT) involved 
in T cell activation (192). Targeting cell division cycle 42 (Cdc42), one of the central 
accumulation impaired proteins, to the centre of the T cell-APC interface restored actin 
accumulation in the Itk knockout T cells. Therefore, it is of interest to investigate LAT 
accumulation patterns in Tg4 T cells. 
 
Central, invagination and distal accumulation patterns of LAT-GFP were main dominant 
patterns found in Teffs and iTregs (Figure 4.10 A-D). LAT central accumulation is 
associated with efficient T cell activation and IL-2 production (126), while specific roles of 
LAT invagination accumulation is yet to be discussed. Invagination accumulation pattern 
localises at the centre of the interface and reaches µm deep into a T cell, possibly removes 
receptors such as CD2 away from the centre of the interface in T cell activation and reset 
proximal T cell signalling (170). Therefore, invagination accumulation is considered to be a 
diminished central accumulation and indicative of protein transporting away from the 
cSMAC. As both the central and invagination pattern describe sensor accumulation near the 
centre of the interface, we tentatively consider the invagination pattern to be a diminished 
central pattern. The difference between the central and invagination is that the latter is >1 
μm away from the interface and reaches deep into a T cell (130). We first compared both 
patterns together between Teffs and iTregs and then compare each pattern separately.  
 
In MBP Ac1-9 [4K]-primed Teffs and iTregs, the former showed significantly more LAT-GFP 
central + invagination accumulation compared at seven time points (p<0.05, 0s-120s) 
(Figure 4.11 A).  With the Bonferroni correction, significant differences were observed at the 
20s (p<0.004) and 40s (p<0.001) time points. Consistently, when comparing only central 
accumulation, Teffs displayed more central LAT-GFP accumulation than iTregs (Figure 4.11 
B) at similar time points (p<0.05, 0s-80s and 120s).  Differences were still significant at 
three time points (p<0.001, 0s, 20s and 40s) with the Bonferroni correction. No significant 
differences were found when comparing LAT-GFP invagination accumulation of Teffs and 
iTregs (Figure 4.11 C). Only a few iTregs showed LAT-GFP central accumulation as the 
percentages of these cells were lower than 10% across all time points, while the percentage 
of iTregs with LAT-GFP invagination accumulation was similar to that in Teffs.  Together, 
these results show that MBP Ac1-9 [4K]-primed Teffs display more LAT-GFP central 
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accumulation in the first two minutes of T cell-APC interaction, compared to in MBP Ac1-9 
[4K]-primed iTregs. Proximal LAT-mediated signal transduction is likely to be impaired in 
iTregs owing to a reduction of LAT central localisation.  
 
In anti-CD3/28-primed T cells, percentage of cells showing central + invagination LAT-GFP 
accumulation together were significantly lower in iTregs, compared with Teffs at six time 
points (Figure 4.11 D, 0s-100s). These differences all remained significant with the 
Bonferroni correction (p<0.004). When comparing only the LAT-GFP central accumulation 
of Teffs and iTregs (Figure 4.11 E), significant differences were found at the 40s, 80s and 
100s time point but these were no longer significant with the Bonferroni correction 
(0.004<p<0.05). However, when comparing the invagination pattern, Teffs show more LAT-
GFP invagination accumulation than iTregs at six time points (Figure 4.11, 0s-100s, p<0.05). 
Differences at the 40s and 60s time point remained significant with the Bonferroni correction 
(p<0.004). These comparisons show that in anti-CD3/28-primed Teffs, more central and 
invagination accumulation of LAT-GFP at the interface was found near the centre of the IS 
within the first 100 seconds of T cell activation, compared to anti-CD3/28-primed iTregs. 
Differences were mainly found when comparing their invagination accumulation pattern 
within the same time period. Consistent with the observations found in peptide-primed T 
cells, LAT localisation near the centre of the interface is also diminished in anti-CD3/28-
primed iTregs which impairs proximal LAT signalling in early T cell activation.  
 
One of the key questions mentioned previously is whether different ways of priming Tg4 
naïve T cells (peptide vs antibody), will change how Teffs and iTregs behave. To investigate 
this in the aspect of spatiotemporal organisation, we compared LAT-GFP distributions within 
MBP peptide and anti-CD3/28 prime Teffs and iTregs. In Teffs, (Figure 4.10 A and C), the 
percentage of anti-CD3/28-primed Teffs showing LAT-GFP overall accumulation was 
significantly higher at six time points (Figure 4.10 E, third row, p<0.05, 80s-420s), and such 
differences were still significant at the 180s, 300s and 400s time point with the Bonferroni 
correction (p<0.004), compared to MBP Ac1-9 [4K]-primed Teffs. Moreover, the peak of 
LAT-GFP accumulation was delayed by 40 seconds in anti-CD3/28-primed Teffs. LAT-GFP 
was more likely to remained at the interface in anti-CD3/28-primed Teffs after this peak. 
 
When jointly compared, LAT-GFP central + invagination accumulation of MBP peptide and 
anti-CD3/28-primed Teffs displayed similar patterning (Figure 4.11 A and D). In both priming 
condition, percentage of Teffs with central + invagination accumulation peaked at the 40s 
time point and gradually decreased afterwards. However, MBP peptide-primed Teffs 
showed more central localisation preference for LAT-GFP, particularly in the first two 
minutes of cell coupling (Figure 4.10 A). LAT-GFP central accumulation pattern was 
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dominant in MBP peptide-primed Teffs in the first two minutes, and the percentage of 
peptide-primed Teffs with such accumulation peaked at the 40s (42%). In contrast, both 
LAT-GFP central and invagination accumulation patterns were found to be dominant during 
this period in anti-CD3/28-primed Teffs (Figure 4.11 C). In addition, LAT-GFP diffuse 
accumulation pattern was more dominant after the 120s time point.  
 
When comparing the iTreg data sets, more LAT-GFP overall accumulation in anti-CD3/28-
primed iTregs (Figure 4.10 B and D) were found and differences were significant at four 
time points (Figure 4.10 E, fourth row, p<0.01, 120s-420s), and were still significant except 
at the 300s time point with the Bonferroni correction. The peak of LAT-GFP accumulation 
was delayed by one minute in anti-CD3/28-primed iTregs and after reaching the peak at the 
120s time point, LAT-GFP accumulation also sustained at the interface. Percentage of 
iTregs showing any accumulation pattern of LAT-GFP in both priming conditions was 
relatively low (<20%) at all time points. A dominant LAT-GFP invagination pattern was found 
in MBP peptide-primed iTregs in the first 80s of cell coupling.   
 
These comparisons show that in early activation of MBP peptide and anti-CD3/28-primed 
Tg4 T cells, more LAT-GFP overall accumulation was found in anti-CD3/28-primed T cells, 
particularly at later time points (after 120 seconds). The central LAT-GFP accumulation 
observed in anti-CD3/28-primed Teffs was not as dominant as it was in MBP peptide-
primed Teffs. Together these results indicate that, in MBP peptide-primed T cells, LAT is 
more likely to be recruited to the centre of the interface within the first minute after the 
synapse is formed, and later be removed from the interface. While in early activation of anti-
CD3/28-primed T cells, LAT localisation at the interface is delayed and more likely to 
maintain at the interface after the first two minutes of cell coupling. As the cSMAC regulates 
effective recruitment of large number of signalling proteins to the interface centre in the first 
two minutes of cell coupling (55), it is possible that this inefficient transport and clearance of 
LAT at the interface during anti-CD3/28-primed T cell activation, could hinder cSMAC 
formation and disrupt the regulation of signalling intermediates localisation in proximal T cell 
signalling. In other word, T cell activation in anti-CD3/28-primed cells might be less effective.    
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Figure 4.11 LAT-GFP central accumulation at the IS in MBP Ac1-9 [4K]-primed iTregs 
and invagination accumulation in anti-CD3/28-primed iTregs are diminished. 
Direct comparisons of percentages of cell couples with LAT-GFP central + invagination, 
central and invagination spatiotemporal patterns in MBP AC1-9 [4K]-primed A-C) and anti-
CD3/28-primed D-F) Teffs and iTregs. A-C) MBP Ac1-9 [4K]-primed Teffs: 49 cell couples, 
four experiments, MBP Ac1-9 [4K]-primed iTregs: 72 cell couples two experiments, D-F) 
anti-CD3/28-primed Teffs: 42 cell couples, two experiments, anti-CD3/28-primed iTregs: 48 
cell couples, four experiments. A two proportion z-test was applied to calculate statistical 
significance. Asterisks indicate p-values and colours indicate whether differences remain 
significant with the Bonferroni correction (0.004<*<0.05, 0.004<**<0.01, 0.001<**<0.004, 
***<0.001). Error bars indicate standard error of the mean. 
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The distal accumulation pattern was mainly found to be dominant before the formation of 
tight cell couples in iTregs (Figure 4.10 B and D). As the distal pattern describes localisation 
of a sensor at the distal end of a T cell, away from the interface, which is excluded from 
“any interface” accumulation patterns. Thus, we compared distal accumulation patterns 
within MBP peptide and anti-CD3/28-primed Teffs and iTregs. 
 
Percentages of MBP Ac1-9 [4K]-primed iTregs with distal LAT-GFP accumulation was 
significantly higher at the -20s and 0s time point, compared with Teffs (Figure 4.12 A, 
p<0.01) and the difference was only significant at the 0s time point with the Bonferroni 
correction (p<0.001). No significant differences were found between anti-CD3/28-primed 
Teffs and iTregs (Figure 4.12 B). Then we compared the distal accumulation between same 
cell types with a different priming method (peptide vs antibody). Anti-CD3/28-primed Teffs 
show more distal accumulation of LAT-GFP, compared with Teffs primed with MBP Ac1-9 
[4K], at four time points (Figure 4.12 C, p<0.05). The differences remained significant at the 
0s and 20s time point with the Bonferroni correction (p<0.001). Significant difference was 
only found at the 0s time point when comparing the LAT-GFP distal accumulation between 
the two type of iTregs (Figure 4.12 D, p<0.05), which was not significant with the Bonferroni 
correction. The distal pattern of LAT-GFP was mainly observed before the 60s time point in 
three out of four cell types and barely observed in MBP Ac1-9 [4K]-primed Teffs.  
 
These comparisons indicate that before the formation of the IS in early activation, some 
LAT-GFP molecules are transiently recruited towards the distal end in MBP peptide-primed 
iTregs and anti-CD3/28-primed Teffs/iTregs. They diffuse away from the site after tight cell 
coupling. Recruitment of LAT-GFP to the interface centre in MBP peptide-primed Teffs is 
not disrupted as that in the other three cell types. Therefore, distal localisation in MBP 
peptide-primed iTregs and anti-CD3/28-primed Teffs/iTreg appears to slow down LAT 
transition to the centre and possibly reduces the total amounts of LAT at the interface centre 
upon the IS formation. This might partially contribute to the reduced LAT central localisation 
found in iTregs and anti-CD3/28-primed Teffs. These observations also suggest that anti-
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Figure 4.12 Distal LAT-GFP accumulation was observed in MBP Ac1-9 [4K]-primed 
iTregs, anti-CD3/28-primed Teffs and iTregs at early time points.  
Direct comparisons of percentages of cell couples showing LAT-GFP accumulation in MBP 
AC1-9 [4K] and anti-CD3/28-primed Teffs and iTregs. Comparing LAT-GFP distal 
accumulation between A) MBP Ac1-9 [4K]-primed Teffs and iTregs B) anti-CD3/28-primed 
Teffs and iTregs, C) MBP Ac1-9 [4K] and anti-CD3/28-primed Teffs and D) MBP Ac1-9 [4K] 
and anti-CD3/28-primed iTregs. MBP Ac1-9 [4K] Teffs: 49 cell couples, four experiments, 
MBP Ac1-9 [4K]-primed iTregs: 72 cell couples, two experiments, anti-CD3/28-primed Teffs: 
42 cell couples, two experiments, anti-CD3/28-primed iTregs: 48 cell couples, four 
experiments. A two proportion z-test was applied to calculate statistical significance. 
Asterisks indicate p-values and colours indicate whether differences remain significant with 
the Bonferroni correction (0.004<*<0.05, 0.004<**<0.01, <0.001**<0.004, ***<0.001). Error 
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4.9 Computational analyses show reduced LAT overall and central 
accumulation at the IS of Tg4 iTregs  
Manually identifying spatiotemporal patterns of various GFP-sensors potentially allows 
biases to occur. First, localisation which shows ambiguous features of more than one 
pattern does occur. Secondly when analysing imaging data, knowing a cell type and sensor 
subconsciously affects how we identify the patterns. Blind scoring is a good way to reduce 
these biases, and part of our analysis on morphological data has been processed in this 
way. Nevertheless, a general and automated approach could help to assess interface 
accumulation better in our study. Previously, with the help from the Computational Biology 
Department from Carnegie Mellon University, we have developed a large-scale 
computational approach (173). For a given GFP-labelled sensor imaging data set, 
coordinates and time points indicating onsets of each cell couple were manually identified 
with a mid-plane DIC image. This DIC image and GFP images of 12 time points (including 
all 21 z stacks) relative to the formation of tight cell couples could be used to generate a 
three-dimensional (3D) model map. Fluorescent images were segmented and shape-
normalised into a standardised semi-spheroid cell shape displaying sensor distributions 
within a T cell. 
 
Representative fluorescent 3D images of Teffs and iTregs transduced with LAT-GFP are 
displayed below (Figure 4.13 A). From top to bottom, slices of images from five time points 
(0s, 60s, 120s, 180s and 300s) relative to the synapse formation are shown. Image slices 
close to the middle plane across these five time points reveal that after the IS was formed, 
LAT-GFP in Teffs and iTregs mainly localised near the T cell-APC interface. 
 
Utilising GFP images of 21 z stacks from all 12 time points, two 3D model maps displaying 
relative probabilities of LAT-GFP accumulation during Teff/iTreg-APC interactions were 
generated (Figure 4.13 B, upper row in each panel). Relative fluorescence values were 
scaled to a fraction of total fluorescence of the sensor, which indicate average probabilities 
of enrichment, across all time points. To compare LAT-GFP distributions near the IS formed 
by Teffs and iTregs, we defined a region contains the highest 10% of fluorescent 3D pixels 
as an approximation of the IS (173) (Figure 4.13 B, lower row in each panel). Relative 
enrichment of each sensor of all 12 time points could be extracted from the 3D models. 
Sensor enrichment describes a ratio of the amount of the sensor in a defined region to the 
average amount in the entire cell, across all time points (173). Result (Figure 4.13 C) shows 
in MBP Ac1-9 [4K]-primed Teffs, LAT-GFP mean enrichment was the lowest at the -20s 
time point, gradually increased over time and reached its peak at the 420s point. While in 
the MBP Ac1-9 [4K]-primed iTregs, the enrichment of LAT-GFP also started increasing from 
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the -20s time point but reached the peak at the 40s time point and maintained with a minor 
reduction afterwards. Statistical analysis shows that upon Teff activation, LAT-GFP 
enrichment at the synapse was significantly higher at five time points (p<0.05, 80s, 120s-
420s), compared to iTregs. Mean enrichment of LAT-GFP in the Teff condition at the other 
seven time points was also higher than that in iTregs but not significant. With the Bonferroni 
correction, significant differences were only found at the 420s time points (p<0.001). 
 
In summary, MBP Ac1-9 [4K]-primed Teffs show more LAT accumulation at the IS, when 
compared with MBP Ac1-9 [4K]-primed iTregs and such differences are more prominent 
after the first minute of cell coupling. This again suggests that the total amount of LAT 
transported to the synapse in iTregs to be reduced which is mostly consistent with the 












Chapter 4  
Figure 4.13 Computational model maps indicate that MBP Ac1-9 [4K]-primed iTregs 
show diminished LAT-GFP accumulation in the defined IS region.  
Computational 3D model maps were generated by analysing DIC and GFP images with 
coordinates and time points indicating onsets of cell couples. T cells are rotated with the IS 
facing upward. Slices are placed left to right indicating their z positions relative to the middle 
plane. False-colour scales are applied to indicate relative fluorescence intensity.  
A) Representative single image slices of 3D models showing average LAT-GFP 
distributions in MBP Ac1-9 [4K]-primed Teffs and iTregs when activated. Time points 
relative to the formation of cell couples are listed vertically and false colour scales indicate 
relative fluorescence. B) Computational 3D model maps showing average probabilities of 
LAT-GFP distributions in the whole cell (overall enrichment) and defined IS region (top 10% 
enrichment) during the activation of MBP Ac1-9 [4K]-primed Teffs and iTregs. False-colour 
scales indicate relative probability. C) Comparing LAT-GFP enrichment in the defined IS 
region (top 10% enrichment) during the activation of MBP Ac1-9 [4K]-primed Teffs and 
iTregs. Images are aligned from left to right indicating their z positions relative to the middle 
plane. Teffs: 28 cell couples, four experiments, iTregs: 28 cell coupes, two experiments. 
Log-transformed ratio data (enrichment) were analysed with unpaired Student’s test to 
calculate statistical significance. Asterisks indicate p-values and colours indicate whether 
differences remain significant with the Bonferroni correction (0.004<*<0.05, 0.004<**<0.01, 
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As compared with Teffs, LAT-GFP central accumulation during iTreg activation was found 
to be diminished (Figure 4.11 B), we further investigated whether this could also be found in 
the 3D models. We defined a “central core” region with a cylindrical shape near the IS, 
shown below (Figure 4.14 A). A standardised cell shape is a semi-ellipsoid and rotated so 
that the interface of contact is facing upward. We set the relative radius of the interface to 
be “1”, and the relative radius and height (depth into the cell) of the cylinder to be “0.5”. This 
is an approximated central region of the IS. Two 3D model maps were generated to show 
average LAT-GFP enrichment in the whole cell (Figure 4.14 B, upper row) or central region 
of the IS in MBP peptide-primed Teffs and iTregs (Figure 4.14 B, lower row). LAT-GFP 
enrichment in the central region in both Teff and iTreg was observed (Figure 4.14 C), as 
enrichment mainly concentrated in their middle planes. LAT-GFP central accumulation in 
Teffs started low at the -20s time point and increased over time. It peaked at the 300s time 
point. In iTregs, LAT-GFP central enrichment was the lowest at the -20s time point and 
peaked at the 40s time point, but slowly decreased afterwards. At all 12 time points, the 
mean enrichment of LAT-GFP within the central core of Teffs was higher than that of iTregs 
and the differences were significant at five time points (p<0.05, 120s, 180s, 300s and 420s). 
However, no significant differences were found with the Bonferroni correction (p>0.004).  
 
These results suggest that in early T cell activation, LAT accumulation in the central region 
of the IS in MBP peptide-primed iTregs is diminished, particularly after the first minute of 
activation, compared to Teffs. 
 
Computational 3D model analysis offered us an automated and systemic approach to 
compare GFP-labelled protein distributions in Teffs and iTregs in T cell activation. All GFP 
images of a protein of interest could be inputted to visualise its enrichment at any of or all 
12 time points. Combined results above, after the first minute of the IS formation, LAT-GFP 
in MBP primed Teffs displayed more overall and central accumulation at the IS than that in 
iTregs. Notably, time points where significant differences were found in LAT-GFP datasets 
were not identical between our manual scoring and computational analysis (Figure 4.10 E 
and 13 C). The former identified differences mainly before the 120s time point while the 
latter identified differences after the 60s time point. In addition, the trends of LAT-GFP 
accumulation showed by these two approaches were partly diverse, as LAT-GFP 
accumulation identified in the manual scoring system usually peaked around or before the 
60s time point and decreased afterwards, while such accumulation identified in the 
computational analysis system sustained after the 60s time point. As the computational 
analysis approach is still under development, it has limitations. Diverse spatiotemporal 
distribution patterns cannot be fully recognised by the computational analysis. Central and 
invagination accumulation patterns which describe different localisation conditions of the 
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cSMAC associated proteins are indistinguishable by the computational analysis system at 
present. Moreover, the computational system includes and analyses vesicular LAT 
accumulation, which is removed by manual pattern analysis. In addition, at the current stage, 
fewer cell couples can be recognised and analysed by the programme (e.g. for LAT-GFP 
accumulation, 28 of 48 cell couple of Teffs were recognised by the computer), which limits 
the utilisation of our current datasets. Therefore, manual identification of spatiotemporal 
patterns of senor distributions is a well-defined reliable approach, and combined with 
supplementary automated computational models, we could further quantify and investigate 
diverse spatiotemporal distributions of different signalling intermediates in T cell signalling in 
a comprehensive context. Because of the superior ability to distinguish closely related 
patterns at the centre of the interface, we will use manual pattern classification as a main 




















Chapter 4  
Figure 4.14 MBP Ac1-9 [4K]-primed iTregs show diminished central LAT-GFP 
accumulation in the defined IS region, compared to Teffs. 
A central core region was defined in 3D computational models to compare LAT-GFP central 
accumulation at the IS bewteen MBP Ac1-9 [4K]-primed Teffs and iTregs. A) A diagram 
showing the definition of the “central core”, an approximated cylinder near the interface. The 
interface is regarded as a circle with a relative radius of “1” and the relative radius and 
height of the cylinder is “0.5”. B) Computational 3D model maps showing average 
probabilities of LAT-GFP distribution in the whole cell (overall enrichment) and defined 
central core region during the activation of MBP Ac1-9 [4K]-primed Teffs and iTregs. False 
colour scales indicate relative probability. C) Comparing LAT-GFP accumulation in the 
central core during the activation of MBP Ac1-9 [4K]-primed Teffs and iTregs. Images are 
aligned from left to right indicating their z positions relative to the middle plane. Teffs: 28 cell 
couples, four experiments, iTregs: 28 cell coupes, two experiments. Ratios (enrichment) 
were log-transformed and analysed with unpaired Student’s test to calculate statistical 
significance. Asterisks indicate p-values and colours indicate whether differences remain 
significant with the Bonferroni correction (0.004<*<0.05, 0.004<**<0.01). Error bars indicate 
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4.10 TCR-ζ accumulation at the IS of Tg4 iTregs is diminished but 
increased at the distal pole 
As LAT signalling was most likely to be impaired owing the diminished LAT central 
localisation in iTregs, we next investigated whether LAT associated signal transductions 
were also defective. The engagement of TCR and pMHC of TCR-MHC is a key step to 
initiate T cell activation. It is commonly acknowledged that proximal TCR signalling to be the 
upstream of LAT recruitment at single molecular level. However, this is not the case from 
the perspective of supramolecular signalling complexes. LAT nucleated signalosome is the 
upstream of TCR central clustering at the interface, as we discuss below.  
 
Similar to LAT, a TCR-ζ-GFP fusion protein was generated to study its roles at the IS (193). 
In a previous study by Singleton et al, upon pMHC-TCR induced T cell activation, TCR-ζ in 
5C.C7 TCR transgenic T cells was efficiently recruited, mostly from the distal pole of the cell, 
to the centre of the T cell-APC interface, at the beginning of tight cell coupling (0s) (130). 
Interestingly, LAT started to localise at the centre of the interface before the synapse was 
steadily formed and central LAT-GFP accumulation peaked at the 0s time point (126). After 
the peak, LAT central accumulation diminished and reached its lowest point at the 120s 
time point while TCR-ζ continued to localise at the interface centre after the 60s time point, 
and still showed relatively a high level of central clustering after the 300s time point. 
Together these data suggest that at the supramolecular level, LAT central clustering at the 
interface subsequently promotes TCR-ζ central clustering at the cSMAC of the interface. 
Consistently, we have shown in the last section that LAT accumulation in Tg4 Teffs showed 
a similar pattern of accumulation with pronounced central clustering around the 20s time 
point (Figure 4.10-11). In brief, initial proximal TCR signalling is required for LAT activation 
and recruitment but the assembly of LAT signalosome in the cSMAC promotes downstream 
TCR central clustering.  
 
Investigation of TCR-ζ localisation at the IS of Tg4 T cells will provide ideas to study its 
roles in the cSMAC and relation with the upstream LAT signalosome. Same as described 
earlier, we transduced Tg4 T cells with TCR-ζ-GFP and compared its accumulation 
patterning in Teffs and iTreg upon activation. In this dataset, Teffs were all primed with MBP 
peptides, while iTreg were MBP peptide and anti-CD3/28-primed. iTregs transduced with 
TCR-ζ-GFP were >75% Foxp3+. 
 
Representative images of TCR-ζ-GFP accumulation in Teffs and iTregs in the first two 
minutes of T cell activation are shown below (Figure 4.15). Images are from the DIC and 
GFP channel.  
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Figure 4.15 Representative live cell images of Tg4 Teffs and iTregs transduced with 
TCR-ζ-GFP from four time points in early T cell activation. 
Top: DIC images from four time points. Bottom: matching top-down maximum projections of 
three-dimensional TCR-ζ-GFP fluorescent images (intensity is encoded in pseudocolour 
and increases from purple to red). Time is given in seconds relative to the formation of a 
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In MBP Ac1-9 [4K]-primed Teffs (Figure 4.16 A), TCR-ζ-GFP accumulation peaked at the 
60s time point with 58% Teffs showing accumulation at the IS. After the first minute of cell 
coupling, TCR-ζ-GFP showed sustained accumulation at the interface for six minutes and 
the 69% of Teffs showing TCR-ζ-GFP accumulation at the last time point (420s) showing an 
increasing trend of accumulation. Such pattern was not observed in MBP Ac1-9 [4K]-primed 
iTregs (Figure 4.16 B). TCR-ζ-GFP accumulation only peaked once at the 40s time point 
with 55% of iTregs showing accumulation and decreased afterwards. This showed that in 
MBP peptide-primed Teffs, TCR-ζ-GFP was recruited to the interface in the first minute after 
the IS formation and remained for sustained TCR signalling transduction in the next six 
minutes. On the contrary, in MBP peptide-primed iTregs, although TCR-ζ-GFP was being 
driven to the interface at early time points, such accumulation was not retained at the 
interface and gradually diminished after the 80s time point. A direct comparison (Figure 4.16 
D, upper row) between MBP Ac1-9 [4K]-primed Teffs and iTregs showed that Teffs 
displayed significantly more TCR-ζ-GFP accumulation at later time points (p<0.05, 100s-
420s). However, iTregs showed more TCR-ζ-GFP accumulation at the -20s and 0s time 
point (p<0.05). Differences remained significant at the 180s and 420s time points with the 
Bonferroni corrections (p<0.004). This may indicate that after the first 80s of cell coupling, 
more TCR-ζ molecules are recruited to the IS in Teff activation, compared with iTregs.   
 
Among all accumulation patterns, no dominate accumulation patterns of TCR-ζ-GFP at the 
interface were observed in MBP Ac1-9 [4K]-primed Teffs (Figure 4.16 A) as several patterns 
were found at multiple time points. TCR-ζ-GFP central accumulation of the IS of Teffs 
showed an increasing trend after the 180s time point and peaked at the last time point with 
38% of cell showing TCR-ζ-GFP central accumulation. TCR-ζ-GFP peripheral and 
asymmetric accumulation were mostly observed in Teffs at early time points and gradually 
diminished after the 120s time point. While in MBP peptide-primed iTregs (Figure 4.16 B), 
TCR-ζ-GFP peripheral accumulation was mainly observed, as the percentage of cells with 
TCR-ζ-GFP peripheral accumulation at the interface was dominant at six time points (-20s-
80s) and peaked at the 20s time point (41%). 
 
When comparing TCR-ζ-GFP central accumulation between MBP peptide-primed Teffs and 
iTregs (Figure 4.16 E), the mean percentage of Teffs showing such accumulation was 
continuously higher after two minutes of cell coupling. The difference was only significant at 
the 420s time points, but prominent (p<0.001).  Apart from localising at the interface, TCR-ζ-
GFP also showed distal accumulation in MBP peptide-primed iTregs (Figure 4.16 B). Distal 
TCR-ζ-GFP accumulation in these iTregs also showed an increasing trend from the 120s 
time point. Percentage of in MBP peptide-primed iTregs with distal accumulation peaked at 
the -20s (40%) and 420s (45%) time point. While in Teffs (Figure 4.16 A), low distal TCR-ζ-
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GFP accumulation was observed before the 60s time point (<30% cells showing distal 
accumulation) and barely detected afterwards. A direct comparison of TCR-ζ-GFP distal 
accumulation (Figure 4.16 F) showed TCR-ζ-GFP distal accumulation was significantly 
higher in MBP Ac1-9 [4K]-primed iTregs at eight time points (p<0.05, 0s, 60s-420s), 
compared with Teffs. Differences were still significant at four time points (60s, 180s, 300s 
and 420s) with the Bonferroni correction.  
 
Together, these results show that in early T cell activation, TCR-ζ overall and central 
accumulation in MBP Ac1-9 [4K]-primed iTregs are diminished, particularly after two 
minutes of cell coupling. Upon activation, TCR-ζ-GFP was recruited to the periphery of the 
synapse in MBP Ac1-9 [4K]-primed Teffs and iTregs at early time points (within the first 
minute of cell coupling). In Teffs, TCR-ζ-GFP then stabilised at the interface after the 120s 
time point and showed an increasing trend of central TCR-ζ-GFP accumulation and distal 
TCR-ζ-GFP accumulation was only observed before the 60s time point with low percentage 
of cells displaying such pattern. This sustained accumulation of TCR clusters at the 
interface indicates that a stable cSMAC at the IS begin to form after the first two minutes of 
cell coupling in early Teff activation. While in iTregs, TCR-ζ-GFP accumulation at the 
interface was not persistent and diminished after the 40s time point, and more TCR-ζ-GFP 
molecules localised at the distal end of the cell during iTreg activation. Scarcely detectable 
central accumulation across all time points and increased distal accumulation of TCR-ζ-
GFP after the first minute of cell coupling suggest that the transport of TCRs to the interface 
is inefficient and TCRs are prematurely cleared from the interface and barely released from 
the distal pole. Therefore, the cSMAC is not properly formed in early iTreg activation which 
would attenuate downstream tyrosine kinase signalling cascades and lead to defective T 
cell activation. 
  
In addition, we also investigated TCR-ζ-GFP spatiotemporal accumulation patterns in early 
activation of anti-CD3/28-primed iTregs (Figure 4.16 C). TCR-ζ-GFP overall accumulation at 
the interface of anti-CD3/28-primed iTregs was relatively low across all time points, and it 
peaked at the 100s time point with 36% of the cells showing TCR-ζ-GFP accumulation and 
decreased afterwards. TCR-ζ-GFP diffuse accumulation was dominant at six time points 
(40s-180s) but the percentage of cells showing such accumulation was <20% across all 
time points.  However, prominent distal TCR-ζ-GFP accumulation was observed before the 
60s and at the 420s time point. Distal accumulation of TCR-ζ-GFP peaked at the 0s time 
point with 56% iTregs showing such accumulation and decreased afterward untill the 180s 
time point. The percentage of iTregs with distal TCR-ζ-GFP accumulation started to 
increase again from the 180s time point and showed an ascending trend till the last time 
point. When comparing these two types of iTregs, the percentage of cells with TCR-ζ-GFP 
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overall accumulation was higher in MBP peptide-primed iTregs at six time points (p<0.01, -
40s-40s, 420s). Differences remained significant with the Bonferroni correction at five time 
points (p<0.004, -40s-40s). 
 
Combined with the result above, these observations indicate that in early iTreg activation, 
more TCR-ζ-GFP accumulation was found at the interface in MBP Ac1-9 [4K]-primed iTreg 
at early time points (before the 40s time point). In MBP peptide-primed iTregs, TCR-ζ-GFP 
also transported to the interface more efficiently, as the peak of TCR-ζ-GFP overall 
accumulation was delayed for 60 seconds in anti-CD3/28-primed iTregs. Peripheral TCR-ζ-
GFP accumulation was hardly found anti-CD3/28-primed iTregs but both types of iTregs 
displayed similar distal TCR-ζ-GFP accumulation patterning which peaked at early time 
points and showed an increasing trend at late time points. These suggest that in early T cell 
activation, fewer TCR-ζ subunits are recruited to the interface of anti-CD3/28-primed iTregs 
activation, and the translocation of TCRs to the synapse is less effective, compared to that 
in MBP peptide-primed iTregs. Thus, during early IS formation, the recruitment of TCR-CD3 
complexes to the interface in anti-CD3/28-primed iTreg and cSMAC formation is likely to be 
more defective than that in MBP peptide-primed iTregs. Thus, anti-CD3/28 priming partially 
reduces the ability to transport TCRs to the interface in iTregs. These data are consistent 
with those observed in LAT accumulation analyses, which suggest that anti-CD3/28 priming 
tends to generate T cells which activate less efficiently. In summary, both iTregs display 
impaired TCR localisation at the interface of the IS, which would diminish TCR signal 
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Figure 4.16 TCR-ζ-GFP accumulation in MBP Ac1-9 [4K]-primed iTregsϮ is diminished 
at the IS but increases at the distal pole, compared to TeffsϮϮ.  
TCR-ζ-GFP transduced Teffs and iTregs were activated by MBP Ac1-9 [4Y]-primed PL8 
cells and imaged every 20 seconds for 15 minutes. DIC and GFP images were analysed to 
identify formations of tight cell couples and investigate spatiotemporal distribution patterns 
of TCR-ζ-GFP of A) MBP Ac1-9 [4K]-primed Teffs (51 cell couples, four experiments), B) 
MBP Ac1-9 [4K]-primed iTregs (66 cell couples, three experiments), C) anti-CD3/28-primed 
iTregs (50 cell couples analysed, three experiments). D) Statistical comparisons of TCR-ζ-
GFP accumulation at the IS of difference cells using a two proportion z-test. Comparing E) 
central and F) distal TCR-ζ-GFP accumulation between MBP Ac-19 [4K]-primed Teffs and 
iTregs. Numerals and asterisks indicate p-values and asterisk colours indicate whether 
differences remain significant with the Bonferroni correction (0.004<*<0.05, 0.004<**<0.01, 
0.001<**<0.004, ***<0.001). Error bars indicate standard error of the mean. 
 
Ϯ TCR-ζ-GFP imaging data of Tg4 iTregs were generated and analysed (MBP peptide-primed) by former lab 
member Silvia Cirillo, data of anti-CD3/28-primed iTregs were analysed by Christoph Wuelfing. 
 ϮϮ TCR-ζ-GFP imaging data of Tg4 MBP peptide-primed Teffs were generated and analysed by former PhD 
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4.11 PKC-θ accumulation at the IS increases in Tg4 iTreg showing 
more diffuse and lamellal patterning  
Diminished spatiotemporal distributions of LAT and TCR-ζ were identified above and we 
further investigate the downstream of LAT signalosome. Apart from the TCR-CD3 complex, 
the protein kinase C-theta (PKC-θ) is another central element of the cSMAC and 
translocation of PKC-θ to the immune synapse is associated with T cell activation and 
proliferation (121, 122). In early T cell activation, PLC-γ1 cleaves PIP2 and generates a 
second messenger, DAG, which binds the C1 domains of PKC-θ and meditates its 
translocation to the IS (194). In addition, Lck directly phosphorylates PKC-θ, which also 
recruits it to the membrane (195). GCK-like kinase (GLK, or MAP4K3) activated by SLP-76, 
further phosphorylates and activates PKC-θ (196), which subsequently leads to activation of 
NF-κB, AP-1 and NFAT (197-199).  
 
However, roles of PKC-θ in Tregs function seem to be more elusive. PKC-θ is important in 
Treg development in vivo, as PKC-θ knockout mice have a significantly reduced number of 
tTregs and pTregs, but PKC-θ deficient Tregs are as potent as wild-type Tregs in 
suppressive functions (200). In a model using planar bilayers with ICAM-1 and anti-CD3 
antibodies to form the IS with Teffs and Tregs (201), PKC-θ was sequestered in the distal 
pole of Tregs and the level of PKC-θ recruitment to the IS was significantly lowered, 
compared to Teffs. Moreover, PKC-θ was found to negatively regulate a feedback loop and 
reduce suppressive functions of Tregs which could be enhanced by PKC-θ blockade (201). 
While in vitro, PKC-θ mediates inhibition of iTreg differentiation via an AKT-Foxo1/3A 
pathway, and using PKC-θ inhibitors or knocking out PKC-θ enhances iTreg differentiation 
(202). These results together suggest that PKC-θ mediates immune response by shifting a 
balance between Teff and Treg responses (202, 203).  
 
In the previous study by Singleton et al (130), PKC-θ-GFP displays a strong preference for 
central accumulation at the IS in 5C.C7 and DO11.10 TCR transgenic T cells, and 
substantial phosphorylation of PKC-θ observed in these T cells validates its activation at the 
cSMAC. Therefore, to further study and compare PKC-θ localisation at the interface in both 
Teffs and iTregs, we next transduced Tg4 Teffs and iTregs with PKC-θ-GFP to investigate 
its spatiotemporal distributions during their activation. These T cells were all MBP peptide-
primed and iTregs transduced with PKC-θ-GFP were >75% Foxp3+. Representative images 
from the DIC and GFP channel of PKC-θ-GFP accumulation in Teffs and iTregs in the first 
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Figure 4.17 Representative live cell images showing PKC-θ-GFP accumulation in Tg4 
Teffs and iTregs from four time points (0s-120s) in early T cell activation. 
Top: DIC images from four time points. Bottom: matching top-down maximum projections of 
three-dimensional PKC-θ-GFP fluorescent images (intensity is encoded in pseudocolour 
and increases from purple to red). Time is given in seconds relative to the formation of a 
tight cell couple and arrows show accumulation of the sensor. 
 
In MBP Ac1-9 [4K]-primed Teffs (Figure 4.18 A), PKC-θ-GFP started to accumulate at the 
IS from the -40s time point (13% of cell showing accumulation) and the percentage of Teffs 
showing accumulation peaked at the 0s time point (61%). The percentage gradually 
decreased afterwards. This indicates that in Teffs, PKC-θ-GFP was initially recruited to the 
interface and then driven away from the IS right after a stable IS was formed. The dominant 
accumulation pattern of PKC-θ-GFP was the central pattern. PKC-θ-GFP accumulation at 
the centre of the interface peaked at the 0s time point with 26% of Teffs displaying such 
accumulation.  
 
Unlike what we found in the sensors above, PKC-θ-GFP accumulation at the IS in iTregs 
was enhanced across all time points observed, compared with Teffs. In MBP Ac1-9 [4K]-
primed iTregs (Figure 4.18 B), about 47% of iTreg cell couples showed PKC-θ-GFP 
accumulation at the IS at the -40s time point and the percentage peaked at the 20s time 
point (74%). The accumulation remained at the interface for several minutes and 68% of 
iTregs at the last time point still showed PKC-θ-GFP accumulation at the IS. PKC-θ-GFP 
localisation at the IS during iTreg activation displayed mixed accumulation patterns (central, 
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diffuse and lamellal patterns were mainly found) and no dominate patterns were identified. 
A statistical comparison (Figure 4.18 C) shows that PKC-θ-GFP displayed significantly more 
accumulation at the IS in iTregs at seven time points (p< 0.05, -40s, -20s, 80s, 100s, 180s, 
300s and 420s), compared to that in Teffs. With the Bonferroni correction, significant 
differences remained at three time points (p<0.001, -40s, -20s and 420s). This indicates that 
overall accumulation of PKC-θ at the IS of iTregs is increased, in comparison to Teffs.  
 
As the central localisation of PKC-θ at the immune synapse is one of the key components of 
the cSMAC, we compared PKC-θ-GFP central accumulation during Teff and iTreg 
activation. MBP Ac1-9 [4K]-primed Teffs and iTregs (Figure 4.18 D) showed comparable 
central PKC-θ-GFP accumulation and iTregs only showed more central patterning at the 
420s time point (p<0.05). This was not significant with the Bonferroni correction. In addition, 
among other patterns of PKC-θ-GFP accumulation in Teffs and iTregs, significant 
differences could be found when comparing their diffuse and lamellal patterns. In general, 
the mean percentage of iTregs showing PKC-θ-GFP diffuse and lamellal patterning at the 
IS were higher than that of Teffs at all 12 time points (Figure 4.18 E and F). PKC-θ-GFP 
showed more diffuse accumulation (Figure 4.18 E) at the IS at five time points (p<0.05, -20s, 
40s, 60s, 80s and 120s), and differences remained significant at the 60s, 80s, and 120s 
time points after the Bonferroni correction (p<0.004). When comparing the their lamellal 
accumulation pattern of PKC-θ-GFP (Figure 4.18 F), more accumulation could be found in 
iTregs at seven time points (p<0.05, -40s-60s, 420s). Differences found at the -40s and 0s 
remained significant with the Bonferroni correction (p<0.004). Thus, iTregs showed more 
diverse accumulation patterns of PKC-θ-GFP than Teffs.  
 
Together, these results show that the overall accumulation of PKC-θ at the IS in MBP Ac1-9 
[4K]-primed iTregs was enhanced in early activation, compared to that in Teffs with the 
same priming method. This was particularly prominent before the 0s and at the 420s time 
point. At most time points, the levels of PKC-θ overall accumulation in Teffs and iTregs are 
comparable. These results are contradictory to those in the previous study by Zanin-Zhorov 
et al, where they found PKC-θ was sequestered away from the IS of human Tregs by 
investigating T cell-APC conjugates on planar bilayers (201). However, more diverse 
accumulation patterns (central, diffuse and lamellal) of PKC-θ were observed in early iTreg 
activation, which suggests that iTregs are less likely to focus PKC-θ accumulation to the 
centre, compared to Teffs. Therefore, PKC-θ localisation at the IS of iTregs does not show 
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Figure 4.18 More PKC-θ-GFP molecules accumulate at the IS of iTregs Ϯ. 
Live cell imaging was performed on cell interactions of PKC-θ-GFP transduced MBP Ac1-9 
[4K]-primed Teffs or iTregs and MBP Ac1-9 [4Y]-primed PL8 cells. Spatiotemporal 
distribution patterns of PKC-θ-GFP of A) MBP Ac1-9 [4K]-primed Teffs (106 cell couples, 
six experiments) and B) MBP Ac1-9 [4K]-primed iTregs (53 cell couples, four experiments) 
were analysed and compared. C) Statistical comparisons of PKC-θ-GFP accumulation at 
the IS of difference cells using a two proportion z-test. Direct comparisons of PKC-θ-GFP D) 
central, E) diffuse, and F) lamellal accumulation at the IS of Teffs and iTregs using a two 
proportion z-test. Numerals and asterisks indicate p-values and asterisk colours indicate 
whether differences remain significant with the Bonferroni correction (0.004<*<0.05, 
0.004<**<0.01, 0.001<**<0.004, 0.0001<***<0.001, ****<0.0001). Error bars indicate 
standard error of the mean. 
 
Ϯ PKC-θ-GFP imaging data of Tg4 Teffs were generated and analysed by former PhD student Helen Tunbridge 
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4.12 Vav1 accumulation is enhanced at the IS of anti-CD3/28-
primed Tg4 iTregs 
In pMHC-TCR induced early T cell activation, SLP-76 is recruited to the LAT signalosome 
and phosphorylated SLP-76 continues to transport Vav1, a guanine nucleotide exchange 
factor (GEF) for Rho family, to the IS by binding the SH2 domain of Vav1 (204). The 
localisation of Vav-1 to the IS requires the presence of its SH2 and SH3B domain, and  
mutations of these domains completely (SH2) or partially (SH3B) reduced the transport of 
Vav1 to the IS and impaired Vav1 phosphorylation (204). Vav1 plays crucial roles in T cell 
activation as it is required for TCR-induced intracellular Ca2+ influx, activates 
phosphoinositide 3-kinases (PI3K), and regulate activation of extracellular signal-regulated 
kinase (ERK) MAP kinases, transcriptional factor NF-κB and NAFT (204-208). Moreover, 
defective antigen-receptor clustering, actin polymerisation and reorganisation, LFA-1 
mediated adhesion and cell polarisation observed in Vav1 deficient T cells suggest Vav-1 to 
be an important regulator of actin cytoskeleton in T cell activation (209, 210).  
  
Previously, Roybal et al used a Vav1-GFP fusion protein (made by Victor Tybulewicz) to 
investigate Vav1 spatiotemporal distributions upon peptide-induced T cell activation in 
5C.C7 T cells (134). Vav1 showed mainly lamellal and peripheral localisation which could 
be regulated by modest interference with actin network (165). Transient early accumulation 
in the cSMAC was also observed. In this project, we further studied and compared Vav1-
GFP spatiotemporal localisation at the IS MBP Ac1-9 [4K]-primed Teffs and anti-CD3/28-
primed iTregs, however, imaging data of anti-CD3/28-primed Teffs and MBP Ac1-9 [4K]-
primed iTregs transduced with Vav1-GFP were not acquired. iTregs transduced with Vav1-
GFP were >74% Foxp3+. Representative images displaying Vav1-GFP accumulation in 
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Figure 4.19 Representative live cell images of Tg4 Teffs and iTregs transduced with 
Vav1-GFP from four time points in early T cell activation. 
Top: DIC images from four time points. Bottom: matching top-down maximum projections of 
three-dimensional Vav1-GFP fluorescent images (intensity is encoded in pseudocolour and 
increases from purple to red). Time is given in seconds relative to the formation of a tight 
cell couple and arrows show accumulation of the sensor. 
 
In MBP Ac1-9 [4K]-primed Teffs (Figure 4.20 A), Vav1-GFP started to accumulate at the IS 
from the first time point and peaked at the 0s (49% of cells showing accumulation) time 
points. The accumulation remained stable at the IS with a slight fluctuation between the 40s 
and 100s time point.  Vav1-GFP accumulation slowly decreased from the 100s time point to 
the last, 420s time point (still with 38% of cells showing accumulation). The peripheral and 
asymmetric patterns were two main patterns observed. In contrast, in anti-CD3/28-primed 
iTregs (Figure 4.20 B), Vav1-GFP overall accumulation maintained a relative high level of 
accumulation from the 0s to 180s time point, as more than 67% of cells showing 
accumulation at all these eight time points, and the percentage of cells showing 
accumulation gradually decreased afterwards. Vav1-GFP showed mainly peripheral and 
lamellal patterning in anti-CD3/28-primed iTregs. 
 
A statistical comparison of overall Vav1-GFP accumulation shows (Figure 4.20 C) that anti-
CD3/28-primed iTregs showed more Vav-1-GFP accumulation at seven time points (20s-
180s), compared with MBP Ac1-9 [4K]-primed Teffs. All these differences remained 
significant with the Bonferroni correction suggesting the differences to be prominent. 
However, results in section 4.14 and 4.10 indicate that the method of cell priming (MBP 
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peptide and anti-CD3/28) could have impacts on spatiotemporal distribution of signalling 
molecules. Although significant differences were found when comparing percentages of 
cells showing accumulation of a same sensor (LAT-GFP and TCR-ζ-GFP) in peptide and 
antibody primed iTregs (Figure 4.10 E, 4.16 D), such differences were mostly observed 
within a period of time points and were not found intensively across most time points. Thus 
it is possible that partial enhanced Vav1-GFP accumulation would still be observed in MBP 
peptide-primed iTregs. In summary, these results suggest that Vav1 localisation at the anti-
CD3/28-primed iTregs is upregulated, compared to MBP Ac1-9 [4K]-primed Teffs, but it is 
uncertain whether similar results would still be observed when comparing Teffs and iTregs 
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Figure 4.20 Anti-CD3/28-primed iTregsϯ display more Vav1-GFP accumulation at the 
IS, compared to MBP Ac1-9 [4K]-primed Teffsϯϯ. 
Vav1-GFP transduced MBP Ac1-9 [4K]-primed Teffs or anti-CD3/28-primed iTregs were 
activated with MBP Ac1-9 [4Y]-primed PL8 cells and image for 15 minutes. Spatiotemporal 
distribution patterns of Vav1-GFP of A) MBP Ac1-9 [4K]-primed Teffs (61 cell couples, 
seven experiments) and B) anti-CD3/28-primed iTregs (57 cell couples, two experiments) 
analysed and compared. C) Comparing Vav1-GFP overall accumulation at the IS between 
MBP Ac1-9 [4K]-primed Teffs and anti-CD3/28-primed iTregs with a two proportion z-test. 
Numerals and asterisks indicate p-values and all differences observed remained significant 
with the Bonferroni correction (0.001<**<0.004, 0.0001<***<0.001, ****<0.0001). Error bars 
indicate standard error of the mean. 
 
Ϯ Vav1-GFP imaging data of Tg4 iTregs were analysed by Christoph Wuelfing. 
Ϯϯ Vav1-GFP imaging data of Tg4 Teffs were generated and analysed by former PhD student Helen. 
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4.13 F-actin accumulation at the IS of Tg4 iTregs is delayed 
Together these results above show that the IS formation and LAT nucleated signalling 
complexes are impaired in Tg4 iTregs. As morphological data suggest that T cell spreading 
and cell coupling in iTregs are also defective, we speculate the cytoskeleton network which 
drives T cell spreading to be also impaired. In leukocytes, actin filaments (F-actin, the 
polymerised form of actin) regulate membrane plasticity which generates force to drive cell 
movements (211). Triggered by TCR-pMHC engagement, rapid accumulation and dynamic 
remodelling of F-actin have been observed at the interface (171, 212). F-actin 
polymerisation at the T cell-APC interface forms a lamellipodium structure which increases 
the area of contact during the IS formation (102). Intact actin dynamics are required for the 
formation of a mature IS, central TCR-pMHC accumulation at the interface and efficient T 
cell proliferation (171). Moreover, a F-actin-rich peripheral ring has been widely observed at 
the IS (p-SMAC) and plays key roles in stabilising the interface, Ca2+ signalling and 
centralisation of proximal signalling complexes (168, 213, 214). At the IS of CD8+ T cells, 
the peripheral F-actin ring formed upon contact is essential for initiating lytic granule 
secretion for killing (215). Disruption of F-actin cytoskeleton inhibits the formation of TCR 
microclusters, TCR-induced calcium signalling and IFN-γ production (214, 216), and 
depletion of actin dynamic regulators also impairs cytoskeletal rearrangement, T cell 
activation, proliferation and cytokine secretion (217, 218).  
 
As mentioned in the last section, Vav1 regulates F-actin accumulation at the IS and most 
likely by catalysing the GDP/GTP exchange on cell division control protein 42 homolog 
(Cdc42) and Ras-related C3 botulinum toxin substrate 1 (Rac1), small GTPases of the Rho 
family (102, 207).  Localised and activated Cdc42 binds Wiskott-Aldrich syndrome protein 
(WASP) (219), while Rac1 further activates WASP-family verprolin-homologous protein-2 
(WAVE2) (101). Both WASP and WAVE2 interact with Arp2/3 complex and induce actin 
polymerisation (101, 102). Vav1 also directly binds haematopoietic-cell-specific protein-
1(HS1) which stabilise F-actin accumulation at the IS (220). Moreover, the interaction of 
Vav1 and dynamin-2 (DNM2) is required for T cell activation, as DNM2 regulates actin 
reorganisation and modulates Vav1-mediated signalling events (221).  
  
Therefore, by controlling cell motility, stabilising T cell-APC conjugates and the IS formation, 
F-actin network regulates T cell activation, and regulation of F-actin polarisation in T cells is 
mediated by downstream TCR signalling cascades. It is of great interest to investigate how 
F-actin accumulation at the synapse interacts with the LAT signalosome. 
  
F-tractin-GFP binds F-actin, as a reporter to visualise dynamic actin network at the IS in T 
cell activation (222). We have previously constructed a F-tractin-GFP protein to investigate 
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F-actin localisation and enrichment during early T cell activation in 5C.C7 cells (134). F-
actin was found to drive transient lamellal signalling organisation which is important for 
efficient T cell activation. In addition, by using a drug which disrupts F-actin structure, we 
showed that modest interference of actin dynamics could alter lamellal signalling 
localisation, impair activation of lamellal signalling molecules and calcium signalling (165). 
Finally, in this chapter, we performed live cell imaging on Tg4 Teffs and iTregs transduced 
with F-tractin-GFP to study and compare spatiotemporal localisation of F-tractin-GFP during 
their activation. F-tractin-GFP transduced iTreg were > 75% Foxp3+.  Representative 
images of Teffs and iTregs transduced with F-tractin-GFP in the first two minutes of T cell 




Figure 4.21 Representative live cell images of Tg4 Teffs and iTregs transduced with 
F-tractin-GFP from four time points in early T cell activation. 
Top: DIC images from four time points. Bottom: matching top-down maximum projections of 
three-dimensional F-tractin-GFP fluorescent images (intensity is encoded in pseudocolour 
and increases from purple to red). Time is given in seconds relative to the formation of a 
tight cell couple and arrows show accumulation of the sensor. 
 
In MBP Ac1-9 [4K]-primed Teffs (Figure 4.22 A), F-tractin-GFP accumulation at the synapse 
was observed from the -40s time point with 40% of cell showing accumulation and the 
percentage peaked at the 40s time points (100%). F-tractin-GFP steadily maintained at the 
interface till the last time point (94%). F-tractin-GFP mainly displayed peripheral, diffuse and 
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lamellal patterning in MBP peptide-primed Teffs before the 120s time point, and peripheral, 
and diffuse F-tracin-GFP accumulations were mainly observed afterwards. In MBP Ac1-9 
[4K]-primed iTregs (Figure 4.22 B), F-tractin-GFP accumulation at the IS also gradually 
increased from the -40s time point with 37% of iTregs showing this accumulation, but the 
percentage peaked later at the 120s time point (76%). F-tractin-GFP accumulation at the 
interface remained stable till the last time point. The peripheral accumulation pattern was 
dominant in MBP peptide-primed iTregs at nine time points (20s to 420s). Similar 
observations were found in anti-CD3/28-primed iTregs (Figure 4.22 C): overall F-tractin-
GFP accumulation peaked at the 180s time point (81% of the cells showing F-tractin-GFP 
accumulation) and was stable afterwards. Across all time points recorded, peripheral, 
asymmetric and diffuse F-tractin-GFP accumulation were mainly observed in anti-CD3/28-
primed iTregs.  
 
In a direct comparison (Figure 4.22 D, upper row), more cells displayed overall F-tractin-
GFP accumulation in MBP Ac1-9 [4K]-primed Teffs at six time points (0s-100s), compared 
to MBP Ac1-9 [4K]-primed iTregs (p<0.05). All these differences were significant with the 
Bonferroni correction (p<0.004), suggesting diminished accumulation of F-tractin-GFP at 
these time points. In addition, the peak of F-tractin-GFP accumulation (120s) in MBP 
peptide-primed iTregs was delayed, compared with Teffs (40s). These data together 
suggest that before the IS formation in early T cell activation, F-actin is recruited to the 
interface in MBP peptide-primed Teffs and iTregs but iTregs starts to show significantly 
reduced F-actin accumulation at the interface after the formation of a stable IS. The 
restored F-tractin-GFP accumulation in iTregs after the 120s time point indicates that F-
actin accumulation in early iTreg activation is delayed, possibly owing to the inefficient 
recruitment of F-actin to the IS. Such diminished and delayed F-actin accumulation in iTregs 
is consistent with their weaker ability to form a mature synapse observed in section 4.7. As 
F-actin serves as a scaffold in the formation of the IS and TCR microclusters, defective F-
actin cytoskeleton contributes to impaired T cell spreading and proximal signal transduction 
in early iTreg activation.  
 
When comparing F-tractin overall accumulation in MBP Ac 1-9 [4K] and anti-CD3/28-primed 
iTregs (Figure 4.22 D lower row), only one significant difference was found at the -20s time 
point (p<0.05). It was not significant with the Bonferroni correction (p>0.004). This indicates 
that F-tractin-GFP accumulation at the IS in MBP peptide-primed and anti-CD3/28-primed 
iTreg activation is similar. The differences found when comparing two types of iTregs 
(peptide and anti-CD3/28-primed) transduced with a same sensor are variable (LAT/TCR-
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Figure 4.22 F-tractin-GFP distribution during MBP Ac1-9 [4K]-primed iTreg activation 
is delayedϯ.  
Live cell imaging was performed on F-tractin-GFP transduced MBP Ac1-9 [4K]-primed 
Teffs/iTregs and anti-CD3/28-primed iTregs activated with MBP Ac1-9 [4Y]-primed PL8 
cells, for 15 minutes. F-tractin-GFP distribution patterns of A) MBP Ac1-9 [4K]-primed Teffs 
(three experiments, 45 cell couples), B) MBP Ac1-9 [4K]-primed iTregs (five experiment, 49 
cell couples), C) anti-CD3/28-primed iTregs (three experiments, 48 cells). D) Direct 
comparisons of F-tractin-GFP accumulation in different cells using a two proportion z-test. 
Numerals and asterisks indicate p-values and asterisk colours indicate whether differences 
remain significant with the Bonferroni correction (0.004<*<0.05, 0.001<**<0.004, ***<0.001). 
Error bars indicate standard error of the mean. 
 
Ϯ F-tractin-GFP imaging data of Tg4 Teffs and iTregs were generated and analysed by former lab member Silvia 
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4.14 Discussion  
In this chapter, we have investigated immunological functions (suppression on T cell 
proliferation, IFN-γ and IL-10 secretion), morphological characteristics and spatiotemporal 
distributions of five important and related signalling molecules (LAT, TCR-ζ, PKC-θ Vav1 
and F-actin) in early TCR-pMHC induced Tg4 Teff and iTreg activation.  
 
4.14.1 Suppressions from Tg4 Teffs, iTregs and Clone 4 Teffs are different 
We hypothesised that Tg4 iTregs would be able to suppress Tg4 naïve CD4+ T cells 
proliferation and Tg4 Teffs which mainly consist of Th1 cells (154), should not.  Upon cell-
cell contact, purified CD4+CD25+ Tregs can suppress CD4+CD25- T cell proliferation and 
block IL-2 production when activated by anti-CD3 or APCs or both (174, 223). Tg4 iTregs 
also showed suppression on naïve CD4+ T cell proliferation when activated with MBP Ac1-9 
peptide and irradiated APCs (139). Such immunosuppressive activity with minimum antigen 
specificity of iTregs distinguishes from other CD4+ helper subsets (21). Therefore, in this 
project, we measured and compared the level of suppression induced by both Tg4 Teffs 
and iTregs. 
  
When activated by MBP Ac1-9 [4K], Tg4 anti-CD3/28-primed iTregs and MBP Ac1-9 [4K]-
primed Teffs showed a comparable suppressive ability to inhibit Tg4 naïve CD4+ T cell 
proliferation, and higher ratios of Teffs/iTregs to naïve CD4+ T cells were related with 
stronger suppression. Similar results were found in control experiments measuring 
suppression of Clone 4 CD8+ Teffs on Tg4 naïve T cells. However, such suppression was 
not observed when cells were activated with plate-bound anti-CD3/28 instead of PL8 cells 
and MBP peptide, suggesting interactions between Tg4 Teffs, iTregs, or Clone 4 Teffs and 
PL8 cells play key roles in inducing suppression on Tg4 naïve T cell proliferation. 
  
The existence of PL8 cells, might partially contribute to suppression observed. It is curious 
that higher ratios of PL8 cells to responder cells partially enhanced suppression, though this 
could be a result of variability from only one set experiments.  PL8 cells die a few days after 
treated with mitomycin C, however, as B lymphoma cells, they might deprive nutrients of the 
culture before their apoptosis. Adding additional Teff or iTregs might enhance such process. 
Tg4 Teffs or iTregs may also compete for MBP peptides with the Tg4 naïve T cells as they 
all form the same pMHC-TCR interaction, while this does not apply to Clone 4 cells. It is 
also suspected that IL-2 consumption by activated CD4+ or CD8+ cells in the culture might 
partially lead to the suppression. The trimeric IL-2R consists of three chains, CD25 (IL-2Rα), 
CD122 (IL-2Rβ) and CD132 (IL-2Rγ) (224). Naïve CD4+ T cells do not express expression 
CD25 and express low levels of CD122 and CD132, while upon TCR activation, CD25 is 
highly expressed by CD4+ and CD8+ T cells (225). Tregs suppress T cell proliferation by 
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inhibiting IL-2 production (174). With a high level of CD25, Tregs also compete with naive 
CD4+ T cells for IL-2, and IL-2 and TCR signals promote IL-10 production in Tregs (226). 
Tg4 CD4+ Teffs and Clone CD8+ Teffs had been continuously cultured with exogenous IL-2 
and likely express high levels of IL-2R. Therefore, their high affinity for binding IL-2 might 
contribute to the suppression of Tg4 naïve T cells. However, additional IL-2 added in wells 
with Clone 4 CD8+ Teffs might be sufficient for the naïve T cells to overcome this. Moreover, 
interactions of PL8 cells and Clone 4 T cells should be considered. PL8 cells were 
generated by fusing blast cells with M12 C3 cells which originated from BALB/c B 
lymphoma cells expressing H-2d MHC (137, 227). Clone 4 T cells originated from B10.D2 
mice and were homozygous for H-2d (175). However, Clone 4 TCRs were specifically 
selected to recognise HA peptides presented by MHC class I H-2Kd, and such selection 
would also apply to MHC class I of PL8 cells. Therefore, PL8 cells should not be able to 
activate CL4 cells in the presence of MBP peptides which are not agonist peptides for their 
TCRs. A control condition containing PL8 cells, Clone 4 T cells and MBP peptides without 
additional IL-2 should better clarify this argument.  
  
One possible explanation for not detecting suppression in plate-bound anti-CD3/28 
activated cells might be that the TCR stimulation was too strong. Suppression was hardly 
found in conditions activated by plate-bound anti-CD3 (174). Shevach suggested that when 
T cells bound anti-CD3 attached to a plate, they receive a continuous potent signal which 
allows cells to overcome Treg-induced suppression (228). Even when induced by lower 
concentrations of anti-CD3, this resistance to suppression remains. Moreover, the use of 
anti-CD28 in addition to soluble anti-CD3 and irradiated accessory cells is not 
recommended, as stronger costimulation hinders Treg-mediated suppression by enhancing 
IL-2 production (228).  Additional anti-CD28 or exogenous IL-2 abrogates CD4+ CD25+ Treg 
suppression on CD4+CD25- T cells when activated by anti-CD3 or peptide-primed APCs 
(223). In this project, the level of costimulation from 2 µg/ml anti-CD28 has not been 
assessed. Some anti-CD3/28 activated CD4+ naïve T cells showed even enhanced 
proliferation in the presence of Teffs/iTregs, indicating that they might have received more 
IL-2 produced by activated Teffs/iTregs. Therefore, these data suggest that using plate-
bound anti-CD3 and additional anti-CD28 to obtain suppression in this assay to be difficult.  
 
Overall, the in vitro iTreg suppression applied in this study has several defects. The direct 
cell to cell contact of iTregs and naive T cells were not monitored. Experimental controls 
and repeated experiments were neither sufficient to draw clear conclusions. Cells activated 
by plate-bound anti-CD3/28 were likely to overcome Treg suppression owing to the 
continuous stimulation. Further adjustments are required to better assess the suppressive 
capabilities of iTregs. For example, using irradiated endogenous Tg4 accessory cells or 
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anti-CD3 only should be more appropriate to activate Tg4 naïve cells in the presence of Tg4 
iTregs or Teffs. To verify whether the suppression is induced via cell to cell contact or 
cytokines, a membrane previously described (229) which allows soluble molecules but not 
cells to penetrate, could be added to wells.  
 
4.14.2 Tg4 iTregs secrete less IFN-γ and potentially more IL-10 
Cytokines produced by different subsets of T cells are linked with their functions. As 
mentioned, IFN-γ is a signature cytokine produced by Th1 cells for effector functions and 
induces innate and T cell response (21). Activating Tg4 naïve T cells in vitro with MBP 
peptides triggers a dominant Th1 response (154). This was observed in our Teff-inducing 
conditions as high concentrations of IFN-γ were detected 24 hours after MBP priming. 
Lower levels of IFN-γ were detected in iTreg-inducing conditions and intracellular cytokine 
staining also confirmed that both Tg4 Teffs and iTregs secrete IFN-γ. The levels of IFN-γ in 
the two conditions were significantly different on day 2 and 3. The ratio of Foxp3+ to Foxp3- 
cells gradually increased from day 2-5 indicates the transformation of iTregs from naive 
CD4+ T cells. On day 2, most cells in iTreg-inducing conditions did not express Foxp3. 
Therefore, it might be that Th1 cells in iTreg-inducing conditions still contributed to the main 
production of IFN-γ at early stages of iTreg induction. These Th1 cells eventually either died 
out or transformed into iTregs. On day 3, about 40% of the cells were Foxp3+ in iTreg-
inducing condition. The different levels of IFN-γ detected on this day could be owing to a 
weaker capability of iTregs to produce IFN-γ, and these Tg4 iTregs likely maintained some 
Th1 phenotypes. This could be an intrinsic feature of Tg4 T cells. IFN-γ production of Tregs 
has been associated with their regulatory function. A lower suppressive capacity of 
CD4+CD25+ Treg against collagen-induced arthritis (CIA) was previously found in IFN-γ 
receptor (IFN-γR) deficient mice, suggesting IFN-γ could mediate Treg-induced suppression 
(230). Besides, restimulation of alloantigens in vivo led to a transient increase of IFN-γ 
mRNA in alloantigen-reactive CD4+CD25+ Tregs, and neutralisation of IFN-γ upon adoptive 
transfer of Tregs abrogated their immunoregulatory function (231).  CD4+CD25+Foxp3+ 
Tregs isolated from spleens and lymph nodes do not express IFN-γ, but IFN-γ and T-bet 
expression can be detected in after culturing them with IL-12 for 72 hours (232). This 
suggests the plasticity of Teffs and Tregs could be regulated via an epigenetic mechanism. 
Moreover, IFN-γ production of stable Foxp3+ iTregs also helps to prevent experimental 
GVHD (233). Possibly, rapid and transient production of IFN-γ inhibits immune response by 
inducing apoptosis of naïve and Th2 cells, as they express both IFN-γR1 and IFN-γR2 and 
are more sensitive (234). In summary, IFN-γ detected during Tg4 iTreg development is 
secreted by both Th1 cells and iTregs which hold a weaker IFN-γ-secreting ability. These 
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A relatively low amount of IL-10 has been detected during the generation of both Tg4 Teffs 
and iTregs, particularly on day 3 of induction. IL-10 can be secreted by a wide range of cells 
such as DCs, macrophages, mast cells, NK cells, eosinophils, neutrophils, B cells, CD8+ T 
cells and several subsets of CD4+ T cells including Th1, Th2, Th17, Foxp3- (Tr1) and 
Foxp3+ Tregs (reviewed by Ng et al (156)).  Tg4 Th1 cells could be induced to secrete IL-10 
by chronic repeated intranasal administration of MBP peptides in vivo (92). A subsequent 
study revealed that Th2-derived IL-4 could promote IL-10 production by these Th1 cells, 
and IL-4 blockade could inhibit their IL-10 expression (235).  Also, high antigen dose and IL-
12 can promote IL-10 production by Th1 cells (236). Possibly, transient IL-10 production by 
Teffs was owing to a relatively high concentration of MBP-peptides and IL-12 released by 
PL8 cells in cell culture. When Tg4 Teffs from day 5 of culture were reactivated, they 
produced IL-10. As mixed splenocytes and lymphocytes were used for cell priming, direct 
sources of the transient IL-10 production on day 3 were uncertain. Using markers in addition 
to Foxp3 for other T cells subsets (such as T-bet for Th1, GATA3 for Th2 and ROR-γt for 
Th17 (21)) and accessory cells alongside with IL-10 staining would be a possible solution. 
During the generation of Tg4 iTregs, the percentage of Foxp3+ cells in iTreg-inducing 
conditions peaked on day 5 and Tg4 iTregs showed a trend to sustain IL-10 production on 
day 5 and 6. They secreted slightly but not significantly more IL-10 when restimulated on 
day 5. These observations combined indicate that Tg4 Foxp3+ iTregs tend to produce more 
IL-10 than Tg4 Teffs. Further IL-10 staining or IL-10 mRNA determination would help to 
assess the production of IL-10 by Tg4 Teffs and iTregs. 
 
4.14.3 Defective IS formation is associated with delayed F-actin accumulation 
in Tg4 iTregs 
There are three different stages of interactions between T and antigen-presenting B cells: 
contact, recognition and stabilisation (163). The initial two minutes of activation of Tg4 T 
cells mostly fall into the contact and recognition phases, where dynamic morphological 
changes and increased Ca2+ influx occur. At these early stages in antigen presentation to B 
cells, T cells increase their interface of contact, pulling the cell body towards and engulf a 
proportion of the APC. During these early phases, LAT transduced Tg4 iTregs show a 
reduced contact length and are more likely to form an extended lamella, compared to Teffs. 
In the first two minutes of activation, the interface of contact in Tg4 iTregs does not spread 
as wide that in Teffs. It should be noted that F-actin accumulation at the IS of iTregs is also 
significantly reduced within the two minutes of activation. These data suggest that defective 
T cell spreading of iTregs at the synapse is associated with delayed actin polymerisation. 
Moreover, iTregs also display a more elongated cell shape within these two minutes and 
they formed more extended lamellae at early time points (0s and 20s). Proximal T cell 
activation signals subsequently induce actin polymerisation at the interface, which increases 
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the area of contact and stabilises IS formation (102). Defective F-actin-dependant scaffolds 
impair the formation of proximal TCR microclusters and more elongated cell shapes are 
indicative of less efficient T cell activation (164, 214). Thus, compared to that of Teffs, 
morphological features of iTregs in the first two minutes of T cell activation suggest that the 
IS formation of iTregs are defective, which most likely are associated with diminished F-
actin polarisation within this period.  
 
4.14.4 Impaired assembly of LAT supramolecular complexes contributes to 
less efficient activation of Tg4 iTregs  
Proximal T cell activation signalling is triggered by TCR-pMHC engagement with the 
assistance of CD4 or CD8 co-receptor and cytokine signals, which subsequently recruits the 
tyrosine kinase Lck to phosphorylate ITAMs of TCR-ζ chains. When phosphorylated, ITAMs 
bind ZAP-70 which continues to phosphorylate LAT and promotes the formation of LAT 
nucleated supramolecular signalling complexes (94). As a signalling hub, LAT binds Grb2, 
Gad, and PLC-γ 1 and eventually drives more signalling intermediates including Sos1, SLP-
76, Nck and Vav to the LAT signalosome via multivalent interactions, and further leads to F-
actin polarisation, Ca2+ influx and activation of transcriptional factors such as AP-1, NF-κB 
and NFAT. These signalling events, together with signals from costimulatory and cytokine 
receptors, eventually induce T cell proliferation, cell migration, cytokine secretion and 
effector functions (185, 237).  
 
As defective IS formation has been observed in Tg4 iTregs, likely, proximal TCR signal 
transduction is also impaired. To investigate and compare TCR-induced signal transduction 
in early activation of Tg4 Teffs and iTregs, we have acquired and analysed live cell imaging 
data of five GFP-tagged signalling intermediates (LAT, TCR-ζ, PKC-θ, Vav1 and F-tractin) 
during the first few minutes of activation. Spatiotemporal pattern analyses show that Tg4 
iTregs display impaired spatiotemporal distributions of LAT, TCR ζ, F-actin in early T cell 
activation but increased overall PKC-θ accumulation at the T cell-APC interface. When 
analysing spatiotemporal organisation of signalling intermediates of the cSMAC in these 
several minutes, two different time-dependent roles played by the cSMAC needed to be 
considered (126). In the first 60-120 seconds of T cell activation, the cSMAC efficiently 
induces central clustering of various signalling intermediates including LAT, Grb2, SLP-76, 
PKC-θ (126, 130, 135). After the 120s time point, many of these molecules withdraw from 
the cSMAC and some (such as SLP-76, Vav1, PIP2 and Itk) intensively spread around the 
IS forming actin-associated lamellal complexes (126, 134, 135).  In addition, rapid 
translocation of NFAT and NF-κB to the nucleus also occurs after the 60s or 120s time point, 
which indicates that rapid accumulation of proximal signalling intermediates at early time 
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points are sufficient to activate these transcriptional factors and promote further T cell 
activation (130, 135). 
 
Spatiotemporal localisation of LAT in this study consistently reflects the time-dependent 
roles played by the cSMAC. In the first 60-120 seconds of Tg4 Teff activation, LAT rapidly 
accumulates at the centre of the T cell-APC interface and simultaneously induces clustering 
of PKC-θ, Vav1 and TCR-ζ, and F-actin polymerisation at the IS. After the first two minutes 
of activation, LAT localisation at the IS gradually diminishes, as well as that of PKC-θ and 
Vav1. While TCR-ζ accumulation remains at the interface with an increasing trend of central 
clustering and F-actin accumulation remains at a high level at the IS. They continue to 
stabilise the mature IS. This cSMAC-regulated spatiotemporal organisation in early 
activation is impaired in Tg4 iTregs. Overall accumulation of LAT and F-actin are 
significantly reduced at the IS of iTregs in the first two minutes and TCR-ζ clustering at the 
immune synapse is also attenuated, particularly after the 120s time point. These data 
illustrate that in iTregs, diminished LAT accumulation fails to rapidly assemble LAT 
signalosome, subsequently upsets actin polymerisation and TCR central clustering at the IS. 
This interaction is bi-directional, as Roybal et al showed that in costimulation blocked 5C.C7 
T cells, enhancing actin polarisation restores LAT central clustering (173). Together, 
morphological studies and spatiotemporal pattern analyses of proximal signalling 
intermediates indicate that early T cell activation and IS formation are defective in iTregs. It 
is unclear why PKC-θ accumulation in iTregs is increased with diverse accumulation 
patterns and its roles in Treg function is complicated (200, 201). Moreover, the fact that 
PKC-θ is not directly recruited to the cSMAC by LAT signalosome, but CD28 (238) may 
partially explain why its localisation in iTreg activation is more intact.  
 
As early activation signalling events are defective in iTregs, translocation and activation of 
transcriptional factors including NFAT and NF-κB at the downstream are likely to be 
affected. Compared to Teffs, iTregs secrete less IFN-γ upon activation, which could be 
partially associated with attenuated activation of NFAT, as NFAT also induces IFN-γ 
production in CD4+ T cells (239).  
 
In conclusion, in early TCR-induced activation of Tg4 iTregs, defective assembly of LAT 
signalosome subsequently results in impaired proximal TCR clustering and F-actin 
polarisation at the IS. These diminished signalling events together contribute to less efficient 
activation of iTregs, with unstable IS formation and a weakened ability to produce IFN-γ. It 
is of interest to investigate whether enhancement or restoration of LAT localisation could 
change proximal T cell signalling in iTregs and alter how iTregs behave. We attempt to 
answer this question in the rest of the thesis. 
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 Dual CTLA-4 and PD-1 blockade inhibits Chapter 5
development but improves activation of MBP peptide-
primed Tg4 iTregs   
 
5.1 Introduction 
Tg4 iTregs display a reduced ability to secrete IFN-γ and forming a mature IS, which is 
associated with their defective proximal T cell signalling events. Therefore, the 
enhancement of these events could promote better iTreg activation and subsequently affect 
their function. Another key element required for T cell activation apart from TCR signalling is 
costimulation, which is negatively regulated by coinhibitory (or checkpoint) receptors (116). 
As Tregs express several coinhibitory molecules including CTLA-4, PD-1, TIGIT and LAG3, 
blocking their coinhibitory pathways should enhance activation of iTregs. CTLA-4 and PD-1 
have been extensively studied for their therapeutic potentials in autoimmunity and cancer 
(240-243). In this chapter, we investigated the roles of CTLA-4 and PD-1 in iTreg cell 
development, activation and function. 
 
CTLA-4 is a homolog of CD28 but with a much higher affinity for binding CD80 and CD86 
expressed on APCs by a factor of 50-2000-fold (244).  Resting T cells do not express 
CTLA-4 and can be induced by activation, but Tregs constitutively express CTLA-4 (245, 
246). Unlike CD28, binding of CTLA-4 and CD80/86 does not induce costimulatory signals, 
thus by competing with CD28 for binding sites, CTLA-4 negatively regulates T cell activation 
(244). CTLA-4 induced inhibition of T cells could be regulated by the strength of TCR 
stimulation. Reviewed by Buchbinder et al (247), upon weak TCR stimulation, CD28 
predominantly binds CD80/86 and enhances IL-2 production, cell proliferation and survival. 
While upon strong TCR stimulation, CTLA-4 competes with CD28 as its expression on the 
cell surface is upregulated, which inhibits T cell activation. Other studies suggest that CTLA-
4 could also induce direct inhibition by antagonising TCR-mediated signals and increasing T 
cell motility to reduce the efficiency of TCR-pMHC engagement (248, 249). Takahashi et al 
showed that blockade of CTLA-4 in vivo and in vitro impairs the suppressive function of 
Treg in mice, thus the expression of CTLA-4 contributes to Tregs mediated immune 
suppression and self-tolerance (246). Moreover, specific deletion of CTLA-4 in Foxp3+ 
Tregs lead to systemic lymphoproliferation and fatal autoimmune disease which indicates 
CTLA-4 is required by naturally occurring Tregs for their immune regulatory function (250). 
A recent study shows that CTLA-4 expressed by Tregs can directly capture CD80 and 
CD86 from migratory DCs via a process of trans-endocytosis, which may contribute to Treg-
mediated suppression (50). 
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PD-1 is a member of the B7-CD28 family and binds its ligand PD-L1 and PD-L2 to inhibit T 
cell proliferation and cytokine production (251, 252). Activated T cells, B cells and myeloid 
cells express PD-1 and PD-L1 is constitutively expressed by T cells, B cells, macrophages 
and DCs(251, 253). While PD-L2 is more restrictedly expressed in DCs, macrophages and 
some resting peritoneal B1 cells (254). Upon T cell-ACP interactions, PD-1 ligation induces 
phosphorylation of its immunoreceptor tyrosine-based switch motif (ITSM) and 
immunoreceptor tyrosine-based inhibitory motif (ITIM), which recruit phosphatases including 
SHP-1 and SHP-2 (255). These phosphatases induce dephosphorylate signalling molecules 
and antagonise TCR and CD28 triggered activation signalling (e.g ZAP-70, PI3K and Ras 
signalling pathways), thus inhibit T cell activation (256). PD-L1 also plays a key role in iTreg 
development and cell function. PD-L1 deficient APCs show an impaired ability to induce 
Foxp3+ iTregs, and PD-L1-coated beads maintain Foxp3 expression and enhance iTreg-
mediated immune suppression on Teffs (257, 258).  
 
Early studies showed that blocking CTLA-4 and PD-1 pathway enhances anti-tumour 
immune responses respectively (259, 260). Monoclonal antibodies (mAbs) targeting CTLA-
4, PD-1 and PD-L1 have been intensively studied for their immunotherapeutic potentials 
and some have been approved for treating different types of cancers including melanoma, 
lung cancer, breast cancer and B-cell lymphoma (243). Moreover, both anti-CTLA-4 and 
anti-PD-1 antibodies have been shown to effectively induce deletion of Tregs in the tumour 
microenvironment in mouse models (261, 262). While Sharma et al showed two mAbs for 
CTLA-4, ipilimumab and tremelimumab do not delete Tregs in human cancers (263). 
 
How CTLA-4 and PD-1 directly regulate development and suppressive function of Tregs is 
not fully understood. In this section, we aim to investigate their roles in the induction and 
activation of Tg4 iTregs. Thus, we first treated Tg4 naive T cells with anti-CTLA-4 or anti-
PD-1 or both mAbs during their induction to become iTregs. Frequencies of Foxp3+ cells in 
controls and mAb-treated conditions were examined from day 2-6 of culture. Moreover, IFN-
γ and IL-10 ELISAs were applied to monitor changes of cytokine production in each 
condition during iTreg induction. To study whether the dual blockade could change how 
iTregs behave, we blocked CTLA-4 and PD-1 pathways during the first several minutes of 
iTreg activation and live cell imaging was performed. Morphological parameters and LAT 
localisation of anti-CTLA-4/PD-1 blocked iTregs were analysed to assess the effects of the 
dual blockade on T cell morphology and impaired spatiotemporal distributions of LAT in 
early iTreg activation. Experiments were conducted mainly on MBP peptide-primed iTregs 
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5.2 Chapter aims 
• To treat naïve Tg4 T cells with anti-CTLA-4 or anti-PD-1 or both mAbs during induction 
of iTregs and assess their Foxp3 expression from day 2-6 of culture.  
• To assess the impacts of anti-CTLA-4, anti-PD-1, and both mAbs on IFN-γ and IL-10 
production during iTreg induction. 
• To conduct live cell imaging on LAT-GFP transduced iTreg treated with dual blockade of 
CTLA-4 and PD-1, and compare their morphological parameters and LAT-GFP 
spatiotemporal distributions to that of untreated Teffs and iTregs.  
  
 
A table is shown below indicating symbols used in this chapter for different conditions. 
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5.3 Dual blockade of CTLA-4 and PD-1 inhibits Tg4 iTreg 
development 
First, we investigated the roles of CTLA-4 and PD-1 in Tg4 iTreg development by blocking 
CTLA-4 or PD-1 or both using mAbs during iTreg induction. Tg4 naïve T cells were primed 
with MBP Ac1-9 [4K] and endogenous APCs as described above. Cells were cultured in 
Treg-inducing medium containing IL-2 and TGF-β for five days. Additional anti-CTLA-4 or 
anti-PD-1 or both blocking mAbs were added into experimental groups from day 1 with a 
final concentration of 10 µg/ml. Cell medium was exchanged daily with supplemental mAbs 
and cells were split when required, usually on day 3. To track the differentiation of iTregs, 
cell samples were collected on a daily base from day 2 and stained for Foxp3 to identify 
iTreg populations in each condition. 
 
Figure 5.1 A summarises frequencies of Foxp3+ cells in each condition from day 2-6 of 
culture. Consistently, the percentage of Foxp3+ cells in each condition gradually increased 
from day 3 and peaked on day 5. This pattern was consistently observed in all four repeated 
experiments.  The percentage of Foxp3+ cells in the control condition where no blocking 
mAbs were added, was the highest among the four conditions from day 3 to 6. Treating 
iTreg-inducing cells with anti-CTLA-4 or anti-PD-1 or both continuously reduced the 
frequency of Foxp3+ cells from day 3-6 and using both mAbs led to a most remarkable 
reduction. On day 6, the percentage of Foxp3+ cells decreased by an average of 11% (anti-
CTLA-4), 14% (anti-PD-1) and 24% (anti-CTLA-4/PD-1) respectively. In the condition 
treated with both anti-CTLA-4/PD-1, the percentage of Foxp3+ cells was the lowest on those 
four days. The inhibition induced by these mAbs were cumulative. Multiple comparisons 
using Two-way ANOVA show that no significant differences were identified when comparing 
the percentages of Foxp3+ cells among all conditions. However, by normalising the 
frequencies of Foxp3+ cells in treatment groups to control groups from day 3-6, differences 
observed were prominent (Figure 5.1 B). Blockade of CTLA-4, PD-1 and both significantly 
reduced the frequency of Foxp3+ cells (p<0.05). Anti-PD-1 showed slightly better inhibition 
of Foxp3 expression than anti-CTLA-4. Additional data from experiments where iTregs-
inducing cells were treated with and without both mAbs for five days were compared. These 
cells were only stained for Foxp3 on day 6. A direct comparison (Figure 5.1 C) shows that 
the percentages of Foxp3+ cells in iTreg-inducing cells treated with anti-CTLA-4/PD-1 on 
day 6 were significantly reduced by an average of 20%, compared to untreated iTreg-
inducing cells (p<0.0001).  
 
These results indicate that during the induction of Tg4 iTregs primed with MBP peptide, 
blocking both CTLA-4 and PD-1 downregulates the proportion of Foxp3+ cell in these cells 
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and therefore inhibit iTreg development. Blocking CTLA-4 or PD-1 alone moderately inhibits 
iTreg development and using both mAbs leads to a most significant reduction of Foxp3+ 
populations. Foxp3+ T cells were mainly identified from day 3 of culture, which suggests that 
naïve T cells need about 24 hours of priming to express Foxp3. Therefore, CTLA-4 and PD-
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Figure 5.1 Dual CTLA-4 and PD-1 blockade inhibits induction of Foxp3+ iTregs. 
iTreg-inducing cells were treated with anti-CTLA-4 or anti-PD-1 or both mAbs with a final 
concentration of 10 µg/ml and were cultured for five days. Cell samples were collected daily 
from day 2-6 of culture for identifying Foxp3+ cell populations. Data of untreated iTreg-
inducing cells refer to Figure 4.5. A) A summary plot graph of percentages of Foxp3+ cells 
from four conditions from day 2-6, data are from four experiments, B) The relative 
percentages of Foxp3+ cells from four conditions on day 3-6, cells without treatments were 
used as controls for normalisation, data are four experiments, C) Comparing the 
percentages of Foxp3+ cells of untreated and anti-CTLA-4/PD-1 daily treated iTregs on day 
6, data are from eight experiments. Proportions were arcsine transformed or normalised to 
control, and statistical significance was calculated using A) Two-way ANOVA, B) One-way 
ANOVA, C) paired Student’s T-test. Asterisks indicates p-values (*<0.05, **<0.01, ***<0.001, 
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5.4 Dual blockade of CTLA-4 and PD-1 slightly enhances IFN-γ and 
IL-10 production during Tg4 Teff and iTreg development 
As we have shown in the last chapter that Tg4 iTregs are less capable to produce IFN-γ 
and tend to maintain IL-10 secretion during their induction, we further investigated whether 
IFN-γ and IL-10 secretion during iTreg development could be altered by CTLA-4 and PD-1 
blockades. In addition, we applied the same treatments on Teff-inducing cells (cultured with 
less IL-2 and no TGF-β). A series of cell supernatants were collected daily from cell cultures 
and ELISAs were performed to assess IFN-γ and IL-10 production during the five days of 
culture. Data from a total of five experiments were plotted (Figure 5.2) and three of these 
experiments did not contain conditions treated with only anti-CTLA-4 or anti-PD-1.  
 
IFN-γ ELISAs show that during the induction of Teffs (Figure 5.2 A), increased IFN-γ 
production were found in cells treated with anti-CTLA-4 or anti-PD1 or both mAbs, mainly 
on day 2, 4 and 5. Among all conditions, the amounts of IFN-γ detected peaked on day 3 
and a combination of blocking CTLA-4 and PD-1 had best outcomes in enhancing IFN-γ 
secretion, which significantly increased IFN-γ secretion of Teffs on day 4 (p<0.05). IFN-γ 
secretion detected was relatively low on day 5 and 6.  
 
Different observations were found in iTreg-inducing conditions (Figure 5.2 B and C), as 
blocking CTLA-4 or PD-1 or both during iTreg development only slightly increased IFN-γ 
production, compared to that of untreated iTregs. As single antibody treatments using anti-
CTLA-4 or anti-PD-1 were only performed in two paired experiments, we analysed two 
separate graphs showing data from all paired experiments to reduce experimental variability. 
IFN-γ secretion detected also peaked on day 3 and 4 in all iTreg-inducing conditions and 
was barely detected on day 6. Blocking PD-1 and blocking both CTLA-4 and PD-1, tended 
to enhance IFN-γ secretion better than blocking CTLA-4 in iTreg-inducing cell cultures on 
day 3 and 4 (Figure 5.2 B). Overall, IFN-γ secretion by iTreg was barely affected by the 
blockades. 
 
To summarise, these data suggest that blocking both CTLA-4 and PD-1 mostly enhances 
IFN-γ production during Tg4 Teff development. Stronger enhancement of IFN-γ secretion in 
Teff-inducing conditions was observed suggesting Teffs are more responsive to the 
blockades than iTregs, regarding IFN-γ secretion. Moreover, in iTreg-inducing conditions, 
enhanced IFN-γ secretion might not only contributed by iTregs, as the blockades 
downregulated the proportions of these cells during iTreg induction (shown in Figure 5.1). It 
is likely that this slightly increased IFN-γ secretion was owing to reduced Foxp3+ and 
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increased Teff cell populations, as we have shown in section 4.6 that Tg4 Foxp3+ iTregs 
secrete less IFN-γ, compared to Teffs. 
 
 
Figure 5.2 Blocking CTLA-4 and PD-1 during the induction of Teffs and iTregs slightly 
increases IFN-γ production. 
ELISAs were performed on daily collected supernatants from cell cultures of A) Teff and B 
and C) iTreg-inducing cells treated with anti-CTLA-4, anti-PD-1 or both, to assess IFN-γ 
production. Data from a total of five experiments are used. To show all paired experiments, 
the number of repeated experiments in each condition is different: three in A), two in B) and 
five in C). Statistical significance was calculated using Two-way ANOVA. Asterisks indicate 





Chapter 5  
As shown in section 4.6, IL-10 secretion was relatively low during both Tg4 Teff and iTreg 
development. In addition, using a combination of anti-CTLA-4/PD-1 had a better effect on 
enhancing IFN-γ secretion, so we applied IL-10 ELISAs to investigate whether this 
combination with both mAbs would alter IL-10 production during Teff and iTreg development. 
Data are from a total of five experiments and two experiments did not contain conditions of 
Teff-inducing cells treated with anti-CTLA-4/PD-1. 
 
Again, results from IL-10 ELISAs show that blocking both CTLA-4 and PD-1 slightly 
enhanced IL-10 secretion during Tg4 Teff and iTreg induction (Figure 5.3 A). In untreated 
and anti-CTLA-4/PD-1 treated Teff-inducing conditions, IL-10 was mainly detected on day 
3-5. Blocking both CTLA-4 and PD-1 during Teff-induction slightly increased the amounts of 
IL-10 on day 3-5. For untreated iTreg-inducing conditions, IL-10 secretion detected was 
relatively low and dual mAb treatment slightly enhanced IL-10 secretion of iTreg-inducing 
cells on day 3-6. Although no significant differences were identified when comparing any 
two of these conditions, this is likely owing to the variability of experiments and trends of 
enhancement could be found on day 3-5. Together these results suggest that blocking both 
CTLA-4 and PD-1 shows a trend of enhancing IL-10 production during Tg4 Teff and iTreg 
development. 
 
However, as low levels of IL-10 production were observed during the induction of both types 
of cells, dual mAb treatment might have a limited effect on IL-10 secretion during their 
development. We have shown in section 4.6 that activating mature Teffs and iTregs on day 
5 of culture could induce IL-10 secretion. Therefore, we restimulated untreated Teffs and 
iTregs on day 5 of culture using MBP Ac1-9 [4K] peptides and mitomycin C treated PL8 
cells and measured the amounts of IL-10 released after 18 hours. Additional anti-CTLA-
4/PD-1 mAbs were added into parallel conditions as treatment groups. Figure 5.3 B shows 
that blocking CTLA-4 and PD-1 for 18 hours in restimulated Teffs and iTregs had little 
effects on their IL-10 secretion. This dual mAb treatment marginally downregulated IL-10 
secretion in restimulated iTregs, but the difference was not significant.  
 
In summary, dual CTLA-4 and PD-1 blockade slightly promotes both IFN-γ and IL-10 
production detected during induction of Tg4 Teffs and iTregs. Blocking CTLA-4 and PD-1 




Chapter 5  
 
Figure 5.3 Blocking CTLA-4 and PD-1 slightly increases IL-10 production during Teff 
and iTreg generation but has no impacts on IL-10 production of restimulated Teffs 
and iTregs. 
Cells supernatants from conditions of Teff and iTreg-inducing cells treated with anti-CTLA-4, 
anti-PD-1 or both for five days were collected and used for A) IL-10 ELISAs, data are from a 
total of five experiments. Anti-CTLA-4/PD-1 mAbs were added to restimulated Teffs and 
iTregs (>62% Foxp3+) from day 5 of culture and cells were incubated for 18 hours. 
Supernatants were then collected and B) IL-10 ELISAs were performed, data are from five 
experiments. Statistical significance was calculated using A) Two-way and B) One-way 
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5.5 Blocking CTLA-4 and PD-1 during T cell activation helps to 
stablise the IS formation in Tg4 MBP peptide-primed iTregs 
Morphological comparisons in section 4.7 show that Tg4 iTregs form a less stable IS during 
the first two minutes of T cell activation. In this chapter, we further investigated whether 
blocking both CTLA-4 and PD-1 would affect the IS formation upon Tg4 iTreg activation, 
induced by MBP Ac1-9 [4Y] peptide-primed PL8 cells. Before live cell imaging, we 
resuspended Tg4 iTregs in imaging buffer with anti-CTLA-4/PD-1, both in a final 
concentration of 10 µg/ml. To be consistent with iTregs analysed in section 4.7, LAT-GFP 
transduced iTregs were used (>75% Foxp3+). DIC images were used for measuring 
morphological parameters. The three morphological ratios during the first two minutes of 
activation of Tg4 Teffs, iTregs and iTregs treated with anti-CTLA-4/PD-1 were compared. 
We first analysed experiments using MBP Ac1-9 [4K]-primed cells. 
 
As previously observed in MBP peptide-primed T cells from section 4.7, Teffs formed a 
wider interface in the first two minutes of activation. In the group comparison, the ratio of 
interface width to cell width (Figure 5.4 A) of Teffs was significantly higher than that of 
iTregs at the 0s, 20s and 120s time points (p<0.05). The differences were prominent at the 
0s and 20s time point (p<0.01). The result shows that the ratio of interface width to cell 
width of iTregs treated with ant-CTLA-4/PD-1 during their activation was higher than that of 
iTregs without treatments at all four time points (p<0.05), and the difference was highly 
significant at the 60s and 120s (p<0.0001) time point. While there were no significant 
differences observed when comparing this ratio of iTregs treated with anti-CTLA-4/PD-1 to 
that of Teffs, at all four time points. At the 60s and 120s time point, the mean ratio of 
interface width to cell width of iTregs treated with ant-CTLA-4/PD-1 was even higher than 
that of Teffs. These comparisons show that blocking both CTLA-4 and PD-1 during the first 
two minutes of MBP peptide-primed iTreg activation, significantly extended the interface of 
the IS, particularly at late time points. The dual mAb treated iTregs spread their cell 
membranes as Teffs did, during the first two minutes of cell coupling, which might be related 
with more stable synapse formation. 
 
When comparing the ratios of lamella depth to cell depth among these three conditions, no 
significant differences were found at any time point (Figure 5.4 B), suggesting the dual mAb 
treatment does not change the length of the extended lamellae in MBP peptide-primed T 
cells.  
 
The ratio of lamella depth to interface describes overall shapes of T cells during cell 
coupling. As shown in section 4.7, MBP peptide-primed iTregs showed a significantly higher 
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ratio of lamella depth to interface at the 0s (p<0.0001), 20s (p<0.0001) and 60s (p<0.05) 
time point, compared to Teffs (Figure 5.4 C). This ratio of iTregs treated with anti-CTLA-
4/PD-1 was significantly lower than that of untreated iTreg at the 0s (p<0.05) time point.  
When comparing this ratio of anti-CTLA-4/PD-1 treated iTregs with that of Teffs, one 
significant difference was observed at the 20s time point (p<0.01). The dual mAb treatment 
ether eliminated or diminished the differences observed when comparing this ratio between 
Teffs and iTregs in the first minute of activation. These show that when treated with anti-
CTLA-4/PD-1, MBP peptide-primed iTreg showed a more flattened or less elongated cell 
shape near the IS in the first minute of activation. This indicates that blocking CTLA-4/PD-1 
might induce the formation of tighter cell couples during the activation of MBP peptide-
primed iTregs. 
 
In section 4.7, more MBP peptide-primed iTregs were found to form an extended lamella at 
early time points (0s and 20s) of activation, therefore, we investigated whether the dual 
mAb treatment would affect this. The result (Figure 5.4 D) shows that in MBP peptide-
primed cells, no significant differences were found when comparing the frequency of cells 
with an extended lamella in iTregs treated with anti-CTLA-4/PD-1 and without. This 
frequency of iTregs with the treatment was still significantly higher than that in Teffs (p<0.05) 
at early time points, but the level of significance was lowered.  This shows that blocking 
CTLA-4 and PD-1 during the activation of MBP peptide-primed iTregs, partially reduced the 
formation of an extended lamella in the first twenty seconds of cell coupling. 
 
These results together suggest that the CTLA-4 and PD-1 dual blockade during the first two 
minutes of MBP peptide-primed iTreg activation helps to stabilise the IS and pulling the T 
cell, as well as the nucleus closer to the interface by extending the interface of the IS and 
partially shortening their extended lamellae. This help to form a more stable IS and 
























Chapter 5  
Figure 5.4 The dual anti-CTLA-4/PD-1 blockade widens the interfaces of the IS and 
reduces the formation of extended lamellae during the activation of MBP Ac1-9 [4K]-
primed iTregs.  
LAT-GFP transduced MBP Ac1-9 [4K]-primed iTregs were activated with MBP Ac1-9 [4Y]-
primed PL8 cells, with 10 µg/ml anti-CTLA-4/PD-1 mAbs and were imaged for 15 minutes. 
Four morphological parameters were measured within the first two minutes of activation and 
0s indicates the time when a tight cell couple was formed. Data from untreated Teffs and 
iTregs refers to Figure 4.7. Comparing the ratios of A) interface width to cell width, B) 
lamella depth to cell depth, C) lamella depth to interface width of Teffs, untreated and anti-
CTLA-4/PD-1 treated iTregs during the first two minutes of activation. D) Comparing the 
percentages of Teffs, untreated and anti-CTLA-4/PD-1 treated iTregs with an extended 
lamella region. 40 cell couples from two experiments for anti-CTLA-4/PD-1 treated iTregs 
were analysed. Statistical significance of log-transformed data was calculated using A) 
Two-way ANOVA or B-C) mixed-effect model as some values are not recorded for cells 
without an extended lamella. D) Statistical significance was calculated using Chi-square test. 
Asterisks indicate p-values (*<0.05, **<0.01, ****<0.0001). Error bars indicate standard error 









Chapter 5  
5.6 Blocking CTLA-4 and PD-1 partially increase overall and central 
LAT accumulation in MBP peptide-primed iTreg activation 
Finally, we investigated whether CTLA-4 and PD-1 dual blockades would have effects on 
LAT accumulation at the IS during iTreg activation. MBP Ac-1-9 [4K]-primed iTregs 
transduced with LAT-GFP were blocked with anti-CTLA-4/PD-1 and live images were 
acquired. Anti-CTLA-4/PD-1 treated LAT-GFP transduced iTregs were >75% Foxp3+. 
Spatiotemporal distributions of LAT-GFP in this condition were analysed and compared with 
data from MBP peptide-primed iTregs and Teffs.  
 
Representative images show LAT-GFP accumulation during the activation of iTregs treated 
with anti-CTLA-4/PD-1 (Figure 5.5). We referred LAT-GFP imaging data from MBP peptide-
primed Teffs and iTregs described in section 4.8, and compared them with data acquired 
from iTregs treated with anti-CTLA-4/PD-1. When CTLA-4 and PD-1 were blocked in MBP 
peptide-primed iTregs (Figure 5.6 C), LAT-GFP gradually accumulated at the interface and 
the accumulation peaked at the 0s time point with 42% of iTregs showing LAT-GFP 
accumulation at the IS. Afterwards, LAT-GFP accumulation remained relatively stable at the 
IS with minor fluctuations till the last time point, with 30% of iTregs treated with anti-CTLA-
4/PD-1 showing LAT-GFP accumulation. In terms of accumulation patterns observed at the 
IS, LAT-GFP showed mainly central and invagination patterning in the first two minutes of 
activation in iTregs treated with anti-CTLA-4/PD-1. In addition, a few iTregs with the 
treatment displayed LAT-GFP asymmetric and diffuse accumulation patterns, but not 
dominantly. Upon activation, LAT-GFP also accumulated at the distal pole of iTregs treated 
with anti-CTLA-4/PD-1, as LAT-GFP distal accumulation increased rapidly from the -40s 
time point and peak at the 0s time points, with 38% of the cells showing distal LAT-GFP 
accumulation. Distal LAT-GFP accumulation swiftly diminished in the first minute of 
activation but >10% of the cells still showed such accumulation from the 60s to 180s time 
point.  
 
Among MBP peptide-primed T cells, LAT-GFP overall accumulation at the interface of 
iTregs with the dual mAb treatment was compared with that of Teffs and iTregs. The peak 
of LAT-GFP accumulation in dual mAb treated iTregs appeared one minute earlier than that 
in iTregs without the treatment. Statistical analysis shows that the percentage of anti-CTLA-
4/PD-1 treated iTregs with LAT-GFP overall accumulation at the IS was significantly higher 
than that of untreated iTregs at the 0s, 300s and 420s time points (Figure 5.6 D, the second 
row). When compared to Teffs, this percentage was significantly lower at the 20s and 40s 
time points (Figure 5.6 D, the third row). However, all these differences were no longer 
significant with the Bonferroni correction (0.004<p<0.05). Notably, fewer differences were 
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identified when comparing LAT-GFP overall accumulation in iTregs treated with anti-CTLA-
4/PD-1 and Teffs (at two time points), than those found when comparing the accumulation 
in iTregs and Teffs (Figure 5.6 D, the first row, at eight time points). These results and 
comparisons indicate that blocking CTLA-4 and PD-1 during the activation of MBP primed 







Figure 5.5 Representative live cell images showing LAT-GFP distribution in Tg4 
iTregs in the first two minutes of T cell activation (0s, 20s, 60s and 120s time points), 
when CTLA-4 and PD-1 were blocked. 
Top: DIC images from four time points. Bottom: matching top-down maximum projections of 
three-dimensional LAT-GFP fluorescent images (intensity is encoded in pseudocolour and 
increases from purple to red). Time is given in seconds relative to the formation of a tight 
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Figure 5.6 When CTLA-4 and PD-1 are blocked, overall LAT-GFP accumulation at the 
IS in early activation of MBP Ac1-9 [4K]-primed iTregs is increased. 
LAT-GFP transduced MBP Ac1-9 [4K]-primed iTregs were activated by MBP Ac1-9 [4Y]-
primed PL8 cells with a combined blockade of CTLA-4 and PD-1, and imaged for 15 
minutes. Live cell images were analysed to identify the 0s time point when the IS was 
formed. Data from MBP Ac1-9 [4K]-primed A) Teffs and B) iTregs refer to Figure 4.10. C) 
Spatiotemporal distribution patterns of LAT-GFP for 12 time points in MBP Ac1-9 [4K]-
primed iTregs blocked with anti-CTLA-4/PD-1 (48 cell couples analysed, two experiments). 
D) Comparisons of LAT-GFP accumulation among different cell types at the IS using a two 
proportion z-test. Numerals and asterisks indicate p-values, and asterisk colours denote 
whether differences remain significant with the Bonferroni correction (0.004<*<0.05, 
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We then investigated whether the dual blockade of CTLA-4 and PD-1 could change LAT 
central and invagination accumulation at the interface during MBP peptide-primed iTreg 
activation. During the activation of iTregs and anti-CTLA-4/PD-1 treated iTregs, no 
significant differences were found when comparing the percentages of iTregs with either 
LAT-GFP central or invagination accumulation at the interface (Figure 5.7 B). In both 
conditions, LAT-GFP central + invagination accumulation peaked at early time points (0s 
and 40s) and diminished afterwards. This percentage of Teffs was still higher than that of 
iTreg treated with anti-CTLA-4/PD-1 at most time points (0s-420s) and the differences were 
significant at the 20s, 40s, 100s and 120s time points (Figure 5.7 C). The difference was 
only significant at the 20s time point with the Bonferroni correction. When comparing this 
percentage between iTregs and Teffs, more differences were found (Figure 5.7 A). 
Therefore, when CTLA-4 and PD-1 are blocked, the amounts of LAT central and 
invagination accumulation at the interface during the early activation of MBP Ac1-9 [4K]-
primed iTregs are almost unaffected.  
 
When comparing only the central accumulation pattern, the percentage of iTregs blocked 
with anti-CTLA-4/PD-1 showing LAT-GFP central accumulation at the interface was higher 
than that of untreated iTregs at nine time points (Figure 5.8 B, -40s-80s, 120s and 180s). 
However, the difference was only significant at the 0s time point and was not with the 
Bonferroni correction (0.004<p<0.05). Teffs again showed more LAT-GFP central 
accumulation at most time points (0s-420s) and the percentage of Teffs showing central 
accumulation was significantly higher than that in iTregs treated with anti-CTLA-4/PD-1 at 
the 20s and 40s time point (Figure 5.8 C). The difference remained significant at the 20s 
time point with the Bonferroni correction (p<0.001). Thus, the dual CTLA-4 and PD-1 
blockade slightly increases LAT central accumulation during MBP peptide-primed iTreg 
activation. 
 
LAT-GFP invagination accumulation at the interface in iTegs treated with anti-CTLA-4/PD-1 
was comparable to that in Teffs and iTregs, with fewer cells showing this accumulation from 
the 20s-80s time points (Figure 5.8 E-F). The invagination accumulation of LAT-GFP 
peaked at an early time point (20s or 40s) and gradually diminished after the peak, in all 
three cells types. No significant differences were identified when comparing this 
accumulation pattern between any two of the three conditions. 
 
In summary, blocking CTLA-4 and PD-1 during early activation of MBP Ac1-9 [4K]-primed 
iTregs, partially increases LAT overall and central accumulation at the IS. These results are 
consistent with that from the morphological analysis in section 5.5, as they both indicate that 
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early activation of iTregs is enhanced when CTLA-4 and PD-1 coinhibitory pathways are 
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Figure 5.7 The percentage of iTregs with LAT-GFP central + invagination 
accumulation at the IS are comparable in untreated and CTLA-4/PD-1 blocked MBP 
Ac1-9 [4K]-primed iTregs. 
LAT-GFP central + invagination patterning during T cell activation is compared between 
MBP Ac1-9 [4K]-primed A) Teffs and iTregs, B) iTregs and anti-CTLA-4/PD-1 treated iTregs, 
and C) Teffs and anti-CTLA-4/PD-1 treated iTregs. Data of Teffs and untreated iTreg refer 
to Figure 4.11 and 48 cell couples from two experiments for iTregs treated with anti-CTLA-
4/PD-1 were analysed. A two proportion z-test was used to calculate statistical significance. 
Asterisks indicate p-values and colours indicate whether differences remain significant with 
the Bonferroni correction (0.004<*<0.05, 0.004<**<0.01, 0.001<**<0.004, ***<0.001). Error 
bars indicate standard error of the mean. 
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Figure 5.8 Blocking CTLA-4/PD-1 enhances LAT-GFP central accumulation during 
MBP Ac1-9 [primed] iTreg activation. 
Comparing LAT-GFP A-C) central and D-F) invagination accumulation during the activation 
of MBP Ac1-9 [4K]-primed Teffs, iTregs and CTLA-4/PD-1 blocked iTregs. Data of Teffs and 
untreated iTregs refer to Figure 4.11 and 48 cell couples from two experiments for iTregs 
treated with anti-CTLA-4/PD-1 were analysed. Statistical significance was calculated with a 
two proportion z-test. Asterisks indicate p-values and colours indicate whether differences 
remain significant with the Bonferroni correction (0.004<*<0.05, 0.004<**<0.01, ***<0.001). 
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5.7 Computational analyses show increased LAT accumulation at 
the IS of anti-CTLA-4/PD-1 treated iTregs 
With the assistance of the 3D computational model, we built another 3D model map 
showing relative probabilities of LAT-GFP accumulation in MBP peptide-primed iTreg 
activation when blocked with anti-CTLA-4 and PD-1. We first compared the LAT-GFP 
enrichment at the defined IS region which shows the top 10% of the fluorescence of the 
three conditions. As shown previously in section 4.9, LAT-GFP enrichment at the IS of Teffs 
was higher than that of iTregs without the dual mAb treatment across all 12 time points 
(Figure 5.9 A). Significant differences were found at five time points, though none remained 
significant with the Bonferroni correction. When blocked with anti-CTLA-4/PD-1, higher 
levels of LAT-GFP enrichment at the IS of iTregs during their activation were also found at 
all 12 time points, compared to that of iTregs without the treatment (Figure 5.9 B), though a 
significant difference was only observed at the -40s time point. When compared to that of 
Teffs (Figure 5.9 C), less LAT-GFP enrichment was observed at the IS of iTregs treated 
with anti-CTLA-4/PD-1 at most time points (60s to 420s), but the difference was only 
significant at the 420s time point (p<0.01). These observations together show that the level 
of differences of LAT-GFP enrichment observed during the activation of Teffs and iTregs 
was lowered, when CTLA-4/PD-1 pathways were blocked in iTregs. This suggests that 
blocking CTLA-4/PD-1 during iTreg activation help to transport LAT to the IS.  
 
LAT-GFP enrichment in the centre of the IS of Teffs was higher than that of iTregs at all 12 
time points and significant differences were found at five time points, which were not 
significant with the Bonferroni correction (Figure 5.9 D). Blocking CTLA-4/PD-1 did not 
enhance LAT-GFP central accumulation at the interface in iTregs, as iTregs with and 
without the treatment showed comparable LAT-GFP enrichment in the central region during 
activation (Figure 5.9 E). It is notable that the level of differences was increased when 
comparing LAT-GFP enrichment in the central region of the IS of Teffs and iTregs with the 
dual mAb treatment (Figure 5.9 F). Significant differences were found at more time points 
(20s, 60s-420s) and were prominent at the 120s, 180s and 420s (p<0.004). Therefore, 
blocking CTLA-4/PD-1 results in a slight reduction of LAT accumulation in the central core 
of the IS during iTreg activation.    
 
In summary, computational analysis shows that blocking CTLA-4 and PD-1 pathways during 
MBP peptide-primed iTreg activation enhances LAT accumulation at the IS but slightly 
downregulates LAT accumulation in the central core of the IS. These are partially consistent 
with the observations from the spatiotemporal distribution analysis in section 5.6. An 
increased overall LAT accumulation at the IS of CTLA-4 and PD-1 blocked iTregs is 
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detected by both spatiotemporal patterning and computational analysis but decreased LAT 
accumulation in the central core is found by the latter, though the reduction is mild. However, 
the computational system detects fewer cells couples and does not distinguish LAT-GFP 
central and invagination accumulation, which are both detected in the central core. This 
might explain the inconsistency. In general, both spatiotemporal pattern-based and 
computational analysis show that the impacts of CTLA-4/PD-1 blockades on central + 
invagination accumulation of LAT during MBP peptide iTreg activation is minor and the 
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Figure 5.9 Computational analysis show that anti-CTLA-4/PD-1 enhances overall LAT-
GFP accumulation during the activation of MBP Ac1-9 [4K]-primed iTregs. 
LAT-GFP accumulation in anti-CTLA-4/PD-1 treated iTregs were computationally analysed 
and 3D model maps were generated. Comparing LAT-GFP enrichment in the defined IS 
region (top 10% enrichment) during the activation of MBP Ac1-9 [4K]-primed A) Teffs and 
iTregs, B) iTregs and anti-CTLA-4/PD-1 treated iTregs, C) Teffs and anti-CTLA-4/PD-1 
treated iTregs. Comparing LAT-GFP enrichment in the central core of the IS during the 
activation of MBP Ac1-9 [4K]-primed D) Teffs and iTregs, E) iTregs and anti-CTLA-4/PD-1 
treated iTregs, F) Teffs and anti-CTLA-4/PD-1 treated iTregs. Data of Teffs and iTregs refer 
to Figure 4.13 and 4.14, and 26 cell couples from two experiments for anti-CTLA-4/PD-1 
treated iTregs were analysed. Log-transformed data were analysed with unpaired Student’s 
T-test to calculate statistical significance. Asterisks indicate p-values and colours indicate 
whether differences remain significant with the Bonferroni correction (0.004<*<0.05, 
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5.8 Anti-CD3/28-primed iTregs show complex phenotypes in 
response to CTLA-4 and PD-1 blockades during activation 
As shown in chapter 4, MBP peptide-primed and anti-CD3/28-primed iTregs have some 
differences in spatiotemporal patterns of LAT-GFP and TCR-ζ-GFP, which indicates that 
their proximal T cell signalling events are not entirely the same. To verify whether blocking 
CTLA-4 and PD-1 has the same effects on both types of iTregs, we repeated some imaging 
experiments using anti-CD3/28-primed, LAT-GFP transduced iTregs (>75% Foxp3+). 
Moreover, we included additional data from treatments using single blockades (only anti-
CTLA-4 or anti-PD-1) to investigate their impacts during iTreg activation.  
 
However, blockades of CTLA-4, PD-1 and both induced fairly complicated responses of 
anti-CD3/28-primed iTregs. In brief, morphological analyses in the first two minutes of 
activation (Figure 5.10) show that blocking either CTLA-4, PD-1 or both, widens the 
interface of contact but results in the formation of longer extended lamellae and more 
elongated cell shapes of anti-CD3/28-primed iTregs. As wider interfaces and shorter 
lamellae are signs for stable IS formation, it is difficult to judge whether these treated ant-
CD3/28-primed iTregs were forming stable or labile cell couples.  
 
Moreover, anti-CTLA-4, anti-PD-1 and their combination regulate the spatiotemporal 
organisation of LAT differently in the first several minutes of anti-CD3/28-primed iTreg 
activation (Figure 5.11-13). Anti-CTLA-4 enhanced both LAT overall and central 
accumulation, while anti-PD-1 affected neither. Blocking both CTLA-4 and PD-1 in early 
anti-CD3/28-primed iTreg activation significantly reduced LAT overall accumulation and 
barely changed LAT central accumulation (untreated iTregs shows low LAT central 
accumulation in the first place).  Although blocking CTLA-4 alone promotes anti-CD3/28-
primed iTreg activation, dual CTLA-4 and PD-1 blockade has the opposite effect. Therefore, 
anti-CD3/28-primed iTreg have continuously shown phenotypes that are different to that of 
MBP peptide-primed iTregs.  
 
The rest of this section show figures describing observations that we have summarised 
above. It should be noted that currently, we are not able to fully explain the mechanisms of 
these results, as parallel experiments (i.e. blocking CTLA-4 and PD-1 separately) were not 
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Figure 5.10 T cell morphological analysis of anti-CD3/28-primed Teffs, iTregs, iTregs 
treated with anti-CTLA-4, anti-PD-1 and both mAbs, during the first two minute of 
activation. 
LAT-GFP labelled anti-CD3/28-primed iTregs were activated with MBP Ac1-9 [4Y]-primed 
PL8 cells, with 10 µg/ml anti-CTLA-4, anti-PD-1 or both mAbs and were imaged for 15 
minutes. Four morphological parameters were measured within the first two minutes of 
activation and 0s indicates the time when a tight cell couple was formed. Data from 
untreated Teffs and iTregs refers to Figure 4.8. Comparing the ratios of A) interface width to 
cell width, B) lamella depth to cell depth, C) lamella depth to interface width of Teffs, 
untreated, anti-CTLA-4, anti-PD-1 and anti-CTLA-4/PD-1 treated iTregs during the first two 
minutes of activation. D) Comparing the percentages of Teffs, untreated, anti-CTLA-4, anti-
PD-1 and anti-CTLA-4/PD-1 treated iTregs with an extended lamella. Cell couples of iTregs 
analysed: 33 from two experiments (anti-CTLA-4), 38 from two experiments (anti-PD-1) and 
35 from two experiments (anti-CTLA-4/PD-1). Statistical significance of log-transformed 
data was calculated using A) Two-way ANOVA or B-C) mixed-effect model as zero values 
were not analysed for cells without an extended lamella. D) Statistical significance was 
calculated using Chi-square test. Asterisks indicate p-values (*<0.05, **<0.01, ***<0.001, 
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Figure 5.11 Blocking CTLA-4 enhances, but blocking both CTLA-4 and PD-1 reduces 
LAT-GFP overall accumulation at the IS during the activation of anti-CD3/28-primed 
iTregs. 
LAT-GFP transduced anti-CD3/28-primed iTregs were activated by MBP Ac1-9 [4Y]-primed 
PL8 cells, and blocked with anti-CTLA-4, anti-PD-1 or both mAbs. Cells were imaged using 
spinning disk confocal microscopy for 15 minutes. DIC and GFP images were analysed to 
identify T cell-APC cell interactions. LAT-GFP spatiotemporal accumulation data of A) Teffs 
and B) iTregs refer to Figure 4.10. Spatiotemporal distribution patterns of LAT-GFP during 
the activation of C) anti-CTLA-4 treated anti-CD3/28-primed iTregs, (33 cell couples from 
two experiments), D) anti-PD-1 treated anti-CD3/28-primed iTregs (38 cell couples from two 
experiments), E) anti-CTLA-4/PD-1 treated anti-CD3/28-primed iTregs (35 cell couples 
analysed from two experiments. F) Comparisons of LAT-GFP overall accumulation at the IS 
among different cell types using a two proportion z-test. Numerals and asterisks indicate p-
values, and asterisk colours indicate whether differences remain significant with the 
Bonferroni correction (0.004<*<0.05, 0.004<**<0.01, 0.001<**<0.004, ***<0.001, 
****<0.0001). Error bars indicate standard error of the mean.  
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Figure 5.12 Blocking CTLA-4 enhances LAT-GFP central accumulation at the IS 
during the activation of anti-CD3/28-primed iTregs. 
LAT-GFP central accumulation at the interface is compared between anti-CD3/28-primed A) 
Teffs and iTregs, B) iTregs and anti-CTLA-4 treated iTregs, C) Teffs and anti-CTLA-4 
treated iTregs, D) iTregs and anti-PD-1 treated iTregs, E) Teffs and anti-PD-1 treated iTregs, 
F) iTregs and anti-CTLA-4/PD-1 treated iTregs and G) Teffs and anti-CTLA-4/PD-1 treated 
iTregs.  Data of Teffs and untreated iTreg refer to Figure 4.11, 33 cell couples from two 
experiments for iTregs treated with anti-CTLA-4, 38 cell couples from two experiments for 
iTregs treated with anti-PD-1 and 35 cell couples from two experiments for iTregs treated 
with anti-CTLA-4/PD-1 were analysed. A two proportion z-test was used to calculate 
statistical significance. Asterisks indicate p-values and differences observed were not 
significant with the Bonferroni correction (0.004<*<0.05, 0.004<**<0.01). Error bars indicate 
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Figure 5.13 Blocking CTLA-4 restores LAT-GFP invagination accumulation at the IS 
during the activation of anti-CD3/28-primed iTregs. 
Comparisons of LAT-GFP invagination accumulation at the interface between anti-CD3/28-
primed A) Teffs and iTregs, B) iTregs and anti-CTLA-4 treated iTregs, C) Teffs and anti-
CTLA-4 treated iTregs, D) iTregs and anti-PD-1 treated iTregs, E) Teffs and anti-PD-1 
treated iTregs, F) iTregs and anti-CTLA-4/PD-1 treated iTregs and G) Teffs and anti-CTLA-
4/PD-1 treated iTregs.  Data of Teffs and untreated iTreg refer to Figure 4.11, 33 cell 
couples from two experiments for iTregs treated with anti-CTLA-4, 38 cell couples from two 
experiments for iTregs treated with anti-PD-1 and 35 cell couples from two experiments for 
iTregs treated with anti-CTLA-4/PD-1 were analysed. At two proportion z-test was used to 
calculate statistical significance. Asterisks indicate p-values and differences observed were 
not significant with the Bonferroni correction (0.004<*<0.05, 0.004<**<0.01, **<0.004). Error 
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5.9 Discussion 
In summary, dual CTLA-4 and PD-1 blockade inhibits generation of Tg4 Foxp3+ iTregs and 
slightly enhances IFN-γ and IL-10 secretion during Teff and iTreg development. Blocking 
both CTLA-4 and PD-1 also improves iTreg activation and enhances LAT overall 
accumulation at the T cell-APC interface. These results were acquired using MBP peptide-
primed cells. Anti-CD3/28-primed iTregs treated with anti-CTLA-4, anti-PD-1 and both mAbs 
display complex and elusive phenotypes in early activation, which are different to that of 
MBP peptide-primed iTregs. However, peptide-primed iTregs are more physiologically 
relevant to naturally occurring Tregs while antibody-primed iTregs do not receive cytokine 
signals and direct regulation from APCs upon cell priming, and they show different 
phenotypes (discussed in section 3.8). Therefore, we mainly address the research 
questions in this chapter based on data generated using peptide-primed Teffs and iTregs.  
 
5.9.1 CLTA-4 and PD-1 play roles in Treg differentiation and regulatory 
function 
Tregs express CTLA-4, PD-1 and PD-L-1 which play roles in Treg-mediated suppression 
and tolerance (247). Blocking CTLA-4, PD-1 or both coinhibitory pathways significantly 
downregulates induction of Tg4 Foxp3+ iTregs, which could be observed on day 3 to 6 of 
culture. The effects are cumulative as the combination of both mAbs most significantly 
reduces the frequency of Tg4 Foxp3+ iTregs. 
 
CTLA-4 contributes to self-tolerance maintained by Tregs and CTLA-4 deficiency impairs 
their suppressive function (246, 250).  However, in vivo studies show that CTLA-4 blockade 
enhances proliferation of Foxp3+ Tregs in mice and human (264, 265). Moreover, previous 
work by Verhagen et al shows that CTLA-4KO Tg4 mice are resistant to induction of EAE, 
owing to an increased number of Foxp3+ Tregs in the thymus and spleen (266). Later the 
same group found that CTLA-4 is expressed in the thymus of Tg4 T cells, and deletion of 
CTLA-4 skews thymocytes towards a Foxp3+ Treg phenotype by modulating TCR repertoire 
(267). These results suggest that CTLA-4 regulates the development of tTregs and control 
their expansion in the periphery. A subsequent study shows that deficiency of CTLA-4 
impairs Tg4 Foxp3+ iTreg differentiation (268), which is consistent with our results. CTLA-4 
likely plays different roles in regulating the development of naturally occurring and 
extrathymically induced Tregs (268). PD-1-PD-L1 pathway regulates Treg-mediated 
suppression and peripheral tolerance. PD-1 expression on Tregs inhibits PD-1L+ CD8+ T 
cell proliferation during infection and PD-L1 promotes conversion and maintenance of 
iTregs (258, 269). PD-1 blockade significantly reduces the suppressive activity of Tregs 
(258). Tumour-infiltrating Tregs also express high levels of both CTLA-4 and PD-1, which 
contribute to Treg-mediated suppression in the tumour microenvironment (270). A recent 
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study shows that the combination of anti-CTLA-4 and anti-PD-1 also additively reduces the 
frequencies of Tregs, and promotes the expansion of CD4+ and CD8+ Teffs in a murine 
tumour (271). In summary, CTLA-4 and PD-1 are key modulators of the 
immunosuppressive function of Tregs and blocking their corresponding coinhibitory 
pathways impairs the induction of iTregs. 
 
5.9.2 Dual blockade of CTLA-4 and PD-1 enhances cytokine secretion by 
promoting T cell activation 
Blocking both CTLA-4 and PD-1 during the induction of Tg4 Teffs and iTregs tends to 
promote cytokine production detected in cell cultures. The enhancement is more obvious on 
IFN-γ production by Teff-inducing cells. Moreover, iTreg-inducing cells treated with the dual 
blockade secreted more IL-10 at later stages of induction (day 5 and 6). As described in 
chapter 4, Tg4 iTregs hold a weaker ability to secrete IFN-γ but are potentially more 
capable of secreting IL-10, while Teffs secrete both cytokines with a slightly weaker ability 
to maintain IL-10 production at later stages of induction. Our results suggest that blocking 
both CTLA-4 and PD-1 coinhibitory pathways promotes T cell activation (possibly by 
enhancing CD28 costimulation) in initial priming of Teffs and iTregs, which is likely to 
enhance their intrinsic cytokine-secreting abilities. In other words, when these two 
coinhibitory pathways are blocked, Teffs and iTregs potentially secrete more IFN-γ and IL-
10 respectively. However, it should be noted that anti-CTLA-4, anti-PD-1 and their 
combination reduce frequencies of Foxp3+ cells during iTreg induction. Therefore, it is 
unclear whether increased IL-10 production induced by blockades was purely owing to an 
increasing ratio of Teffs to iTregs in iTreg-inducing conditions. Ideally, staining these cells 
for Foxp3, T-bet, IFN-γ and IL-10 together would help to address this question. Moreover, 
investigating CTLA-4 and PD-1 expression on Tg4 Teffs and iTregs would also be useful for 
assessing direct impacts of the blockades on these cells. 
 
5.9.3 Blocking both CTLA-4 and PD-1 improves iTreg activation and partially 
restores LAT overall accumulation 
Morphological analyses show that in the first two minutes of activation, anti-CTLA-4/PD-1 
treated iTregs formed a wider interface of contact, compared to untreated iTregs. These 
results suggest that anti-CTLA-4/PD-1 dual blockade helps to stabilise the IS formation of 
iTregs and enhances activation. However, the continuous extension of the T cell-APC 
interface is not required at later stages of activation. In T-B cell interactions, after the 
contact length of the interface and Ca2+ signalling reach their peak level,  T cells enter a 
stabilisation phase and partially retracts from the B cell, which causes cell rounding (163). 
During interactions of T cells with B cells or DCs, stable conjunctions and effective T cell 
activation are correlated with a round cell shape (163, 164). The relative interface width of 
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anti-CTLA-4/PD-1 treated iTregs was even wider than that of Teffs at late time points (60s 
and 120s), suggesting that that the dual blockade of CTLA-4 and PD-1 might excessively 
extend that interface of contact and might prevent cell rounding. Their activation might not 
be as efficient as that of Teffs. 
 
Spatiotemporal patterning analyses also indicate that iTreg activation is improved by 
blocking CTLA-4 and PD-1 during activation. Dual blockade of CTLA-4 and PD-1 partially 
increases LAT overall accumulation at the interface upon iTreg activation. However, 
impaired LAT central accumulation at the interface is only slightly enhanced by the dual 
blockade, suggesting the dual blockade has limited effects on the cSMAC assembly. Clark 
et al have shown that cSMAC associated signalling intermediates such as LAT, Grb2 and 
SLP-76, are rapidly recruited to the centre of the interface in early T cell activation and 
transient LAT accumulation at the interface centre is associated with efficient IL-2 
production (126). Moreover, costimulation blockade also impairs LAT overall and central 
accumulation and downregulates IL-2 secretion (126). CTLA-4 and PD-1 both downregulate 
CD28 induced costimulation and inhibit T cell proliferation and survival (247, 256). Most 
likely, inefficient iTreg activation partially contributes to their expression of CTLA-4 and PD-
1. Therefore, blocking CTLA-4 and PD-1 enhances costimulation and partially improves 
proximal T cell signalling in iTreg activation. 
 
To understand the respective roles of CTLA-4 and PD-1 play in iTreg activation, the same 
imaging experiments will need to be conducted on MBP peptide-primed iTregs treated with 
only CTLA-4 or PD-1. Although data acquired using anti-CD3/28-primed iTregs suggest that 
impacts of anti-CTLA-4, anti-PD-1 and their combination on iTreg activation are different, it 
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 Enhanced LAT localisation at the T cell-APC Chapter 6
interface stabilises IS formation and tends to regulate IL-
10 and IFN-γ secretion of iTregs 
 
6.1 Introduction 
The formation of the IS provides a fundamental scaffold for sustained TCR engagement 
with pMHC and signal transduction for T cell activation (120). During such process, 
polarisation and clustering of various signalling intermediates including receptors, kinases, 
adaptor proteins and cytoskeletal compartments are highly diverse in time and space (130). 
Segregation of these molecules into spatial domains, the supramolecular activation clusters, 
are required for efficient T cell activation (121). Supramolecular complexes consist of 
thousands of molecules which closely interact with each other. Upon TCR-induced 
activation, phosphorylated LAT nucleates a multiple signalling complex including Grb2, 
PLC-γ1, Gads, Sos1, and SLP-76 (185), forming the LAT signalosome, as part of the 
central supramolecular activation cluster (cSMAC). When recruited by LAT to the 
membrane, Grb2 binds Sos1 and together can form a 2:1 complex, which cross-links LAT 
molecules and induces oligomerisation of LAT (272). For protein-protein interactions, the 
number of bindng motifs is critical and we refer that as the valence (126). For example, 
Gads can bind two tyrosine-containing motifs of LAT via its SH2 domain, thus the valence of 
LAT for Gads can range from 0 to 2 (185). Therefore multivalent protein interactions 
contribute to LAT clustering and allow the formation of supramolecular complexes.  
 
Upon full stimulus conditions, LAT shows a distinct preference for central localisation at the 
T cell-APC interface in the first two minutes of activation in 5C.C7 T cells (126), as well as in 
Tg4 Teffs in this project. Attenuation of T cell activation can be achieved by costimulation 
blockade or Itk-deficiency, which leads to diminished tyrosine phosphorylation and partial 
loss of the valence in the LAT signalosome (126). This subsequently reduces LAT central 
localisation at the interface and IL-2 production. The V3 domain of PKC-θ contains a 
proline-rich motif which associates with CD28 and is required for the localisation of PKC-θ 
to the cSMAC (238). Therefore, by fusing LAT with the protein domain PKC-θ V3 (LAT V3) 
or Vav1 SH3SH2SH3 (LAT Vav, which also increases the number of protein-binding motifs), 
Clark et al increased LAT valence and restored LAT centrality upon attenuated activation 
conditions (126). However, fusion with the PKC-θ V3 domain excessively sustained LAT 
central accumulation at the interface, which did not enhance IL-2 mRNA production and 
moderately impaired recruitment of Grb2, Lck and Vav1 to the interface under full T cell 
stimulation. While fusion of LAT with Vav1 SH3SH2SH3 domain substantially reconstituted 
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LAT localisation and consistently enhanced the amount of IL-2 mRNA under attenuated 
activation conditions. These data suggest that forcing LAT central localisation at the 
interface to a correct extent, not immoderately, improves IL-2 secretion when T cell 
stimulation is attenuated.  
 
In this study, we have observed defective formation of the IS, impaired LAT central 
localisation and a weakened ability to secrete IFN-γ in Tg4 iTregs under full stimulus 
conditions. Such phenotypes of iTreg are reminiscent to that of Teffs under attenuated T 
cell stimulation. However, polarisation of Teffs and Tregs from naive CD4+ T cells is 
regulated at the level of transcription (273) and acute modification of the proximal T cell 
signalling is unlikely to change their lineage. As increasing LAT valence enhances its 
central localisation, we hypothesise that by fusing LAT with PKC-θ V3 or Vav1 SH3SH2SH3 
domain, impaired LAT central accumulation can be restored in Tg4 iTregs. Essentially, this 
raises a question: will restoration of central LAT localisation polarise iTregs to show more 
Teff-like phenotypes or simply enhance iTreg effector function owing to improved proximal 
signalling? To answer this question, we transduced iTregs with the fusion protein LAT V3-
GFP or LAT Vav-GFP, performed live-cell imaging and ELISAs on these iTregs. Then we 
investigated the impacts of these fusion proteins on T cell morphology, LAT polarisation and 
cytokine production of IFN-γ and IL-10 upon activation of iTregs.  
 
6.2 Chapter aims  
• To measure morphological parameters in the first two minutes of activation of LAT V3-
GFP and LAT Vav-GFP expressing iTregs and compare the relative interface width, 
lamella depth, overall cell shape and frequencies of forming an extended lamella among 
LAT-GFP transduced Teffs and iTregs, LAT V3-GFP and LAT Vav-GFP transduced 
iTregs during this period. 
• To investigate the spatiotemporal organisation of LAT V3-GFP and LAT Vav-GFP in 
iTregs and compare these to LAT-GFP accumulation in iTregs and Teffs in early 
activation. 
• To assess IFN-γ and IL-10 secretion of LAT-GFP, LAT V3-GFP and LAT Vav-GFP 
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A table is shown below denoting main symbols used in this chapter for different cell types  
 




6.3 LAT V3 and LAT Vav widen the T cell-APC interface and 
shorten the elongated cell shape of iTregs in early activation 
First, we investigated whether the expression of LAT V3 and LAT Vav in Tg4 iTregs would 
change the shape of iTregs in the first two minutes of iTreg activation. Live cell imaging was 
performed on LAT V3-GFP or LAT Vav-GFP expressing iTregs and morphological 
parameters were measured. We compared the three defined ratios (the relative interface 
width, relative lamella depth and overall cell shape) of LAT-GFP expressing Teffs and 
iTregs transduced with LAT-GFP, LAT V3-GFP or LAT Vav-GFP to each other, during the 
first two minutes of activation. A wider T cell-APC interface increases the contact area for 
interactions of proximal receptors and ligands, which likely induces stronger signal 
transduction. Moreover, T cells with no or a shorter extended lamella often form a round-
flattened shape upon activation which is associated with effective T cell activation (164). 
Thus comparing the three morphological ratios of the four types of cells allow us to assess 
the level of their activation. Cells were MBP peptide-primed and data of LAT-GFP 
transduced Teffs and iTregs are from Figure 4.7, section 4.7. 
 
To recapitulate, in LAT-GFP expressing cells, Teffs showed a significantly wider interface 
than that of iTregs at the 0s, 20s and 120s time point (p<0.05, Figure 6.1 A). LAT V3-GFP 
expressing iTregs had a significantly higher ratio of interface width to cell width, compared 
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to that of LAT-GFP expressing iTregs at the 60s and 120s time point (p<0.01). Moreover, no 
differences were found when comparing this ratio of LAT V3-GFP expressing iTregs to that 
of LAT-GFP expressing Teffs at all four time points.  These data together indicate that LAT 
V3 expression in iTregs widens the interface of the synapse during the first two minutes of 
activation. While in LAT-Vav-GFP expressing iTregs, the relative interface width was less 
altered. No significant differences were found when comparing the ratios of interface depth 
to cell depth of LAT-GFP and LAT Vav-GFP expressing iTregs at all four time points, thus 
their relative interface width was comparable. LAT-GFP expressing Teffs showed a 
significantly wider interface than that of LAT Vav-GFP expressing iTregs only at the 120s 
time point (p<0.01). These data show that the interface width of iTregs expressing LAT Vav-
GFP is slightly extended, compared to that of LAT-GFP expressing iTregs. In general, in the 
first 20 seconds of activation, expression of LAT V3-GFP and LAT Vav-GFP widens the 
interface of iTregs, and their interface width is more comparable to that in LAT-GFP 
expressing Teffs. Moreover, LAT V3-GFP expressing iTregs also displayed a significantly 
higher ratio of interface width to cell width than that of LAT Vav-GFP expressing iTreg at the 
60s (p<0.001) and 120s time points (p<0.01). Thus, LAT V3 is continuously widening the 
interface throughout the first two minutes of activation. 
 
The relative lamella depth of LAT-GFP expressing Teffs and iTregs was comparable across 
all four time points (Figure 6.1 B). In LAT V3-GFP expressing iTregs, the ratio of lamella 
depth to cell depth was significantly decreased across all time points, compared to that of 
LAT-GFP expressing iTregs (p<0.05). The difference was prominent at the 0s time point 
(p<0.0001). Moreover, this ratio of LAT V3-GFP expressing iTregs was lower than that of 
LAT-GFP expressing Teffs at all four time, though the differences were not significant. 
These results suggest that the extend lamella of LAT V3-GFP expressing iTregs during the 
first two minutes of activation is shortened and its depth is more comparable to that of LAT-
GFP expressing Teffs. Although this ratio of LAT Vav-GFP expressing iTregs was lower 
than that of LAT-GFP expressing iTregs at the 0s time point, no significant differences were 
observed at all four time points. Again at the 60s time point, the relative lamella depth of 
LAT Vav-GFP expressing iTregs was also significantly longer than that of LAT V3 
expressing iTregs (p<0.05). Therefore, the expression of LAT Vav in iTregs only slightly 
reduces the depth of extended lamellae, while the expression of LAT V3 continuously 
shortens the lamellae in the first two minutes of iTreg activation. However, the depth of 
extended lamellae in LAT Vav-GFP expressing iTregs was more comparable to that in LAT-
GFP expressing Teffs. Therefore, the reduction of lamella depth induced by LAT V3 seems 
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Then we compare the overall cell shapes of these cells. LAT-GFP expressing showed a 
more slender cell shape than LAT-GFP expressing Teffs in the first minute of activation 
(p<0.0001 at 0s and 20s, p<0.01 at 60s, Figure 6.1 C). In LAT V3-GFP expressing iTregs, 
the ratio of lamella depth to interface width was significantly lower than that of LAT-GFP 
expressing iTregs at the 0s, 20s and 60s time point (p<0.01). Again, when comparing this 
ratio of LAT-GFP expressing Teffs and LAT V3-GFP expressing iTregs, no significant 
differences at all four time points. These together show that the expression of LAT V3 
reduces the ratio of lamella depth to interface width in iTregs, and the overall cell shape of 
LAT V3 expressing iTregs is more similar to that of LAT-GFP expressing Teffs. LAT Vav-
GFP expressing iTregs showed a reduced ratio of lamella depth to interface width at the 0s 
and 20s time point, compared to that of LAT-GFP expressing iTregs. No significant 
differences were observed when comparing this ratio of these two types of cells. However, 
LAT Vav-GFP expressing iTregs had the highest ratio of lamella depth to interface width at 
the 120s time point, and it was significantly higher than that of LAT-GFP expressing Teffs at 
the 20s (p<0.01) and 120s time point (p<0.05). Again at the 60s, LAT Vav-GFP expressing 
iTregs showed a significantly higher ratio than that of LAT V3-GFP expressing iTregs 
(p<0.05). These comparisons indicate that the expression of LAT Vav in iTregs reduces the 
ratio of lamella to interface width in the first 20 seconds of activation. The slender cell shape 
of LAT Vav-GFP expressing iTregs at the 120 second was mainly owing to their relatively 
narrow interface at that time point (Figure 6.1 A). Teffs still showed the most compressed 
cell shape among the four types of cells but LAT V3 and LAT Vav (to a lesser extent) 
partially changed the slender cell shape of iTregs, making it more comparable to that of 
Teffs. 
 
Finally, we investigated whether the frequencies of iTregs forming an extended lamella was 
affected by the expression of LAT V3 and LAT Vav in the two minutes of activation. As 
described in section 4.7, at early time points of activation (0s and 20s), more LAT-GFP 
expressing iTregs formed an extended lamella than LAT-GFP expressing Teffs (p<0.01, 
Figure 6.1 D). The percentage of LAT V3-expressing iTregs forming an extended lamella 
was not significantly different to that of LAT-GFP expressing Teffs and iTregs in the two 
minutes. While in LAT Vav-GFP iTregs, the percentage of cells forming an extended lamella 
was significantly lower than that of LAT-GFP expressing iTregs at early time points. This 
percentage of LAT Vav-GFP expressing iTregs was the lowest at late time points (60s and 
120s), compared to that of the other three cells. It was also significantly lower than that of 
LAT V3-GFP expressing iTregs at late time points. These comparisons suggest that the 
expression of LAT Vav in iTregs reduces the frequency of iTregs to form an extended 
lamella during the first two minutes of activation, which is likely to improve the IS formation 
and activation signalling. While the expression of LAT V3 is not as effective.  
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In brief, the expression of LAT V3 in iTregs widens the T cell-APC interface in the first two 
minutes of iTreg activation. Moreover, the extended lamella of LAT V3-GFP expressing 
iTregs was significantly shortened, when comparing to that of LAT-GFP expressing iTregs 
in the first minute of activation. Therefore, the main body of LAT V3-GFP expressing iTregs 
is more flattened and shortened, which is more similar to that of LAT-GFP expressing Teffs. 
LAT-V3 expression in Tg4 iTregs help to form a more stable IS with a wider interface and 
shorter extended lamella, compared to that of LAT-GFP expressing iTreg. This is likely to 
enhance T cell signalling throughout the first two minutes of activation.  
 
LAT Vav expression in iTregs extends the interface and reduces the depth of extended 
lamellae in the first 20 seconds of activation. Thus, the overall cell shape of LAT Vav-GFP 
expressing iTregs is more comparable to that of LAT-GFP expressing Teffs at early time 
points. The expression of LAT Vav in iTregs also reduces the formation of extended 
lamellae within this period of time, which contributes to the formation of more tight cell 
couples. Therefore, T cell activation of LAT Vav-GFP expressing iTregs at early time points 
(0s and 20s) is likely to be enhanced, compared to that of LAT-GFP expressing iTregs. 
Notably, morphological differences between LAT-GFP expressing Teffs and iTregs were 
mainly found to be significant at early time points. Such differences were mostly not 
significant when comparing the morphological parameters of LAT Vav-GFP expressing 
iTregs and LAT-GFP expressing Teffs. Therefore, both of the expression of LAT V3 and 
LAT Vav in iTregs improve the IS formation by widening the T cell-APC interface and 
shortening the elongated cell shape of iTregs. iTregs transduced with either of the two 
fusion proteins are more morphological comparable to LAT-GFP expressing Teffs. However, 
such alterations in LAT V3 expressing iTreg sustains throughout the first two minutes of 
activation, which is seemingly excessive, while LAT Vav mainly changes the cell shape of 
iTregs in the first 20 seconds of activation. It is worth considering how the modification of 
LAT V3 and LAT Vav will affect iTreg activation and what phenotypes they drive iTregs to 
show. To address this question, spatiotemporal patterning analyses and cytokine production 
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Figure 6.1 The expression of LAT V3-GFP and LAT Vav-GFP in MBP Ac1-9 [4K]-
primed iTregs widen the interface of the IS and shorten the cell shape of iTregs in 
early activation. 
LAT V3-GFP transduced MBP Ac1-9 [4K]-primed iTregs were activated with MBP Ac1-9 
[4Y]-primed PL8 cells were imaged for 15 minutes using confocal microscopy. Four 
morphological parameters were measured within the first two minutes of activation and 0s 
indicates when a tight cell couple was formed. Comparing the ratios of A) interface width to 
cell width, B) lamella depth to cell depth, C) lamella depth to interface width of LAT-GFP 
expressing Teffs, LAT-GFP, LAT V3-GFP, and LAT Vav-GFP expressing iTregs during the 
first two minutes of activation. D) Comparing the percentages of LAT-GFP expressing Teffs, 
LAT-GFP, LAT V3-GFP, and LAT Vav-GFP expressing iTregs with an extended lamella in 
early activation. Data of LAT-GFP transduced Teffs (40 cell couples of four experiments) 
and iTregs (40 cell couples of two experiments) refers to Figure 4.7. 40 cell couples from 
four experiments for LAT V3-GFP and two experiments for LAT Vav were analysed. 
Statistical significance of log-transformed data was calculated using A) Two-way ANOVA or 
B-C) mixed-effect model as some values are not recorded for cells without an extended 
lamella. D) Statistical significance was calculated using Chi-square test. Asterisks indicate 
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6.4 Fusing LAT with the PKC-θ V3 domain strongly enhances LAT 
localisation at the interface and partially restores LAT central 
accumulation in MBP peptide-primed iTregs 
We have shown that LAT overall and central accumulation at the interface are defective in 
both MBP peptide and anti-CD3/28-primed iTregs upon activation in chapter 4. As the 
morphological phenotypes of MBP peptide-primed iTregs are altered by the expression of 
LAT V3, it is of great interest to investigate the spatiotemporal accumulation patterns of LAT 
V3 in MBP peptide-primed iTreg activation. Therefore, we analysed LAT V3-GFP 
accumulation during the activation of MBP Ac1-9 [4K]-primed iTregs with the acquired live-
cell imaging data. LAT V3-GFP transduced iTregs were >75% Foxp3+. Figure 6.2 shows 
representative images of LAT V3-GFP expressing iTregs in the first two minutes of T cell 





Figure 6.2 Representative live cell images of Tg4 iTregs transduced with LAT V3-GFP 
from four time points in early T cell activation. 
Top: DIC images from four time points. Bottom: matching top-down maximum projections of 
three-dimensional LAT V3-GFP fluorescent images (intensity is encoded in pseudocolour 
and increases from purple to red). Time is given in seconds relative to the formation of a 
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The spatiotemporal accumulation of LAT V3-GFP during early activation of MBP Ac1-9 [4K]-
primed iTregs was analysed and compared to that of LAT-GFP Teffs and iTregs with the 
same priming and activating condition (Figure 6.3). Data of LAT-GFP accumulation in MBP 
peptide-primed Teffs and iTregs refer to Figure 4.10. In iTregs, the overall accumulation of 
LAT V3-GFP in iTregs gradually increased from the -20s time point and peaked at the 40s 
time point with 80% of iTregs showing accumulation (Figure 6.3 C).  This high level of LAT 
V3-GFP accumulation remained at the interface afterwards and was observed in 68% of 
iTregs at the last time point. Among different patterns found at the interface, the diffuse 
accumulation pattern of LAT V3-GFP was dominant at all time points and peaked at the 
120s time point with 40% of iTregs showing this pattern. While LAT-GFP diffuse 
accumulation was barely observed in neither Teffs nor iTregs. Central LAT V3-GFP 
accumulation was found mainly in the first two minutes of activation. The accumulation of 
LAT V3-GFP at the distal pole was found at early time points and peaked at the -20s time 
point with formed with 25% of iTreg showing such accumulation. The distal patterning of 
LAT V3-GFP diminished afterwards, which is similar to what observed in the distal LAT-
GFP accumulation in iTregs. 
 
In the direct comparison, the percentage of iTregs with LAT V3-GFP accumulation at the 
interface during iTreg activation was higher than that of LAT-GFP overall accumulation at all 
12 time points. (Figure 6.3 D, the second row).  The enhancement was extremely prominent 
as highly significant differences were found at all time points (p<0.0001). Moreover, this 
percentage was also higher than the that of Teffs showing overall LAT-GFP accumulation at 
all time points. The differences were significant at all time points except for 0s to 40s 
(p<0.01), and they remained significant with the Bonferroni correction at the -20s, 100s-
420s time point (p<0.004). To summarise, the high level of LAT V3-GFP localisation at the 
interface indicates that fusing LAT to the PKC-θ V3 domain strongly increases LAT overall 
accumulation at the IS in early activation of Tg4 MBP peptide-primed iTregs. The extent of 
enhancement is outstanding as the upregulated accumulation of LAT V3 at the interface 
sustained for at least six minutes after the peak of accumulation, whilst LAT localisation at 
the IS in both Teffs and iTregs diminished after the peak in the first few minutes of activation. 
Such enhancement is likely to reinforce LAT clustering at the cSMAC. It is unclear how the 
inefficient clearance of LAT V3 molecules at the interface would affect the cSMAC and LAT 
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Figure 6.3 LAT V3-GFP displays prominent accumulation at the IS during early 
activation of MBP Ac1-9 [4K]-primed iTregs 
LAT V3-GFP transduced MBP Ac1-9 [4K]-primed iTregs were activated by MBP Ac1-9 [4Y]-
primed PL8 cells and imaged using spinning disk confocal microscopy for 15 minutes. DIC 
and GFP images were analysed to determine formations of a tight cell couple (0s). Data of 
LAT-GFP accumulation in MBP Ac1-9 [4K]-primed A) Teffs (n=49, four experiments) and B) 
iTregs (n=72, two experiments) refer to Figure 4.10. C) Spatiotemporal distribution patterns 
of LAT V3-GFP for 12 time points in MBP Ac1-9 [4K]-primed iTregs (n=57, four 
experiments). D) Comparing the percentages of cells with LAT-GFP or LAT V3-GFP 
accumulation at the interface during the activation of corresponding cell types using a two 
proportion z-test. Numerals and asterisks indicate p-values, and asterisk colours denote 
whether differences remain significant with the Bonferroni correction (0.01<*<0.05, 
0.004<**<0.01, 0.001<**<0.004, 0.0001<***<0.001, ****<0.0001). Error bars indicate 
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Next, we compared the central or invagination patterning of LAT V3-GFP in MBP peptide-
primed iTregs with that of LAT-GFP in Teffs and iTregs in early activation (Figure 6.4). As 
shown in Figure 4.10 of section 4.8, the percentage of Teffs showing either central or 
invagination accumulation of LAT-GFP was higher than that of iTregs from the 0s to 420s 
time point. Significant differences were found at seven time points (p<0.05, 0s-120s) and 
the differences remained significant at the 20s and 40s time point with the Bonferroni 
correction (p<0.004). Figure 6.4 B shows that the percentage of iTregs with LAT V3-GFP 
central + invagination accumulation was higher than that with LAT-GFP central + 
invagination accumulation across all time points. However, a significant difference was only 
found at the 180s time point, but it was not significant with the Bonferroni correction 
(0.004<p<0.05). The percentage of Teffs with LAT-GFP central + invagination accumulation 
was higher than that of iTregs with LAT V3-GFP central + invagination accumulation in the 
first 180 seconds of activation (Figure 6.4 C). The differences were only significant at the 
20s time point but did not remain significant with the Bonferroni correction (0.004<p<0.05). 
These comparisons indicate that in early MBP peptide-primed iTreg activation, LAT 
accumulation near the centre of the interface is upregulated by the fusing LAT to the PKC-θ 
V3 domain, although the defective accumulation is not fully restored.  
 
Then we separately compared the central and invagination accumulation of LAT V3-GFP 
and LAT-GFP in these conditions. The LAT-GFP central accumulation in iTregs was low 
and less than 10% of the cells showing such accumulation at all time points (Figure 6.5 A). 
Teffs showed more central LAT-GFP accumulation than iTregs at 11 out of 12 time points, 
and the percentage of Teffs with LAT-GFP central patterning was significantly higher than 
that of iTreg from the 0s to 120s time point (p<0.01). LAT V3-GFP showed more central 
accumulation than that of LAT-GFP in iTregs, mainly from the 20s to 80s, 180s and 300s 
time point (Figure 6.5 B). Significant differences were found at the 40s (p<0.004) and 60s 
(0.01<p<0.05). Teffs still showed more central LAT-GFP accumulation than LAT V3-GFP 
central accumulation in iTregs, mainly in the first two minutes of activation. The percentage 
of Teffs with central LAT-GFP accumulation was significantly higher than that of iTreg with 
central LAT V3-GFP accumulation at the 20s (p<0.004) and 40s (0.01<p<0.05) time point 
(Figure 6.5 C). These analyses show that fusion of LAT with the PKC-θ V3 domain partially 
restores its central accumulation during early activation of MBP peptide-primed iTregs.  
 
The invagination accumulation of LAT-GFP in MBP peptide-primed Teffs and iTregs was 
similar at all time points (Figure 6.5 D). The percentage of iTregs with LAT V3-GFP 
invagination accumulation was also comparable to that of Teffs or iTregs showing LAT-GFP 
invagination patterning across all time points (Figure 6.5 E and F). No significant differences 
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were observed in both comparisons. Thus, fusion with PKC-θ V3 domain does not affect 
LAT invagination accumulation in iTregs.  
 
In addition, fusion of PKC-θ V3 strongly increases diffuse accumulation of LAT in MBP 
peptide-primed iTregs. Initially, LAT-GFP did not show much diffuse accumulation in either 
MBP peptide-primed Teffs or iTregs in early activation (Figure 6.6 A). It was notable that 
LAT V3-GFP showed significantly more diffuse accumulation than that of LAT-GFP in Teffs 
and iTregs (Figure 6.6 B and C). Highly significant differences were observed in both 
comparisons at almost all time points (-20s-420s). These results indicate that a fair number 
of LAT molecules, which are driven to the interface by the additional PKC-θ V3 domain, 
diffuse at the entire interface during the first few minutes of activation.  
 
Together, these observations indicate that fusing LAT with the PKC-θ V3 domain strikingly 
enhances LAT overall accumulation at the T cell-APC interface and partially restores 
impaired LAT central localisation in the early activation of Tg4 MBP peptide-primed iTregs. 
Also, diffuse LAT accumulation in iTregs is strongly enhanced by fusing it with PKC-θ V3, to 
a greater extent than that observed in Teffs. By increasing the valence of LAT, the PKC-θ 
V3 domain drives more LAT molecules to the interface which provide more docking sites for 
downstream signalling proteins (such as Grab2, Gads and PLCγ-1), thus enhances LAT 
signalosome-mediated early T cell signalling.  
 
In Teffs, LAT-GFP overall accumulation at the interface gradually diminished after the peak 
of accumulation and remained at a low level after the 120s time point. While in iTregs, LAT 
V3-GFP overall accumulation peaked at the 40s time point and such accumulation largely 
remained at the interface for at least six minutes, showing a mixed patterning of 
accumulation. However, sustained localisation of LAT at the interface might not be 
necessary for T cell function. Clark et al (126) showed that upon full and attenuated T cell 
activation, LAT V3 displayed sustained localisation with a strong central preference at the 
interface in 5C.C7 T cells, but the amount of IL-2 mRNA was not affected. Therefore, it is of 
interest to investigate how the expression of LAT V3 would change functions of iTregs. 
Moreover, the enhanced overall accumulation of LAT V3 at the interface consistently 
matches the morphological phenotypes of LAT V3 expressing iTregs observed in the first 
two minutes of activation (Figure 6.1). Thus, fusing LAT with the PKC-θ V3 domain 
increases LAT localisation at the interface to a great extent and simultaneously enhances T 
cell-APC conjunctions of Tg4 MBP peptide-primed iTregs in early activation. As LAT central 
localisation is only partially restored by the fusion of PKC-θ V3 domain in the first two 
minutes of activation, the enhancement on signal transduction regulated by the cSMAC is 
likely to be limited.  
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Figure 6.4 In early activation of MBP Ac1-9 [4K]-primed iTregs, the total amount of 
central and invagination accumulation of LAT V3-GFP at the interface is increased, 
compared to that of LAT-GFP. 
In early activation of MBP peptide-primed T cells, the percentages of cells with central + 
invagination accumulation of A) LAT-GFP in Teffs and iTregs, B) LAT-GFP and LAT V3-
GFP in iTregs and C) LAT-GFP in Teffs and LAT V3-GFP in iTregs were compared. Data of 
LAT-GFP transduced Teffs (n=49, four experiments) and iTregs (n=72, two experiments) 
refer to Figure 4.11, and 57 cell couples of LAT V3-GFP expressing iTregs from four 
experiments were analysed. A two proportion z-test was used to calculate statistical 
significance. Asterisks indicate p-values and colours indicate whether differences remain 
significant with the Bonferroni correction (0.01<*<0.05, 0.004<**<0.01, 0.001<**<0.004, 
***<0.001). Error bars indicate standard error of the mean. 
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Figure 6.5 More LAT V3-GFP central accumulation is found at the interface in early 
activation of MBP peptide-primed iTregs, compared to that of LAT-GFP. 
In early activation of MBP peptide-primed T cells, comparing the percentages of cells 
showing central patterning of A) LAT-GFP in Teffs and iTregs, B) LAT-GFP and LAT V3-
GFP in iTregs and C) LAT-GFP in Teffs and LAT V3-GFP in iTregs, and the percentages of 
cells showing invagination patterning of D) LAT-GFP in Teffs and iTregs, E) LAT-GFP and 
LAT V3-GFP in iTregs and F) LAT-GFP in Teffs and LAT V3-GFP in iTregs. Data of LAT-
GFP transduced Teffs (n=49, four experiments) and iTregs (n=72, two experiments) refer to 
Figure 4.11, and 57 cell couples of LAT V3-GFP expressing iTregs from four experiments 
were analysed. Statistical significance was calculated with a two proportion z-test. Asterisks 
indicate p-values and colours indicate whether differences remain significant with the 
Bonferroni correction (0.01<*<0.05, 0.004<**<0.01, 0.001<**<0.004, ***<0.001). Error bars 
indicate standard error of the mean.  
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Figure 6.6 LAT V3-GFP shows a much stronger preference for diffuse accumulation 
than that of LAT-GFP in MBP peptide-primed Teffs and iTregs.  
In early activation of MBP Ac1-9 [4K] primed T cells, the percentages of cells with diffuse 
accumulation of A) LAT-GFP in Teffs and iTregs, B) LAT-GFP and LAT V3-GFP in iTregs 
and C) LAT-GFP in Teffs and LAT V3-GFP in iTregs were compared. Data of LAT-GFP 
transduced Teffs (n=49, four experiments) and iTregs (n=72, two experiments) refer to 
Figure 4.11, and 57 cell couples of LAT V3-GFP expressing iTregs from four experiments 
were analysed. A two proportion z-test was used to calculate statistical significance. 
Asterisks indicate p-values and colours indicate whether differences remain significant with 
the Bonferroni correction (0.004<**<0.01, 0.001<**<0.004, 0.0001<***<0.001, ****<0.0001). 
Error bars indicate standard error of the mean. 
164 
 
Chapter 6  
6.5 Computational analyses identify increased accumulation of 
LAT V3 at the entire and central core of the IS of iTregs 
Computational analyses were performed using LAT V3-GFP imaging data to validate 
observations found in spatiotemporal patterning analyses. A 3D model map showing 
relative probabilities of LAT V3-GFP accumulation during MBP peptide-primed iTreg 
activation was generated.  
 
We first compared LAT-GFP and LAT V3-GFP enrichment at the defined IS region showing 
the top 10% of the fluorescence in corresponding cells. Data showing LAT-GFP enrichment 
in MBP peptide-primed Teffs and iTregs refer to Figure 4.13, section 4.9. As described 
before, LAT-GFP enrichment at the IS of Teffs was higher than that of iTregs at all 12 time 
points and significant difference were found at the 80s, 120s-420s time point (p<0.05, 
Figure 6.7 A). In iTregs, a higher level of LAT V3-GFP enrichment at the IS during early 
iTreg activation was observed at all 12 time points, compared to that of LAT-GFP 
enrichment (Figure 6.7 B). However, only one significant difference was observed at the -
40s time point (0.01<p<0.05). The level of enrichment of LAT-GFP at the IS of Teffs was 
higher than that of LAT V3-GFP in iTreg at most time points (40s-420s Figure 6.7 C) and 
the difference was significant at the 420s time point (0.004<p<0.01, not significant with the 
Bonferroni correction). These results together indicate LAT accumulation in the defined IS 
region in MBP peptide-primed iTregs is upregulated by fusion with PKC-θ V3. 
 
We compared the accumulation of LAT V3-GFP and LAT-GFP at the centre of the interface 
by focusing on the enrichment inside the central core. As described in section 4.9, the level 
of LAT-GFP enrichment in the central core of Teffs was higher than that of iTregs at all 12 
time points and the differences were significant at the 80s, 120s-420s time point 
(0.004<p<0.05, Figure 6.7 D). In early iTreg activation, more enrichment of LAT V3-GFP in 
the central core was observed at all time points except one (420s), compared to that of 
LAT-GFP (Figure 6.7 E). The differences were significant at the -20s and 0s time point 
(0.01<p<0.05). The level of LAT V3-GFP enrichment in the central core of iTregs was 
comparable to that of LAT-GFP enrichment in the central core of Teffs before the 100s time 
point (Figure 6.7 F). After that, LAT V3-GFP accumulation in the central core in iTregs 
gradually decreased while LAT-GFP accumulation remained at the interface centre in Teffs. 
However, their level of enrichment was only significantly different at the 420s time point 
(0.004<p<0.01). Therefore, fusion of LAT to the PKC-θ V3 domain partially restores its 
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Being consistent with results from the spatiotemporal distribution analyses, the large-scale 
computational approach shows that fusing LAT with the PKC-θ V3 domain enhances LAT 
accumulation at the interface in early activation of MBP peptide-primed iTregs. A higher 
level of LAT V3-GFP accumulation in the central region of iTregs suggests that fusion with 
PKC-θ V3 also enhances LAT accumulation at the centre of the interface. In summary, both 
pattern and computational analyses show that fusion with PKC-θ V3 domain efficiently 
induces more LAT molecules to the interface and partially restores LAT accumulation in the 
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Figure 6.7 Computational analyses show that when fused to the PKC-θ V3 domain, 
LAT-GFP overall and central accumulation at the IS are enhanced in early the 
activation of MBP Ac1-9 [4K]-primed iTregs. 
LAT V3-GFP transduced MBP peptide-primed iTregs were computationally analysed to 
generate 3D model maps which show enrichment of the sensor within a cell. Comparing A) 
LAT-GFP enrichment in Teffs and iTregs, B) LAT-GFP and LAT V3-GFP enrichment in 
iTregs, and C) LAT-GFP enrichment in Teffs and LAT V3-GFP enrichment in iTregs, within 
the IS (top 10% enrichment). Comparing D) LAT-GFP enrichment in Teffs and iTregs, E) 
LAT-GFP and LAT V3-GFP enrichment in iTregs, and F) LAT-GFP enrichment in Teffs and 
LAT V3-GFP enrichment in iTregs, within the central core of the IS. Data of LAT-GFP 
enrichment in Teffs (28 cell couples from four experiments) and iTregs (28 cell couples from 
two experiments) refer to Figure 4.13 and 4.14, and 22 cell couples from four experiments 
of LAT V3-GFP transduced iTregs were analysed. Log-transformed data were analysed 
with unpaired Student’s test to calculate statistical significance. Asterisks indicate p-values 
and colours indicate whether differences remain significant with the Bonferroni correction 
(0.01<*<0.05, 0.004<**<0.01, 0.001<**<0.004, ***<0.001). Error bars indicate standard error 
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6.6 In early activation of anti-CD3/28-primed iTregs, fusing LAT 
with the PKC-θ V3 domain strongly enhances LAT overall and 
central localisation 
Additional imaging data of LAT V3-GFP were acquired using anti-CD3/28-primed iTregs, 
and were compared with that of LAT-GFP accumulation in Teffs and iTregs primed with 
anti-CD3/28 (refer to Figure 4.10, section 4.8). In anti-CD3/28-primed iTregs, LAT V3-GFP 
promptly accumulated at the interface upon the IS formation and peaked around the 80s 
time point with 92% of the cells showing LAT V3-GFP accumulation at the interface (Figure 
6.8 C). At the interface, LAT V3-GFP showed mainly central, invagination and diffuse 
patterning in the first two minutes. The central and invagination accumulation of LAT V3-
GFP remained at the interface till the last time point.  A low level of distal accumulation of 
LAT V3-GFP accumulation was observed before the IS formation and diminished after.  
 
In anti-CD3/28-primed iTregs, the percentage of cells with LAT V3-GFP accumulation was 
higher than that with LAT-GFP accumulation at the interface (Figure 6.8 B) from the 0s to 
420s time point. The differences were highly significant from the 20s to 420s time point 
(p<0.004, Figure 6.8 D, the second row). Moreover, the peak of LAT V3-GFP overall 
accumulation occurred 40 seconds earlier than that of LAT-GFP overall accumulation in 
iTregs. The overall accumulation at the interface of LAT V3-GFP in iTregs was comparable 
to that of LAT-GFP in Teff (Figure 6.8 A) during early activation. Only one significant 
difference was observed at the 120s time point when comparing the percentage of iTregs 
with LAT V3-GFP accumulation to that of Teffs with LAT-GFP accumulation at the interface, 
though it was no longer significant with the Bonferroni correction (0.004<p<0.05, Figure 6.8 
D, the third row). These observations suggest that in early activation of anti-CD3/28-primed 
iTregs, impaired LAT localisation at the interface can be restored by fusing LAT with the 
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Figure 6.8 In early activation of anti-CD3/28-primed iTregs, LAT V3-GFP intensively 
accumulates at the interface with dominant central patterningϮ. 
LAT V3-GFP expressing anti-CD3/28-primed iTregs were activated by MBP Ac1-9 [4Y]-
primed PL8 cells and imaged using spinning disk confocal microscopy for 15 minutes. DIC 
and GFP images were analysed to determine formations of a tight cell couple (0s). Data of 
LAT-GFP accumulation in anti-CD3/28-primed A) Teffs (n=42, two experiments) and B) 
iTregs (n=48, four experiments) refer to Figure 4.10. C) Spatiotemporal distribution patterns 
of LAT V3-GFP in early activation of anti-CD3/28-primed iTregs (n=58, two experiments). D) 
Comparing the percentages of cells with LAT-GFP or LAT V3-GFP accumulation at the 
interface during the activation of corresponding cell types using a two proportion z-test. 
Numerals and asterisks indicate p-values, and asterisk colours denote whether differences 
remain significant with the Bonferroni correction (0.01<*<0.05, 0.004<**<0.01, 
0.001<**<0.004, ***<0.0021, ****<0.0001). Error bars indicate standard error of the mean. 
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Together the central and invagination patterning of LAT V3-GFP or LAT-GFP in anti-
CD3/28-primed T cess during early activation were compared (Figure 6.9). Spatiotemporal 
accumulation patterns of LAT-GFP during the activation anti-CD3/28-primed cells refer to 
Figure 4.11 from section 4.8. As described before, the percentage of anti-CD3/28-primed 
Teffs with central + invagination accumulation of LAT-GFP was higher than that of iTregs at 
most time points (Figure 6.9 A). Highly significant differences were found at six time points 
(0s-100s) and all of them remained significant with the Bonferroni correction (p<0.004). The 
percentage of iTregs with LAT V3-GFP central + invagination accumulation was significantly 
higher than that with LAT-GFP central + invagination accumulation across at most time 
points (0s to 420s, Figure 6.9 B). Particularly within the first two minutes of activation, the 
differences were prominent (p<0.0001). Moreover, the percentage of iTregs showing LAT 
V3-GFP central + invagination accumulation was even higher than that of Teffs with LAT-
GFP central + invagination accumulation from the 20s to 420s time points (Figure 6.9 C). 
Significant differences were observed from the 120s to 420s time point (p<0.05) and were 
still significant at the 120s and 180s time point (p<0.004). These together reveal that LAT 
localisation around the interface centre in early activation of anti-CD3/28-primed iTreg is 
excessively enhanced by fusion with the PKC-θ V3 domain.  
 
We further compared only the central + invagination accumulation of LAT V3-GFP or LAT-
GFP in these three conditions.  As previously described, less LAT-GFP central 
accumulation was observed in anti-CD3/28-primed iTregs during early activation, compared 
to that in Teffs. Significant differences were observed at the 40s, 80s and 180s time point 
when comparing the percentages of iTregs and Teffs with such accumulation 
(0.004<p<0.05, Figure 6.10 A). In anti-CD3/28-primed iTregs, LAT V3-GFP showed a much 
stronger preference for central accumulation at the interface than LAT-GFP after the IS was 
formed (Figure 6.10 B). When comparing the percentages of iTregs with central LAT-GFP 
and LAT V3-GFP accumulation, highly significant differences were found at most time 
points (p<0.004, 20s, 40s, 80s-180s, 420s). Notably, the percentage of iTregs with central 
LAT V3-GFP accumulation was higher than that of Teffs with LAT-GFP central 
accumulation after the IS was formed (20s-420s, Figure 6.10 C). The differences were 
significant from the 120s to 300s time point but were no longer significant with the 
Bonferroni correction (0.004<p<0.05). These comparisons indicate that LAT accumulation in 
early activation of anti-CD3/28-primed iTregs is efficiently driven to the centre of the 
interface by fusion with the PKC-θ V3 domain, and the time range of central accumulation is 
significantly prolonged. 
  
Barely any LAT-GFP invagination accumulation at the interface was observed during anti-
CD3/28-primed iTreg activation, while this was found in Teffs in the first two minutes of 
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activation (Figure 6.10 D). Differences were significant in the first 100 seconds when 
comparing their percentage with LAT-GFP invagination patterning (p<0.05). The percentage 
of iTregs with LAT V3-GFP invagination accumulation was higher than that with LAT-GFP 
invagination accumulation after the IS was formed, and significant differences were 
observed from the 40s to 100s time point (Figure 6.10 E). The invagination patterning of 
LAT V3-GFP in iTregs was comparable to that of LAT-GFP in Teffs in early activation 
(Figure 6.10 F). Therefore, by fusing LAT with the PKC-θ V3 domain, LAT invagination 
accumulation at the interface is restored.  
 
In summary, during early activation of Tg4 anti-CD3/28-primed iTregs, the impaired LAT 
overall, central and invagination accumulation is restored by fusing LAT with the PKC-θ V3 
domain. Moreover, fusion with PKC-θ V3 exceedingly enhances and prolongs LAT 
accumulation at the centre of the interface. These observations in anti-CD3/28-primed 
iTregs are similar to those found in MBP peptide-primed iTregs, except that LAT central 
localisation driven by the fused PKC-θ V3 domain is more pronounced in the former. This 
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Figure 6.9 LAT V3-GFP shows prominent central and invagination patterning at the IS 
in the first seven minutes of anti-CD3/28-primed iTreg activation.   
In early activation of anti-CD3/28-primed T cells, the percentages of cells with central + 
invagination accumulation of A) LAT-GFP in Teffs and iTregs, B) LAT-GFP and LAT V3-
GFP in iTregs and C) LAT-GFP in Teffs and LAT V3-GFP in iTregs were compared. Data of 
LAT-GFP transduced Teffs (42 cell couples from two experiments) and iTregs (48 cell 
couples from four experiments) refer to Figure 4.11, and 58 cell couples of LAT V3-GFP 
expressing iTregs from two experiments were analysed. A two proportion z-test was used to 
calculate statistical significance. Asterisks indicate p-values and colours indicate whether 
differences remain significant with the Bonferroni correction (0.01<*<0.05, 0.001<**<0.004, 
***<0.001). Error bars indicate standard error of the mean. 
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Figure 6.10 Both LAT V3-GFP central and invagination accumulation are significantly 
enhanced in early activation of anti-CD3/28-primed iTregs, compared to that of LAT-
GFP. 
In early activation of anti-CD3/28-primed T cells, comparing the percentages of cells with 
central accumulation of A) LAT-GFP in Teffs and iTregs, B) LAT-GFP and LAT V3-GFP in 
iTregs and C) LAT-GFP in Teffs and LAT V3-GFP in iTregs, and the percentage of cells 
with invagination accumulation of D) LAT-GFP in Teffs and iTregs, E) LAT-GFP and LAT 
V3-GFP in iTregs and F) LAT-GFP in Teffs and LAT V3-GFP in iTregs. Data of LAT-GFP 
transduced Teffs (42 cell couples from two experiments) and iTregs (48 cell couples from 
four experiments) refer to Figure 4.11 and 58 cell couples of LAT V3-GFP expressing iTregs 
from two experiments were analysed. Statistical significance was calculated with a two 
proportion z-test. Asterisks indicate p-values and colours indicate whether differences 
remain significant with the Bonferroni correction (0.01<*<0.05, 0.004<**<0.01, 
0.001<**<0.004, ***<0.001). Error bars indicate standard error of the mean.  
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6.7 Fusion with the Vav1 SH3SH2SH3 domain restores overall 
accumulation and partial central accumulation of LAT in MBP 
peptide-primed iTregs 
SH2 and SH3 domains bind phosphorylated tyrosine residues and proline-rich region 
respectively and are important modules for protein-protein interactions in signal transduction 
(274). In addition to PKC-θ V3, Clark et al fused LAT with another protein domain, Vav1 
SH3SH2SH3, to increase LAT valence under attenuated activation conditions of 5C.C7 
transgenic T cells (126). Unlike the exaggerated LAT central localisation induced by the 
PKC-θ V3 domain, the SH3SH2SH3 domain of Vav1 fairly reconstitutes LAT centrality in 
early activation of 5C.C7 T cells under costimulation blocked and Itk deficient conditions. 
Moreover, restoration of LAT central localisation by the fusion with Va1 SH3SH2SH3 
significantly enhanced IL-2 mRNA production in these attenuated activation conditions (126). 
Thus, the expression of LAT Vav leads to better physiological restoration of 5C.C7 T cells 
under attenuated activation conditions, than that of LAT V3. To investigate whether this 
domain could also help to restore impaired LAT central localisation in early activation of Tg4 
iTregs, we transduced MBP Ac 1-9 [4K]-primed iTregs with the fusion protein LAT Vav-GFP 
and live-cell imaging was performed to track LAT Vav-GFP accumulation during early 
activation of iTregs. LAT Vav-GFP transduced iTregs were >75% Foxp3+. Representative 
images of LAT Vav-GFP transduced iTregs in the first two minutes of T cell activation from 




Figure 6.11 Representative live cell images of LAT Vav-GFP expressing Tg4 iTregs at  
four time points in early T cell activation. 
Top: DIC images from four time points. Bottom: matching top-down maximum projections 
3D fluorescent images (intensity is encoded in pseudocolour and increases from purple to 
red). Time is given in seconds relative to the formation of a tight cell couple and arrows 
show accumulation of the sensor. 
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The spatiotemporal distributions of LAT Vav-GFP during early activation of MBP peptide-
primed iTregs was analysed and the accumulation patterns were compared to that of LAT-
GFP in Teffs and iTregs with the same priming and activating condition (Figure 6.12). Data 
showing LAT-GFP accumulation in MBP peptide-primed Teffs and iTregs refer to Figure 
4.10. During early activation of iTregs, LAT Vav-GFP gradually accumulated at the interface 
from the -40s time point and the accumulation peaked at the 60s time point with 69% of 
iTregs showing LAT Vav-GFP accumulation at the interface (Figure 6.12 C). The 
accumulation decreased slowly after and was still observed in 41% of iTregs at the 420s 
time point. In terms of accumulation patterning, multiple accumulation patterns were 
observed in LAT Vav-GFP transduced iTregs throughout the time points recorded. Central 
LAT Vav-GFP accumulation was found from -20s to 420s time point and the percentage of 
iTregs showing this patterning was around 10-20%. It was still higher than that of iTregs 
with other patterns from the -20s to 300s time point, although this was not dominant. 
Invagination accumulation of LAT Vav-GFP was observed mainly before the 180s time point 
and iTregs with diffuse LAT Vav-GFP accumulation could be found at all time points. 
Accumulation of LAT Vav-GFP at the distal pole was observed in < 20% of iTregs at early 
time points but diminished after the IS was formed.   
 
More iTregs showing LAT Vav-GFP accumulation at the interface during early activation 
was found, compared to that of LAT-GFP, and the differences were prominent (Figure 6.12 
D, the second row). The percentage of iTregs with LAT Vav-GFP accumulation at the 
interface was significantly higher than that with LAT-GFP accumulation at 11 out of 12 time 
points (p<0.05) and the differences were highly significant at the -20s and 20s-420s time 
point (p<0.004). Moreover, this was significantly higher than the percentage of Teffs with 
LAT-GFP accumulation at the -20s, 180s and 300s time point in early activation 
(0.01<p<0.05, Figure 6.12 D, the third row).  
 
In summary, LAT Vav was found to rapidly accumulate at the interface of the IS in the first 
minute of iTreg activation and remain at the interface with a slow reduction afterwards. 
Several accumulation patterns of LAT Vav were observed at the interface in early iTreg 
activation. Thus, fusion of LAT with the Vav1 SH3SH2SH3 domain significantly enhances 
LAT localisation at the T cell-APC interface in early activation of MBP peptide-primed iTregs. 
LAT overall accumulation at the interface is not only restored but also prolonged by this 
additional domain. However, the overall accumulation of LAT Vav at the interface was 
largely comparable to that of unaltered LAT in Teffs, which suggests that enhancement of 
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Figure 6.12 More LAT Vav-GFP accumulation is found at the interface during early 
activation of MBP Ac1-9 [4K]-primed iTregs, compared to that of LAT-GFP. 
MBP Ac1-9 [4K]-primed iTregs expressing LAT Vav-GFP were activated by MBP Ac1-9 
[4Y]-primed PL8 cells and imaged using spinning disk confocal microscopy for 15 minutes. 
DIC and GFP images were analysed to determine formations of a tight cell couple (0s). 
Data of LAT-GFP accumulation in MBP Ac1-9 [4K]-primed A) Teffs (n=49, four experiments) 
and B) iTregs (n=72, two experiments) refer to Figure 4.10. C) Spatiotemporal distribution 
patterns of LAT Vav-GFP for 12 time points in MBP Ac1-9 [4K]-primed iTregs (n=54, three 
experiments). D) Comparing the percentages of cells with LAT-GFP or LAT Vav-GFP 
accumulation at the interface during the activation of corresponding cell types using a two 
proportion z-test. Numerals and asterisks indicate p-values, and asterisk colours denote 
whether differences remain significant with the Bonferroni correction (0.01<*<0.05, 
0.004<**<0.01, 0.001<**<0.004, 0.0001<***<0.001, ****<0.0001). Error bars indicate 
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To investigate LAT Vav-GFP accumulation at the interface centre during early iTreg 
activation, we first focused on iTregs showing either central or invagination patterning of 
LAT Vav-GFP in MBP peptide-primed iTregs. As described in Figure 4.10 from section 4.8, 
the percentage of Teffs showing LAT-GFP central + invagination accumulation at the 
interface was significantly higher than that of iTregs in the first two minutes of activation 
(p<0.05, Figure 6.13 A). In early iTreg activation, the percentage of iTregs with central + 
invagination accumulation of LAT V3-GFP was higher than that of LAT-GFP from the -20s 
to 420s time point (Figure 6.13 B). The differences were significant at the -20s, 40s and 
80s-300s time point (0.004<p<0.05). The total amount of LAT Vav-GFP central and 
invagination accumulation in early iTreg activation was comparable to that of LAT-GFP in 
early Teff activation (Figure 6.13 C). No significant differences were found when comparing 
the percentages of iTregs showing central + invagination patterning of LAT Vav-GFP and 
that of Teffs with LAT-GFP central + invagination accumulation at the interface in early 
activation. These observations indicate that LAT localisation within the central region of the 
interface is enhanced by fusion with Vav1 SH3SH2SH3 domain. 
 
Then we compared only the central accumulation of LAT V3-GFP and LAT-GFP in 
corresponding cells. As described in Figure 4.11, section 4.8, more central LAT-GFP 
accumulation was found in Teffs than that in iTregs at 11 out of 12 time points, and the 
percentage of Teffs with LAT-GFP central patterning was significantly higher than that of 
iTreg from in the first two minutes of activation (p<0.01, Figure 6.14 A). In early iTreg 
activation, more central accumulation of LAT Vav-GFP was found from -20s to 420s time 
point, compared to that of LAT-GFP (Figure 6.14 B). The percentage of iTregs with LAT 
Vav-GFP central accumulation was significantly higher than that with LAT-GFP central 
accumulation at the -20s, 40s and 120s-300s time point (p<0.05).  In Figure 6.14 C, the 
percentage of Teffs with LAT-GFP central accumulation was higher than that of iTregs 
showing LAT Vav-GFP central accumulation mainly in the first 40 seconds of activation. The 
differences were only significant at the 20s time point but not prominent (0.01<p<0.05). 
These comparisons show that fusing LAT with the Vav1 SH3SH2SH3 domain enhances 
LAT central localisation at the interface in early iTreg activation.  
 
No significant differences were found when comparing the percentage of cells with 
invagination patterning of LAT-GFP in Teffs and iTregs at all time points (Figure 6.14 D). 
The percentage of iTregs with LAT Vav-GFP invagination accumulation was also 
comparable to that of Teffs or iTregs with LAT-GFP invagination accumulation at all time 
points (Figure 6.14 E and F). Therefore, fusion of LAT with the Vav1 SH3SH2SH3 domain 
does not have impacts on LAT invagination accumulation in early iTreg activation. 
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In summary, in early activation of MBP peptide-primed iTregs, fusing LAT with Vav1 
SH3SH2SH3 domain restores LAT overall accumulation at the IS and partially restores LAT 
central localisation, which is likely to enhance cSMAC formation and LAT nucleated signal 
transduction. The significantly increased localisation of LAT at the interface driven by the 
Vav1 SH3SH2SH3 domain can also be linked with the improved morphology of LAT Vav 
transduced iTregs, mostly in the first minute after the formation of tight cell couples (Figure 
6.1). These consistent observations suggest that a higher level of LAT accumulation at the 
interface is positively associated with better T cell-APC interactions, and are both indicative 
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Figure 6.13 During early activation of MBP Ac1-9 [4K]-primed iTregs, the amount of 
central and invagination accumulation of LAT Vav-GFP at the interface is upregulated, 
compared to that of LAT-GFP. 
In early activation of MBP Ac1-9 [4K] primed T cells, the percentages of cells with central + 
invagination accumulation of A) LAT-GFP in Teffs and iTregs, B) LAT-GFP and LAT Vav-
GFP in iTregs and C) LAT-GFP in Teffs and LAT Vav-GFP in iTregs were compared. Data 
of LAT-GFP transduced Teffs (n=49, four experiments) and iTregs (n=72, two experiments) 
refer to Figure 4.11, and 54 cell couples of LAT Vav-GFP expressing iTregs from three 
experiments were analysed. A two proportion z-test was used to calculate statistical 
significance. Asterisks indicate p-values and colours indicate whether differences remain 
significant with the Bonferroni correction (0.01<*<0.05, 0.004<**<0.01, 0.001<**<0.004, 
***<0.001). Error bars indicate standard error of the mean. 
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Figure 6.14 LAT Vav-GFP shows increased central patterning at the interface in early 
activation of MBP peptide-primed iTregs, compared to that of LAT-GFP. 
In early activation of MBP peptide-primed T cells, comparing the percentages of cells 
showing central patterning of A) LAT-GFP in Teffs and iTregs, B) LAT-GFP and LAT Vav-
GFP in iTregs and C) LAT-GFP in Teffs and LAT Vav-GFP in iTregs, and the percentage of 
cells showing invagination patterning of D) LAT-GFP in Teffs and iTregs, E) LAT-GFP and 
LAT Vav-GFP in iTregs and F) LAT-GFP in Teffs and LAT Vav-GFP in iTregs. Data of LAT-
GFP transduced Teffs (n=49, four experiments) and iTregs (n=72, two experiments) refer to 
Figure 4.11, and 54 cell couples of LAT Vav-GFP expressing iTregs from three experiments 
were analysed. Statistical significance was calculated with A two proportion z-test. Asterisks 
indicate p-values and colours indicate whether differences remain significant with the 
Bonferroni correction (0.01<*<0.05, 0.004<**<0.01, 0.001<**<0.004, ***<0.001). Error bars 
indicate standard error of the mean. 
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6.8 Computational analyses show that fusion with Vav1 
SH3SH2SH2 significantly increases LAT accumulation at the IS 
and centre of the interface 
In parallel to investigating spatiotemporal distribution patterns, we generated 3D model 
maps with LAT Vav-GFP imaging data showing relative probabilities of LAT Vav-GFP 
accumulation within a T cell (sensor enrichment) upon early activation of MBP peptide-
primed iTreg. Then we compared the enrichment of sensors of interest within the defined IS 
area (overall top 10% enrichment) and central core of the interface. Data showing LAT-GFP 
enrichment in Teffs and iTreg refer to section 4.9. 
 
LAT-GFP enrichment in the defined IS region of Teffs and iTregs were described above in 
Figure 4.13, section 4.9: compared to that in iTreg, more LAT-GFP accumulation was found 
in Teffs across all time points and significant differences were identified after the first minute 
of activation (Figure 6.15 A). In iTregs, the level of enrichment of LAT Vav-GFP at the IS 
was higher than that of LAT-GFP mainly at the -40s, -20s and 60s-420s time points (Figure 
6.15 B). However, the differences were only significant at the -20s time point 
(0.004<p<0.01). Within the defined IS area, the enrichment of LAT Vav-GFP in iTregs was 
comparable to that of LAT-GFP in Teffs mainly before the 80s time point (Figure 6.15 C). 
Teffs displayed a higher level of LAT-GFP enrichment than that of LAT Vav-GFP in iTregs 
from the 80s to 420s time point, and the differences were only significant at the 420s time 
point (0.01<p<0.05). These results show that when fused to the Vav1 SH3SH2SH3 domain, 
more LAT molecules are driven to the synapse in early activation of iTregs. However, the 
enhancement does not fully restore LAT accumulation at the IS, as the enrichment of LAT 
Vav-GFP in iTregs was only partially comparable to that of LAT-GFP in Teffs. 
 
Within the central core of the IS, the level of enrichment of LAT-GFP in Teffs was higher 
than that in iTregs at all time points (Figure 6.15 D). Significant differences were observed 
at the 80s and 120s-420s time points (0.004<p<0.05). In iTregs, LAT Vav-GFP enrichment 
in the central core of the IS was higher than that of LAT-GFP at most time points and the 
differences were significant at the -20s time point (0.01<p<0.05, Figure 6.15 E). Inside the 
central core, LAT Vav-GFP enrichment of iTregs was comparable to that LAT-GFP 
enrichment at early time points (-40s to 80s, Figure 6.15 F). Although the level of LAT-GFP 
enrichment in the central core of Teffs was higher than that of LAT Vav-GFP enrichment 
within this region of iTregs after the 60s time point, no significant differences were identified 
throughout all time points. These observations suggest that the impaired LAT localisation in 
the central core of the IS in early activation of iTregs is partially restored by fusing LAT with 
the Vav1 SH3SH2SH3 domain.  
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In summary, spatiotemporal distributions of LAT Vav-GFP within the entire and central core 
of the IS in early iTreg activation was analysed by the systematic computational approach. 
A higher level of LAT Vav-GFP accumulation at the IS of iTregs was identified, compared to 
that of LAT-GFP.  These results indicate that in early activation of MBP peptide-primed 
iTregs, LAT overall and central accumulation at the immune synapse is enhanced by fusion 
of LAT with the Vav1 SH3SH2SH3 domain. However, the enhancement does not fully 
restore impaired LAT accumulation in iTregs. Again, spatiotemporal pattern-based and 
computational analysis showed partial consistency in detecting increased LAT Vav-GFP 
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Figure 6.15 When fused to the Vav1 SH3SH2SH3  domain, LAT-GFP enrichment 
within the entire and central core of the IS are enhanced in early the activation of 
MBP Ac1-9 [4K]-primed iTregs. 
Computational analyses were performed on LAT Vav-GFP transduced MBP peptide-primed 
iTregs to generate 3D model maps, which show enrichment of the sensor within a cell. 
Comparing A) LAT-GFP enrichment in Teffs and iTregs, B) LAT-GFP and LAT Vav-GFP 
enrichment in iTregs, and C) LAT-GFP enrichment in Teffs and LAT Vav-GFP enrichment in 
iTregs, within the IS (top 10% enrichment). Comparing D) LAT-GFP enrichment in Teffs and 
iTregs, E) LAT-GFP and LAT Vav-GFP enrichment in iTregs, and F) LAT-GFP enrichment 
in Teffs and LAT Vav-GFP enrichment in iTregs, within the central core of the IS. Data of 
LAT-GFP enrichment in Teffs (28 cell couples from four experiments) and iTregs (28 cell 
couples from two experiments) refer to Figure 4.13 and 4.14, and 22 cell couples of LAT 
Vav-GFP transduced iTregs from three experiments were analysed. Log-transformed data 
were analysed with unpaired Student’s test to calculate statistical significance. Asterisks 
indicate p-values and colours indicate whether differences remain significant with the 
Bonferroni correction (0.01<*<0.05, 0.004<**<0.01, ***<0.001). Error bars indicate standard 
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6.9 LAT V3 tends to reduce IFN-γ and IL-10 production while LAT 
Vav slightly enhances IL-10 secretion of iTregs upon activation  
To investigate whether fusing LAT with the PKC V3 or Vav1 SH3SH2SH3 protein domain 
can affect the capability of Tg4 iTregs to secrete IFN-γ and IL-10, we transduced Tg4 MBP 
Ac1-9 [4K]-primed iTregs with LAT-GFP, LAT V3-GFP and LAT Vav-GFP and assessed 
their production of these two cytokines upon activation by ELISAs.  The induction of iTregs 
and retroviral transduction were performed as described in chapter 3. On day 5 of culture, 
successful induction of iTregs was confirmed by Foxp3 staining.  Then GFP+ iTregs within a 
positive FACS gate (1/3 log shift above the negative) were sorted. GFP+ iTregs were 
resuspended in Treg medium and transferred to a 96-well round plate. In each well, 0.5-1 x 
105 cells were restimulated with an equal number of mitomycin C pre-treated PL8 cells and 
10 µg/ml MBP Ac1-9 [4K]. The restimulation lasted for 18 hours and cell culture 
supernatants were collected. ELISAs were performed to quantify the levels of IFN-γ and IL-
10. iTregs used for IFN-γ ELISAs were >86% Foxp3+ and for IL-10 ELISAs were >72% 
Foxp3+. Supernatant samples from untransduced iTregs were used as controls. 
  
Figure 6.1 A show that untransduced iTregs produced significantly more IFN-γ than LAT-
GFP, LAT V3-GFP and LAT Vav-GFP expressing iTregs (p<0.01) after 18 hours of peptide-
induced restimulation. The amount of IFN-γ detected in the cell culture of LAT V3-GFP 
expressing iTregs was slightly but not significantly reduced, compared to that of LAT-GFP 
transduced iTregs. The level of IFN-γ secreted by LAT Vav-GFP and LAT-GFP transduced 
iTregs were comparable. To investigate the relative differences of IFN-γ secretion among 
transduced iTregs, we compared their relative amount of IFN-γ (Figure 6.16 B). The amount 
of IFN-γ detected in LAT-GFP expressing iTregs in each experiment was set as control (as 
“1”) and data from the same experiment were normalised to controls. Consistently, no 
significant differences were observed when comparing the relative IFN-γ production among 
transduced iTregs, but LAT V3-GFP expressing iTregs showed a trend of secreting less 
IFN-γ, compared to LAT-GFP transduced iTregs (p=0.06).  
  
Results from IL-10 ELISAs (Figure 6.16 C) show that the amount of IL-10 detected in 
untransduced iTregs upon restimulation was the highest among all four conditions. However, 
no significant differences were found when comparing IL-10 production in any two of the 
four conditions. This partially owes to the variability of experiments, as in one repeated 
experiment, the amount of IL-10 secreted by untransduced iTregs was nearly ten-fold 
higher than that in the other three experiments. The relatively low levels of IL-10 secreted 
by LAT-GFP, LAT V3-GFP or LAT Vav-GFP expressing iTregs were comparable. When 
comparing normalised IL-10 production (Figure 6.16 D), the relative IL-10 amount secreted 
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by LAT V3-GFP expressing iTregs was significantly lower than that of LAT-GFP expressing 
iTregs (p<0.01). Moreover, the expression of LAT Vav in iTregs slightly but not significantly 
increased IL-10 production.   
 
In conclusion, retroviral transduction of iTregs with LAT-GFP, LAT V3-GFP or LAT Vav-GFP 
significantly reduces their ability to produce IFN-γ and IL-10 when activated by MBP 
peptides. Retroviral transduction or overexpression of LAT is likely to impair cytokine 
secretion in T cells.  When transduced iTregs were restimulated with MBP peptides, the 
expression of LAT V3 consistently showed a trend of downregulating IFN-γ and IL-10 
production. While LAT Vav expression in iTregs barely affected IFN-γ but showed a trend of 
enhancing IL-10 secretion. These results suggest that fusion of LAT with the PKC-θ V3 and 
Vav1 SH3SH2SH3 domain affect cytokine secretion differently in iTregs, and LAT Vav 
tends to induce more IL-10 secretion and possibly better regulatory function of iTregs. Again, 
these results are consistent with the previous study, where LAT V3 does not affect the 
amount of IL-2 mRNA and LAT Vav enhances IL-2 mRNA production under attenuated T 
cell activation conditions in 5C.C7 Teffs (126). Fusion with the PKC-θ V3 domain has been 
shown to enhance T cell-APC interactions, strongly drives and prolongs LAT localisation at 
the interface of the IS in early activation of iTregs. Most likely, the excessive LAT 
polarisation induced by the additional PKC-θ V3 domain disturbs signalling complex 
spatiotemporal organisation at late time points in the cSMAC and subsequently affect 
cytokine production of iTregs. In contrast, full but not an excessive restoration of LAT overall 
accumulation at the IS induced by Vav1 SH3SH2SH3 mildly promotes better iTreg function 
by enhancing IL-10 production. Hence, increasing LAT valence to a moderate extent in Tg4 
iTregs restores impaired LAT overall localisation at the interface and improves iTreg 
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Figure 6.16 Retroviral transduction of iTregs with LAT related sensors impairs 
cytokine secretion and expression of LAT V3 and LAT Vav iTregs tends to have 
different impacts on IFN-γ and IL-10 production. 
MBP peptide-primed iTregs transduced with LAT-GFP, LAT V3-GFP or LAT Vav-GFP were 
restimulated on day 5 of culture with MBP peptides and PL8 cells (1:1 ratio, 5-10 x 104 cells 
each) for 18 hours. Cell culture supernatants were collected and used for ELISAs to assess 
the amount of IFN-γ and IL-10. Untransduced iTregs were used as a control. The level of A) 
IFN-γ (n=3) and C) IL-10 (n=4) produced by untransduced, LAT-GFP, LAT V3-GFP and 
LAT Vav-GFP transduced iTregs when restimulated. Normalised B) IFN-γ (n=3) and D) IL-
10 (n=5) levels among GFP-tagged groups. Statistical significance was calculated using 
One-way ANOVA (A and C) and multiple paired Student’s T-test (B and D). Asterisks 
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6.10 Discussion 
Previous work by Clark et al has shown that fusion of LAT with the PKC-θ V3 (LAT V3) and 
Vav1 SH3SH2SH3 protein domain (LAT Vav) increases LAT valence and restores its 
centrality upon attenuated activation conditions of 5C.C7 T cells (126). Moreover, 
restoration of LAT central clustering to a level comparable to that seen under full stimulus 
conditions by Vav1 SH3SH2SH3 enhances IL-2 mRNA production upon attenuated T cell 
stimuli, while the excessive LAT V3 central clustering does not. Therefore, complete, but not 
excessive reconstitution of LAT clustering in the cSMAC promotes better effector function of 
T cells. In this chapter, we measured morphological parameters, LAT polarisation and 
cytokine secretion in LAT V3 and LAT Vav expressing Tg4 iTregs to investigate whether 
increasing LAT valence could change how Tg4 iTregs behave in T cell activation. 
 
6.10.1 LAT V3 and LAT Vav induce iTregs to show more morphological 
phenotypes of Teffs upon activation 
As described in chapter 4, upon IS formation, LAT transduced Tg4 iTregs display a narrow 
contact interface and are more likely to form an extended lamella, compared to Teffs. Such 
morphological features are indicative of less effective T cell activation. The expression of 
LAT V3 in Tg4 iTregs elongates the interface of contact and induces the formation of more 
compressed cell couples in the first two minutes of activation. LAT V3 transduced iTregs 
and LAT transduced Teffs are morphologically similar in these two minutes. Therefore, LAT 
V3 largely restores the morphological changes of iTregs and most likely improves antigen 
presentation upon activation. However, as mentioned in section 5.9.3, a wide interface of 
contact is not always needed in early T cell activation. At the stabilisation stage, part of a T 
cell retracts from a B cell, forming a round cell shape (163). This cell rounding process is 
partially recovered by the expression of LAT V3. Although the expression of LAT V3 
reduces that lamella depth and extends the interface within the first two minutes of 
activation, it does not reduce the frequency of forming an extended lamella in iTregs. 
Moreover, the percentage of LAT V3 transduced iTregs showing an extended lamella was 
the highest among the four types of cells at late time points (60s and 120s), though the 
difference was not significant. Therefore, the restoration of T cell morphology induced by 
fusion with the PKC-θ V3 domain is not complete. Sustained extension of the contact 
interface in LAT V3 expressing iTregs promotes better formation of cell couplings but might 
impede cell rounding at later stages of T cell-APC interactions.  
 
Morphological alterations induced by LAT V3 and LAT Vav in iTregs are not entirely the 
same. In terms of widening the interface and shortening the lamella depth at early stages of 
activation, LAT Vav is not as potent as LAT V3. However, the expression of LAT Vav 
reduces the frequency of showing an extended lamella in iTregs, particularly in the first 20 
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seconds of activation, which helps to pull iTregs towards APCs. Overall, they both promote 
the formation of more stable and compressed T cell-APC conjunctions which are observed 
in Teffs.  Most likely such phenotypes are related to their enhanced LAT accumulation at 
the interface.  
 
6.10.2 Excessive and full restoration of LAT overall accumulation at the 
interface are induced by fusion with PKC V3 and Vav1 SH3SH2SH3 
respectively 
Impaired LAT overall accumulation at the interface of Tg4 MBP peptide-primed iTregs is 
excessively enhanced by fusing LAT with PKC-θ V3, which is consistent with the previous 
study (126). The first two minutes of tight cell coupling are characterised by rich 
accumulation of a large number of signalling intermediates of the cSMAC, including LAT, 
SLP-76, Grb2, Vav1 and PKC-θ (126, 134, 135). Such a transient peak of this biochemically 
detectable signalling activity is important for translocation of NFAT and NF-κB (130, 134). 
Under full and attenuated stimulus conditions, LAT centrality at the interface of 5C.C7 T 
cells can be exaggeratedly enhanced by fusion with PKC-θ V3 domain. In the former 
condition, excessively forced LAT central clustering diminishes recruitment of Grb2, Lck and 
Vav1, thus disturbs the finely regulated signalling system (126). Therefore, Clark et al 
suggest that in the first to two minutes of T cell activation, the cSMAC rapidly recruits key 
proximal signalling intermediates via multivalent interactions to form supramolecular 
complexes. Then, a number of these large proteins depart from the cSMAC and form 
smaller clusters which spread over the entire interface driven by a lamellal actin 
network(126, 135) Sustained LAT V3 central accumulation in 5C.C7 T cells possibly 
impedes transformation of these two different roles of the cSMAC and subsequently upset 
proximal T cell signalling. However, in Tg4 iTregs, impaired LAT central clustering is only 
partially restored by fusion with PKC-θ V3, mainly in the first two minutes of activation 
(Figure 6.5 A-C). In addition, fusing LAT with PKC-θ V3 significantly increases LAT diffuse 
accumulation at most time points. These data suggest that fusion with PKC-θ V3 
excessively enhance LAT overall accumulation in iTregs, but does not specifically enhance 
central LAT accumulation. Notably, in anti-CD3/28-primed iTregs, fusion with PKC V3 
excessively enhanced LAT central clustering, particularly after the 120s time point. The 
reactions of anti-CD3/28 and MBP peptide-primed iTreg to manipulation of LAT localisation 
are not identical, but comparable. Possibly, less efficiently activated anti-CD3/28-primed 
iTregs are more sensitive to such manipulation but currently, we do not understand the 
mechanisms. Given that MBP peptide-primed iTregs are more physiological comparable to 
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In contrast, fusing LAT with Vav1 SH3SH2SH3 fully restores LAT overall accumulation at 
the T cell-APC interface. One key feature of LAT Vav-GFP accumulation at the interface of 
iTregs is that after reaching the peak at the 60s time point, the accumulation gradually 
decreased and was comparable to that of LAT-GFP in Teffs at most time points. Impaired 
central LAT clustering in iTregs is also partially restored by fusion with Vav1 SH3SH2SH3, 
which slightly increases LAT accumulation with other localisation preferences. These results 
are partially consistent with the previous study: LAT Vav fully restores overall and central 
accumulation under attenuated activation conditions of 5C.C7 Teffs (126). However, as a 
full restoration of central LAT localisation induced by fusion with Vav1 SH3SH2SH3 was not 
observed in Tg4 iTregs, partially enhanced LAT Vav central accumulation possibly improve 
cSMAC clustering in a minor fashion. In brief, fusion of LAT with Vav1 SH3SH2SH3 domain 
restores overall LAT accumulation at the interface with an increased central localisation 
preference.  
 
Enhanced LAT accumulation at the interface driven by fusion with PKC-θ V3 and 
Vav1SH3SH2SH3 contributes to morphological alterations of iTregs during T cell-APC 
interactions via actin network. Tyrosine phosphorylation of LAT results in recruiting SLP-76 
and subsequently Nck and Vav1 to the LAT signalosome, and the assembly of a tri-
molecular complex of Nck, SLP-76 and Vav1 is required for TCR-induced actin 
polymerisation (100, 275). More directly, LAT deficient T cells are characterised with 
irregular and transient T cell spreading driven by the actin cytoskeleton and reconstitution of 
LAT restores most of the morphological changes in these cells (212). We have also shown 
in chapter 4 that Tg4 iTregs displayed impaired LAT and delayed F-actin accumulation, 
particularly in the first two minutes of activation (Figure 4.10 and 4.22). These data suggest 
that defective LAT accumulation from upstream proximal signalling attenuates subsequent 
actin polymerisation and result in inefficient T cell spreading and IS formation. Therefore, 
excessive and full restoration of LAT accumulation at the interface by fusion of PKC-θ V3 
and Vav1 SH3SH2SH3 enhance actin polymerisation and help to promote more stable and 
efficient T cell-APC interactions.  
 
6.10.3 Restoration of LAT accumulation at the interface by fusion with Vav1 
SH3SH2SH3 marginally regulates cytokine production of iTregs 
Spatiotemporal organisation of T cell signalling intermediates is associated with cell function. 
As mentioned earlier, the V3 domain of PKC-θ is required for its translocation to cSMAC 
upon activation, and loss or replacement of this domain abrogates activation of transcription 
factors including NF-κB, Ap-1 and NFAT (238).  Research by Singleton et al shows that Itk 
deficiency in DO11.10 T cells impairs Cdc42 central localisation and actin accumulation at 
the T cell-APC interface, and reconstituting Cdc42 central accumulation restore actin 
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accumulation with enhanced peripheral patterning (192). Moreover, Itk deficiency and 
costimulation blockade both reduces LAT central localisation and IL-2 secretion and mRNA 
production upon T cell activation, and fusion with Vav1 SH3SH2SH3 domain restores of 
LAT centrality and consistently enhances the amounts of IL-2 mRNA in both conditions (126) 
 
Results of IFN-γ and IL-10 ELISAs show that retroviral transduction of GFP tagged LAT 
related sensors significantly reduced IFN-γ and IL-10 production in Tg4 iTregs upon 
peptide-induced activation. Increasing the total amounts of LAT in T cells by retroviral 
transduction may change the composition of the cSMAC, and excessive LAT accumulation 
at the interface drives sequestration of LAT. Among the GFP-labelled iTregs, expression of 
LAT V3 in iTregs shows a trend of reducing both IFN-γ and IL-10 while LAT Vav tends to 
enhance IL-10 secretion. As the impacts were both minor, LAT spatiotemporal distribution 
likely regulates cytokine secretion of iTreg to a small extent. Transcription factors such as 
E4BP4, IRF4 and Blimp1 may play a more decisive role in regulating IL-10 production by 
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 General discussion Chapter 7
CD4+ Teffs and Tregs play different roles in immune responses. Teffs release pro-
inflammatory cytokines to activate innate immune cells, enhance antibody production and 
assist the cytotoxic activity of CD8+ T cells (21). Tregs mediate immune suppression by 
secreting anti-inflammatory cytokines, expressing coinhibitory molecules and generating 
immunosuppressive molecules (49). T cell function is closely associated with TCR-induced 
activation, which is regulated by dynamic spatiotemporal organisation of T cell signalling 
intermediates (126, 130, 134, 135).  Our main research aims were to compare 
spatiotemporal organisation of T cell signalling molecules in the activation of Tg4 Teffs and 
iTregs, and investigate how proximal T cell signalling would affect their function. Key 
signalling intermediates analysed in this study were LAT, TCR-ζ, PKC-θ, Vav1 and F-actin.  
 
7.1 Anti-CD3/28 and MBP peptide-priming generate different iTregs 
Tg4 naïve CD4+ T cells were efficiently differentiated into Teffs and iTregs by T cell priming 
using different cytokines. Transcription factor Foxp3 is specifically expressed by Tregs and 
indispensable for their suppressive function (46, 48).  In this project, we have applied two 
priming methods to generate Foxp3+ iTregs: priming naive CD4+ T cells with anti-CD3/28 
antibodies and priming mixed splenocytes and lymphocytes containing endogenous APCs 
with MBP Ac1-9 peptides. These two methods both effectively generated Foxp3+ iTregs, 
and the percentage of Foxp3+ cells induced by the former was significantly higher, as 
previous studies reported (53, 139). Previously Verhagen and Wraith (148) reported that 
anti-CD3/28 and MBP peptide-primed iTreg express different levels of Helios, a 
transcription factor. Here we propose that these two types of iTregs are different for two 
main reasons: (1) Spatiotemporal distribution patterns of LAT and TCR-ζ in anti-CD3/28 and 
MBP peptide-primed iTregs are different. In early activation of anti-CD3/28 primed iTregs, 
more LAT accumulation at the interface was observed after the first 120 seconds of 
activation, but fewer TCR-ζ molecules localised at the interface at early time points (-40s-
40s). (2) When treated with dual CTLA-4 and PD-1 blockade upon activation, they show 
different phenotypes. Anti-CTLA-4/PD-1 treated anti-CD3/28 primed iTregs showed largely 
elongated cell shapes with long lamellae, which is indicative of unstable IS formation. In 
early T cell activation, LAT overall accumulation at the T cell-APC interface of anti-CD3/28 
primed iTregs was significantly reduced by the dual blockade. In contrast, cell couples 
formed by anti-CTLA-4/PD-1 treated MBP peptide-primed iTregs were more compressed, 
and increased LAT overall and central accumulation at the interface were observed in these 
iTregs, suggesting their activation was enhanced. To determine whether these two types of 
iTregs are functionally different, their cytokine profiles, expression of coinhibitory molecules 
(such as CTLA-4 and PD-1) and suppressive functions should be compared. As MBP 
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peptide-primed iTregs are more physiologically comparable to naturally occurring Tregs, 
this research mainly focused on investigating their phenotypes. 
 
7.2 Different IFN-γ and IL-10 production by iTregs  
During Tg4 Teff and iTreg generation, Teffs secreted large amounts of IFN-γ at early stages 
while iTregs produced relatively low levels of IFN-γ throughout induction. IL-10 was initially 
secreted by both cell types but iTregs maintained IL-10 production at late stages of 
induction. Tg4 Teffs show a dominant Th1 phenotype (154). IL-10 production of Th1 cells 
can be induced by IL-12 and a high dose of antigens (236), which might explain transient IL-
10 secretion by Teffs. Restimulated iTregs showed a better capability of secreting IL-10 
than Teffs, although not significantly. Therefore, mature iTregs develop a reduced ability to 
promote immune responses and are more likely to induce suppression by secreting IL-10.  
 
7.3 TCR-ζ and PKC-θ accumulation in Tg4 T cells 
Among the five signalling intermediates that we have studied, accumulation patterns of 
TCR-ζ and PKC-θ in Tg4 T cells were found to be different from those in previous research. 
Lee et al investigated conjunctions formed by AND TCR transgenic naive T cells and 
B10.BR splenic APCs and found that TCR clustering was only observed at the centre of the 
synapse at relatively late time points (between 15-30 min) (127), unlike that in Tg4 Teffs. 
We only observed medium levels of TCR central accumulation at the interface 5 minutes 
after IS formation (Figure 4.16). A similar study using planar bilayers containing adhesion 
molecules and agonist peptides revealed that TCR microclusters containing phosphorylated 
Lck, ZAP-70 and LAT localised at the centre of the IS by 5 min in activated AND TCR 
transgenic T cells (214). Moreover, in 5C.C7 mice, another transgenic model, central TCR-ζ 
accumulation was also observed within the first 5 minutes of T cell activation (134, 193), 
which is more comparable to that in Tg4 T cells. In these previous studies, initial peripheral 
TCR clustering was frequently observed upon early T cell activation, and it later localised at 
the centre and eventually internalised (after 16 min). Likely, the way of activation and level 
of stimulation contributes to the different spatiotemporal accumulation patterning of TCR 
microclusters in these studies. TCR clustering tends to have a delay accumulation pattern in 
T cells activated by supported planar bilayers, and TCR microclusters under weak Ag 
stimulation do not promote the development of the cSMAC (278). Moreover, Singleton et al 
have shown that a same sensor could localise differently in T cells from different transgenic 
mouse models (130). 
 
Significantly more PKC-θ accumulation at the IS of Tg4 iTregs was observed, compared to 
that of Tg4 Teffs (Figure 4.18). Central PKC-θ accumulation at the IS was comparable in 
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both cell types but iTregs displayed more PKC-θ accumulation across the whole interface in 
early activation (i.e. more lamellal and diffuse patterning). However, Zanin-Zhorov et al 
reported that human Tregs activated on planar bilayers shown largely reduced PKC-θ 
recruitment to the IS than Teffs (201). They found that even in the presence of both anti-
CD3 and anti-CD28, human Tregs still had much less PKC-θ accumulation at the IS. 
Moreover, stronger TCR triggering suppressed PKC-θ recruitment to the synapse in human 
Tregs but upregulated such accumulation in human Teffs (201). We have mentioned in 
section 4.14.1 that plate-bound anti-CD3/28 continuously activate target cells and 
eventually leads to a stronger activation. Most likely, such strong stimuli reduce PKC-θ 
accumulation at the IS of Tregs but affect Teffs oppositely. Thus relatively defective TCR 
signalling in Tg4 iTregs might contribute to their increased recruitment and defective 
clearance of PKC-θ at the IS in early activation. In summary, for Teffs, effective T cell-APC 
interactions lead to efficient activation, recruitment of PKC-θ to the IS and eventually 
promote immune responses, but for Tregs, less efficient activation results in defective 
regulation of PKC-θ localisation at the IS and thus they might display impaired immune 
responses, shifting towards a regulatory phenotype. 
 
7.4 Regulating iTreg activation and function with dual CTLA-4 and 
PD-1 blockade 
T cells need to be activated to be functional, thus we focused on studying activation of Tg4 
Teffs and iTregs by comparing their spatiotemporal organising of proximal T cell signalling 
intermediates. Live cell imaging analyses reveal that upon TCR-induced activation, iTreg 
activation is defective from two aspects: (1) iTregs formed unstable T cell-APC junctions, 
with a narrow interface of contact, long extended lamella and elongated cell shape. (2) At 
the T cell-APC interface of iTregs, impaired overall and central accumulation of LAT and 
TCR-ζ, and delayed F-actin polarisation were observed, which indicates assembly of the 
cSMAC is impaired. We hypothesised that iTreg function is associated with their defective 
proximal T cell signalling and by enhancing or restoring these signalling events, iTreg 
function can be tuned. 
 
Our first attempt was to block CTLA-4 and PD-1 coinhibitory pathways during Tg4 iTreg 
activation. As CTLA-4 and PD-1 are both expressed by Tregs and inhibit costimulation 
(247), blocking these pathways should promote better iTreg activation. Results show that 
more stable T cell-APC junctions were formed by iTregs treated with anti-CTLA-4/PD-1 
during their activation. The dual blockade partially enhanced LAT overall and central 
accumulation at the interface in early iTreg activation, but did not affect their IL-10 
production. Moreover, blocking CTLA-4 and PD-1 significantly inhibited the generation of 
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Foxp3+ iTregs during iTreg induction, suggesting CTLA-4 and PD-1 pathways positively 
regulate iTreg development. Dual CTLA-4 and PD-1 blockade also slightly enhanced IL-10 
but barely affected IFN-γ secretion by iTregs during induction. Together these data indicate 
that dual blockade of CTLA-4 and PD-1 promotes Tg4 iTreg activation but marginally affects 
their IFN-γ and IL-10 production.  
 
7.5 Regulating iTreg activation and function by manipulating LAT 
spatiotemporal organisation  
As dual CTLA-4 and PD-1 blockade only partially restored LAT localisation, we then directly 
targeted LAT to regulate iTreg activation. The adaptor protein LAT is important for 
promoting the formation of the cSMAC which is required for efficient T cell activation (121, 
185). Upon TCR-induced activation, phosphorylated LAT rapidly localises at the interface 
centre and recruits multiple signalling intermediates including Grb2, Gads, PLC-γ1 and 
SLP-76 to the interface, forming a LAT signalosome (126, 185). These signalling events are 
critical for actin polymerisation, translocation and activation of key transcription factors such 
as NFAT and NF-κB (237). In particular, central LAT accumulation at the interface in the 
first two minutes is important for IL-2 mRNA production (126). Spatiotemporal patterning of 
LAT in Tg4 iTreg activation is defective. Previous work by Clark et al showed that impaired 
LAT central accumulation upon attenuated T cell activation can be consistently enhanced 
and largely restored by fusion of LAT with PKC-θ V3 domain (LAT V3) and Vav1 
SH3SH2SH3 domain (LAT Vav), respectively (126). Thus we transduced iTregs with GFP-
tagged LAT V3 and LAT Vav respectively and investigated whether we could reconstitute 
cSMAC formation in iTregs and regulate iTreg function. 
 
Results show that LAT V3 and LAT Vav stabilised T cell-APC interactions upon iTreg 
activation but the former continuously enhanced cell spreading and pulled iTregs towards 
APCs during the first two minutes of iTreg activation. Fusion with the PKC-θ V3 and Vav1 
SH3SH2SH3 domain both partially restored LAT central accumulation at the interface in 
iTreg activation. Moreover, the former excessively enhanced LAT overall accumulation, 
while the latter led to a full restoration. These observations indicate that fusing LAT to the 
PKC-θ V3 or Vav1 SH3SH2SH3 domain increases its total functional protein interaction 
motifs, thus enhances assembly of LAT signalosome at the interface in early iTreg 
activation. However, fusion with PKC-V3 excessively maintained LAT accumulation at the 
interface in iTregs to higher levels than that observed in Teffs, leading to sequestration of 
LAT. LAT is one of the key components of the cSMAC. Previous work (126) and this study 
both show that the composition of the cSMAC changes in a time-dependent manner and the 
two-minute borderline is critical. In early Teff activation, key signalling intermediates such as 
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LAT, Grb2, Gads and PKC-θ localise to the interface within the first two minutes to 
efficiently transduce activation signals, and many of them leave the cSMAC afterwards so 
that T cell activation signalling can be controlled and attenuated (126, 130, 134). 
Sequestration of LAT at the interface after the first two minutes would change the 
composition of the cSMAC and affect T cell function.  Clark et al showed that full restoration 
of LAT central accumulation by the Vav1 SH3SH2SH3 domain enhances IL-2 mRNA 
production under attenuated T cell stimulation, but excessively enhanced LAT central 
accumulation by the PKC-θ V3 domain does not (126). Although in this study, fusion of LAT 
with PKC-θ V3 and Vav1 SH3SH2SH3 domain excessively enhanced and fully restored 
overall LAT accumulation in iTreg activation respectively, but their enhancement on central 
LAT accumulation were both partial. Possibly different cell types used contribute to the 
variance, as they used 5C.C7 Teffs and we used Tg4 iTregs.  
 
Upon activation, LAT Vav transduced iTregs secreted slightly more IL-10, while LAT V3 
transduced iTregs secreted less, compared to LAT transduced iTregs. IFN-γ secretion upon 
iTreg activation was less affected by fusing LAT with PKC-θ V3 or Vav1 SH3SH2SH3 
domain. Therefore, the excessive enhancement of LAT overall accumulation induced by the 
PKC-θ V3 domain is more likely to upset cytokine secretion of iTregs, while reasonably 
restored LAT overall accumulation by the Vav1 SH3SH2SH3 domain promotes IL-10 
production of iTregs to a minor extent.  
 
7.6 Tregs in immunotherapy and clinical applications 
Owing to the roles Tregs play in preventing autoimmunity and maintaining immune 
homeostasis, various therapeutic approaches targeting Tregs have been developed. For 
cell-based Treg therapies, ex vivo-expanded Tregs could be infused to treat autoimmune 
diseases such as type 1 diabetes (279). However, therapies using polyclonal Tregs tend to 
induce global immunosuppression and infections could occur in treated patients (280). To 
increase their specificity, Tregs can be modified to express an antigen-specific TCR or 
chimeric antigen receptor (CAR) and several studies have explored their applications in 
treating MS, type 1 diabetes and acquired factor VIII deficiency (281). Non-cell-based Treg 
therapies mainly aim to expand Tregs in vivo while maintaining their suppressive 
phenotypes. For example, a low dose of IL-2 can expand Tregs as they are more 
responsive to IL-2 than other T cells owing to their high surface expression of CD25 (282). 
An mTOR inhibitor, rapamycin blocks T cell responses to cytokines or growth factors and 
induces T cell anergy and deletion (283). It can also induce immune tolerance by enhancing 




Chapter 7  
A previous study reported that adoptive transfer of Tg4 iTregs could delay disease 
progression of EAE in Tg4 mice (268). In this project, we have shown that by transducing 
Tg4 iTregs with LAT V3 or LAT Vav, defective LAT localisation could be partially restored. 
However, the impacts of such LAT manipulation on the regulatory function of Tregs have 
not been directly assessed. Overall, results from ELISAs support that enhancing LAT 
accumulation at the IS is likely to promote a better suppressive function of Tg4 iTregs. 
Therefore, to further verify how such manipulation will affect T cell function and EAE 
progression, adoptive transfer of Tg4 cells transduced with LAT V3 or LAT Vav into Tg4 
mice could be performed. Disease progression can be recorded in Tg4 recipients to 
determine their efficacy. Likely, transduced Teffs and iTregs may have different responses 
to LAT manipulation, thus they should be transferred in parallel for better understanding of 
LAT function in Teffs and iTregs. We expect to observe relieved EAE progression in Tg4 
mice transferred with LAT Vav transduced iTregs while Teffs bearing the same sensor 
might exacerbate EAE. Results from such in vivo experiments shall provide another 
prospective for cell-based therapies. 
 
7.7 Conclusions 
In summary, Tg4 Foxp3+ iTregs can be generated successfully using MBP peptides and 
endogenous APCs in the presence of IL-2 and TGF-β. Activated Tg4 iTregs show a 
reduced ability of secrete IFN-γ and more sustained ability to produce IL-10. Live cell 
imaging shows that in early T cell activation iTregs form unstable T cell-APC junctions, and 
spatiotemporal distribution of signalling intermediates including LAT, TCR-ζ, F-actin at the T 
cell-APC interface are defective, compared to that of Teffs. To explore the relationship 
between activation and immune suppressive function of iTregs, coinhibitory pathways and 
LAT localisation of iTregs were manipulated.  
 
Blocking CTLA-4 and PD-1 pathways significantly inhibit the generation of iTregs and 
enhance IL-10 production by iTregs to a small extent. In early iTreg activation, dual 
blockade of CTLA-4 and PD-1 stabiles cell coupling and partially enhances LAT overall and 
central accumulation at the interface and therefore enhances iTreg activation. Fusion of 
LAT with the PKC-θ V3 and Vav1 SH3SH2SH3 domain both stabilise cell coupling and 
partially restore LAT accumulation at the interface centre during iTreg activation. However, 
fusion with PKC-θ V3 excessively enhances LAT overall accumulation at the interface, 
which slightly reduces IFN-γ and IL-10 secretion by iTregs. Fusion with Vav1 SH3SH2SH3 
fully restores LAT overall accumulation at the interface, which slightly increases IL-10 
production by iTregs. These data suggest that blocking coinhibitory pathways and restoring 
LAT spatiotemporal patterning enhance activation of iTregs, but regulate their 
immunosuppressive function to a lesser extent. Likely, the suppressive function of Tregs is 
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mainly conducted via cell to cell contact. As a variety of cells are capable of secreting IL-10 
(156), its role in immunosuppression induced by Tregs might be limited.  
 
Further spatiotemporal patterning analyses of more key signalling intermediates of the 
cSMAC such as Grb2, Gads, SLP-76 will be required to better understand proximal T cell 
signalling events upon iTreg activation. LAT phosphorylation needs to be examined to 
validate their impaired function in iTreg activation. The in vitro suppression assay requires 
further optimisation to better assess the suppressive function of Teffs and iTreg more 
specifically. Using irradiated endogenous Tg4 APCs or anti-CD3 only for activation and 
membranes that block cell contact may lead to clearer results. Last but not least, optimising 
IL-10 detection, determining CTLA-4, PD-1 and TGF-β expression by Tg4 iTregs will 
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